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Abstract 
 
The effect of combined cytokine and cell therapy in ischaemic cardiomyopathy is unclear. Meta-
analyses suggest improved cardiac function with cell therapy. The optimal cell delivery route 
remains unclear. The mechanism of effect on cardiac function with cell therapy remains to be 
elucidated. This thesis aims to address these unanswered questions. Chapter 1 introduces cell 
therapy in ischaemic cardiomyopathy. Chapter 2 details the methods. This thesis can be divided 
into three projects.  
The first project investigates whether granulocyte-colony stimulating factor (G-CSF) alone or in 
combination with intracoronary (IC) or intramyocardial (IM) injection of autologous bone marrow-
derived cells (BMC) improves cardiac function as well as functional and biochemical parameters in 
patients with ischaemic cardiomyopathy. Chapter 3 details the results of the study which suggests 
an improvement in cardiac function, patient functional characteristics and biochemical parameters 
in patients who received IM BMC therapy along with G-CSF.  
The second and third projects assess the mechanisms by which improvements in cardiac function 
and/or symptoms may have occurred. The second study looked at the association between various 
pro- and anti-inflammatory cytokines as well as pro-angiogenic cytokines with G-CSF/cell therapy. 
Chapter 4 details the results of the cytokine sub-study. Important signals were observed including a 
reduction in certain pro-inflammatory cytokines (e.g. MCP-1, IL-8 and IL-1b) and an increase in the 
pro-angiogenic cytokine VEGF in the group with a significant improvement in cardiac function at 1 
year i.e. the IM BMC group.  
The third project (chapter 5) looked at myocardial scar, diastolic function and cell characteristics in 
relation to G-CSF/cell therapy and cardiac function. The results highlighted important correlations 
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including a significant association between colony-forming unit granulocyte-macrophage counts 
and improvement in cardiac function in the IM BMC group.  
Lastly, in chapter 6, I discuss the findings and the implications of the research in everyday practice. 
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Chapter 1 Introduction  
 
1.1 The burden of Heart failure 
 
The prognosis of patients with heart failure (HF) is still dismal despite decades of advances in 
healthcare.  HF {defined as a structural or functional cardiac abnormality that results in a failure to 
supply oxygen at a rate commensurate with the demands of the metabolising tissues, despite 
normal filling pressures (or only at the expense of increased filling pressures)1} is a common 
condition associated with significant morbidity, mortality and cost to the healthcare system. 
In the UK 900,000 people suffer from HF with more than 5.8 million people affected in the USA.2 
The prevalence of HF is expected to rise in the UK with an increasing ageing population and thus 
highlights the unmet need for better treatment options. Worldwide an estimated 23 million people 
suffer from HF 3 with the estimated prevalence expected to increase by 25% in the next 20 years .4 
The prevalence and incidence of HF are known to be related to age with a prevalence of around 1% 
for those between 45 and 64 years old but 20% in the over 85 age group.2 According to the 
Framingham study, the lifetime risk of developing HF in those over 40 years old is 20%.5 
 
The impact on healthcare systems is substantial. In the UK, 2% of all hospital bed-days and 5% of all 
emergency medical admissions are secondary to a primary diagnosis of HF. On average, a GP looks 
after 30 patients with established HF.2 In the USA, it is estimated that treatment of chronic HF costs 
the US economy more than $29 billion per year.6 The above facts highlight the significant financial 
burden to the health services of looking after patients with chronic HF. 
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1.1.1 Aetiology 
 
Heart failure most frequently occurs as a consequence of ischaemic heart disease (IHD), 7  which 
accounts for more than two-thirds of cases of HF. Hypertension, which had previously been 
considered the commonest cause of HF has been superseded by IHD and is the second most 
important contributory factor. The causes of HF are listed in Table 1.1. 
Table 1.1. Aetiology of chronic heart failure                                                                                                                                                                                                                                                                             
Ischaemic heart disease 
-Myocardial infarction 
-Myocardial ischaemia 
Valvular heart disease 
-obstructive 
-regurgitant 
Hypertension 
Chronic tachy- or brady-arrhythmias 
Non-ischaemic dilated cardiomyopathy 
-genetic/familial 
-toxic/drug-induced 
-infiltrative 
-metabolic 
-post-viral illness 
 
 High-output states  
e.g. thyrotoxicosis, chronic anaemia 
 
Ischaemic heart disease is the UK’s biggest killer and is responsible for approximately 73,000 deaths 
per year.8 The advent of primary percutaneous coronary intervention (PPCI) together with 
advancements in medical therapy with new anti-platelets and anticoagulation has limited the 
damage caused by and improved the treatment of acute myocardial infarction (AMI) by reducing 
mortality and recurrent MI. These improved treatment strategies for AMI have led to the greater 
survival of patients who in the pre-PPCI era would not have survived. However this appears to be at 
the expense of developing HF.  Data from the Framingham study, reported by Velagaleti et al., 
shows that the incidence of HF within 30-days post-MI rose from 10% in the period 1970-79 to 
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23.1% in the period 1990-99.  The 5 year incidence of HF was 27.6% in 1970-79 and increased to 
31.9% in 1990-99.9 A few other studies have also supported the Framingham findings including the 
Worcester Heart Attack Study10 and a cohort study from Canada.11 Not all studies demonstrate this 
trend, however, as in the Olmsted County community study which involved 2596 patients with a 
first acute MI over a period of 20 years (1990-2010) and showed a decline in post-MI HF incidence 
in the period 2004-2010 when compared to 1990-1996. 12 However, it is likely that the improved 
survival of patients undergoing MI is, at least partly, leading to the increasing prevalence of HF. 
1.1.2 From myocardial infarction to chronic ischaemic cardiomyopathy – Pathophysiological basis 
 
During an AMI, up to 109 cardiomyocytes can be lost as a result of ischaemia.13 The resulting acute 
damage activates a chronic, subsequently self-propagating, cascade of biologically active molecules 
(neurohormones e.g. noradrenaline, angiotensin and cytokines e.g. IL-6, TNF) which have 
deleterious effects on the heart. These acute (myocardial damage from MI) and chronic 
(neurohormonal, cytokine activation) insults to the heart set off a progressive, maladaptive change 
in left ventricular (LV) architecture known as ventricular remodelling (Figure 1.1), ultimately leading 
to the clinical manifestations of HF. The condition of impairment of left ventricular ejection fraction 
(LVEF) secondary to IHD is labelled as chronic ischaemic cardiomyopathy.   
1.1.2.1 Left ventricular remodelling 
 
Ventricular remodelling refers to the change in ventricular architecture resulting in increased LV 
volumes and change in the shape of the LV.  In the first few days following AMI, the myocytes 
undergo necrosis followed by thinning and dilatation of the LV wall. This is as a result of expansion 
of the necrotic area, not by further necrosis but, by “slippage” of cells past one another as a result 
of degradation of the intercellular collagen support.14 Cardiac fibroblasts subsequently deposit 
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collagen over the thinned, infarcted territory, resulting in scar formation. Scar formation in the 
short-term has a protective effect by restricting further expansion of the necrotic area, however, in 
the long-term, it serves as a substrate for life threatening arrhythmias. In a significant proportion of 
patients (approximately 30%) the process of LV remodelling continues but in the non-infarcted, 
healthy myocardium. 15  The non-infarcted myocardium undergoes hypertrophy. Hypertrophy in HF 
is usually secondary to a volume overload state and leads to hypertrophy of cardiac myocytes with 
elongation of myocytes and placement of sarcomeres in series, known as eccentric hypertrophy. 
(Figure 1.1). This results in further thinning of the LV wall and dilatation of the LV. According to 
Laplace’s law, the dilatation and thinning of the LV results in increased wall stress and thus 
increased afterload. Although, initially a compensatory mechanism, the increasing afterload and 
the reducing contractility results in a continuing downward spiral to ‘pump failure’. Furthermore, 
the increased wall stress results in sub-endocardial hypoperfusion and thus worsening ischaemia 
and LV function, activation of stretch-induced genes {e.g. angiotensin II, tumour necrosis factor 
(TNF)} and free radical generation resulting in further activation of various cytokines e.g. IL-1β (see 
section 1.1.2.3).16   In addition, the stretching of the LV annulus and increased displacement of the 
papillary muscles, secondary to the annular dilatation, result in functional mitral valve 
regurgitation, which in turn imposes further volume overload on the heart. It has been noted that 
the larger the area of infarction, the greater the extent of remodelling17. 
The biological processes underlying remodelling involves alterations in cardiac myocyte biology, the 
myocardium and left ventricular geometry.18  Changes in myocyte biology involve 1. Myocyte 
hypertrophy 2. Alterations in excitation-contraction coupling thus reducing contractility 3. Down-
regulation of beta-adrenergic receptors 4. Mitochondrial abnormalities causing abnormal 
myocardial energy metabolism 5. Progressive destruction of myofilaments and 6. Distortion of 
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cytoskeletal architecture.16  Changes in the myocardium include 1. Increased myocyte loss 
secondary to increased necrosis and apoptosis and 2. Changes in the extracellular matrix (ECM). 
The composition and mass of the ECM is altered with changes in the amount and subtypes of 
collagen, collagen arrangement and cross-linking and interaction of cells and ECM. These changes 
are driven primarily by the balance between matrix metalloproteinases (MMP), peptidases capable 
of degrading the ECM proteins, and their inhibitors. 18 Ultimately, the LV geometry changes from an 
elliptical shape to a more spherical shape with increased LV volumes.  
1.1.2.2 Neurohormonal mechanisms 
 
The process of LV remodelling is driven by the activation of a number of biologically active 
molecules and pathways. The neurohormonal mechanisms include activation of the sympathetic 
nervous system and the renin-angiotensin-aldosterone system. Activation of the sympathetic 
nervous system is accompanied by a blunted parasympathetic response. The increased sympathetic 
activation occurs relatively early in HF and results in elevated noradrenaline levels in the blood. As 
a result, although an adaptive response initially, the resulting reduction in heart rate variability and 
increase in contractility and peripheral vascular resistance result, in the long-run, in increased 
afterload and increased energy demands on a failing heart and thus becomes a maladaptive 
response.   Relatively late in the course of HF, compared to the sympathetic system, the renin-
angiotensin-aldosterone system (RAS) is activated. This occurs secondary to renal hypoperfusion 
and adrenergic stimulation. Again, similar to the activation of the sympathetic system, activation of 
the RAS is initially a compensatory response that soon becomes maladaptive. Thus, although 
angiotensin II and aldosterone, in the short-term, cause vasoconstriction and salt and water 
retention thus aiding circulatory homeostasis, in the longer term, they result in cardiac fibrosis and 
hypertrophy, endothelial dysfunction and impaired noradrenaline uptake, amongst other 
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deleterious effects.  Angiotensin II is known to have direct cytotoxic effects on the heart including 
promoting fibrosis and cell hypertrophy. Despite the already expanded extracellular volume, the 
stimulation of the RAS leads to further increase in salt and water retention and thus increased 
afterload. Angiotensin II also stimulates the production of arginine vasopressin (antidiuretic 
hormone), another vasoconstrictor, which also results in further volume expansion by increasing 
water reabsorption in the kidneys. The net result is a worsening of haemodynamics and progressive 
LV remodelling all contributing to a downward spiral of worsening LVEF and symptomatic decline.  
To combat this increasing spiral of neurohormonal mediated deleterious effects, proteins with 
natriuretic and vasodilator properties become activated. These include the natriuretic group of 
peptides of which brain natriuretic peptide (BNP) is widely used in clinical practice and is now a 
clinically established marker used in both the diagnosis and prognosis of HF patients. BNP was 
originally detected in the porcine brain, hence the name. However, in humans, it is synthesised, 
along with atrial natriuretic peptide (ANP), another natriuretic peptide, in the heart in response to 
mechanical stress from volume overload.  BNP is synthesised as a pre-prohormone that undergoes 
subsequent cleavage to form the 32 amino acid BNP (the active natriuretic peptide) and the 
inactive, 76-amino acid by-product, NT pro-BNP. Both, BNP and NT pro-BNP, can be measured 
using commercially available immunoassays. BNP, along with ANP, binds to natriuretic peptide 
receptors (NPR-A and NPR-B). This in turn leads to activation of intracellular second messenger 
systems ultimately leading to vasodilatation, loss of sodium and water, inhibition of the RAS and 
inhibition of cardiac fibrosis18.   Although an adaptive response, as HF progresses, the response to 
natriuretic peptides becomes blunted.   
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Fig 1.1. Diagram showing the pathophysiology of heart failure. The initial event is usually a myocardial infarction which 
results in pump failure and subsequent activation of the renin angiotensin system (RAS) and the sympathetic adrenergic system (SAS) as well as 
cytokines. The eventual result is negative remodelling and symptomatic heart failure   
1.1.2.3 Cytokines in heart failure 
 
It has increasingly been recognised that pro- and anti-inflammatory cytokines may play a role in the 
progression of remodelling in HF in addition to the neurohormonal activation discussed above.19  In 
the early 1990’s, Levine et al. were the first to show a link between inflammation and HF by 
showing an elevated level of the pro-inflammatory cytokine, tumour necrosis factor (TNF-α), in 
patients with HF.20 TNF-α has been extensively studied in heart failure patients and animal models.  
Bryant et al, developed transgenic mice expressing TNF-α. These mice subsequently developed 
severe impairment of biventricular cardiac function, ventricular dilatation and ventricular fibrosis.21 
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TNF-α impairs cardiac function by disrupting calcium homeostasis, production of reactive oxygen 
species and increased nitric oxide production. Several other cytokines have been studied since. IL-2 
is a glycoprotein that is produced by lymphocytes and induces T-cell proliferation. IL-2 has been 
shown to cause severe but reversible LV dysfunction in isolated rat heats.22 Furthermore, IL-2 has 
been studied in patients with renal cell carcinoma and metastatic melanoma. In such patients, IL-2 
was found to cause transient, LV dysfunction.23 Similar LV dysfunction was also observed in another 
study by Nora et al. who looked at the cardiotoxic effects of IL-2 in patients with renal cell 
carcinoma, melanoma or colon carcinoma and found similar depressive effects on LV contractility.24 
Another cytokine studied is IL-4, an anti-inflammatory cytokine and pro-fibrotic cytokine that 
stimulates the production of collagen type I and II.  In a study by Gonzalez-Molina et al., they found 
that increased IL-4 levels was correlated with adverse remodelling and cardiac fibrosis. Patients 
with chronic heart failure had higher levels of IL-4 than in controls. 25 IL-6, a pro-inflammatory 
cytokine, has been studied in chronic heart failure patients in several studies and has been found to 
be elevated in such patients. IL-6 is a multifunctional cytokine that is produced by a variety of cells 
including lymphocytes and fibroblasts. TNF-α is known to activate IL-6 expression and IL-6 and TNF-
α levels have been found to be correlated in heart failure patients.26 IL-6 has been shown to be 
raised with deteriorating LV function and is a marker of severity of heart failure and prognosis.27  Il-
6 has been shown to depress LV contractility and potentiate the negative inotropic effect of TNFα 
and IL-1β and induce myocardial hypertrophy. 28 IL-8, a pro-inflammatory cytokine, is known to be 
elevated in patients with chronic HF. Damas et al have studied several different cytokines as a sub-
study of the statin trial CORONA (Controlled Rosuvastatin Multinational Trial  in Heart Failure). 
They found that IL-8 level was prognostic in predicting mortality and worsening heart failure. 29   IL-
1 is a family of cytokines which includes IL-1α and IL-1β, both pro-inflammatory cytokines. Both act 
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on the same receptor. IL-1β has been shown to depress LV function in animal models. Injection of 
IL-1β into mice induced systolic dysfunction.30 In a group of patients with rheumatoid arthritis, 
treatment with the IL-1 receptor blocker Anakinra showed improvement in LV function.31  
IL-10 is an anti-inflammatory cytokine as opposed to the pro-inflammatory cytokines discussed 
above. Although it is raised in heart failure patients, it is not as elevated  in comparison to the 
elevation in levels of the pro-inflammatory cytokine  TNF-α, i.e. the increase in this protective 
cytokine (IL-10) appears to be  inadequate.32 Most recently, Dopheide et al. looked at the IL-
10/TNF-α ratio and found that a low ratio was associated with reduced LVEF and a worse prognosis 
at 10 years.33 Research has also focused on cytokines involved in neovascularisation, particularly on 
vascular endothelial growth factor (VEGF).  VEGF is a cytokine with multiple functions including 
neovascularisation and anti-apoptosis. In heart failure, VEGF levels decrease with progression of 
the disease state, probably by exhaustion of VEGF release.34 Pathological cardiac hypertrophy 
occurs in heart failure and this together with reduced VEGF levels results in reduced capillary 
density, myocardial hypoxia and cardiac dysfunction. Whether VEGF could serve as a novel therapy 
for heart failure patients has been studied in various studies including gene therapy using VEGF but 
with mixed results.  35, 36 Other cytokines studied include interferon-γ (IFN-γ), IL-18 and 
macrophage chemoattractant protein-1 (MCP-1). IFN-γ is a cytokine produced by peripheral blood 
mononuclear cells i.e. mast cells, macrophages, T-cells. The effect of IFN-γ is as yet unclear. IFN-γ 
has been shown to induce cardiomyocyte hypertrophy and increased fibroblast proliferation and 
resultant cardiac fibrosis. However, other data suggest that IFN-γ may have a protective role by 
actually limiting hypertrophy. 37 IL-18, in synergy with IL-12, activates production of IFN-γ. IL-18, a 
pro-inflammatory cytokine, has been shown to induce cardiac hypertrophy, contractile dysfunction, 
myocyte apoptosis and extracellular matrix remodelling. These biological effects of IL-18 are 
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thought to be mainly due to enhanced IFN-γ production. 27  Macrophage chemoattractant protein-
1 (MCP-1) is a chemokine belonging to the C-C chemokine family that has been shown to be 
elevated in chronic heart failure patients.38 Furthermore, in mice studies, MCP-1 antagonist gene 
therapy was shown to attenuate LV dysfunction in post-MI HF models.39  
In HF, the balance between pro-inflammatory cytokines and anti-inflammatory cytokines appears 
to be tilted towards the pro-inflammatory state. The complex interactions of the vast array of 
cytokines in heart failure are still incompletely understood. The cytokines appear to interact with 
the neurohormonal system. In fact, levels of pro-inflammatory cytokines were lower in patients 
with HF receiving RAS blockade therapy thus implying significant cross-talk between the systems. 19, 
40 Several cytokines have shown correlation with disease severity and prognosis. For e.g. 
measurement of TNF-α, IL-6 and MCP-1 has been linked to more severe disease and TNF- α levels 
have been linked with poor prognosis.  Table 1.2 shows some of the important cytokines and 
chemokines associated with the progression and clinical presentation of HF. 
1.1.3 Can remodelling be reversed or halted? 
 
In several trials of therapeutic medicines or devices in HF, a reduction in or attenuation of the 
increase in LV volumes has been noted. The reduction in LV volumes and a change in shape of the 
LV towards a more elliptical shape is termed reverse remodelling. In the Metoprolol CR/XL 
Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) MRI sub-study, 
administration of metoprolol for 6 months significantly reduced indexed LV end-diastolic volume 
(LVEDV) by 16% and indexed LV end- systolic volume (LVESV) by 24% and demonstrated a 28% 
improvement in LVEF.41 In the Valsartan HF trial (Val-HeFT), a reduction in LVEDV and improvement 
in LVEF were also demonstrated with treatment with the angiotensin receptor blocker valsartan.42   
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It was noted in the Val-HeFT trial that patients with worse LVEF at baseline had the greatest degree 
of reverse remodelling.  Observation from several trials indicate that clinical improvement in 
patients and improvements in LVEF have been associated with reverse remodelling.16  Reverse 
remodelling has been a prime target of many therapeutic trials in HF. Reduction in myocyte 
hypertrophy and changes in gene expression including activation of genes involved in sarcomere 
formation, β-adrenergic signalling and excitation-contraction coupling towards the level found in a 
normal heart are likely to account for the observed changes of reverse remodelling.  
        Table 1.2. Effects of selected cytokines/chemokines on cardiac function 
CYTOKINE/CHEMOKINE EFFECT ON MYOCARDIUM / ASSOCIATION WITH CLINICAL OUTCOME 
IL-2  Negative inotropic effect43 
IL-4  Pro-fibrotic effect 44 
IL-6  Negative inotropic effect43; elevated in HF  patients45 
IL-8  Predicts outcomes in HF patients29; increases with declining functional 
class 
MCP-1  Levels correlates with declining LVEF; recruit monocytes and 
macrophages which in turn secrete further pro-inflammatory 
cytokines46 
TNFα  Elevated in patients with HF; inhibits contractility, extracellular matrix 
remodelling, LV hypertrophy 47 
IL-1  Adverse remodelling, enhances apoptosis48 
IL-10  Protective effect in HF; reduced levels in HF; correlates with decline in 
LVEF49 
VEGF  Angiogenic factor; clinical benefit of VEGF gene therapy not seen in 
trials34 
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1.1.4 Clinical presentation 
 
Around 50% of patients with impaired left ventricular systolic function are asymptomatic. 50 
However, over time they ultimately present with symptoms. Symptomatic patients with HF usually 
complain of breathlessness and fatigue.  Clinical assessment involves a detailed history including 
assessment of the severity of symptoms and the functional status. To aid this, the New York Heart 
Association (NYHA) classification is often used. Originally described in 1928 and subsequently 
revised several times, the score grades the symptom severity on a scale of I to IV (table 1.3). The 
score is helpful to assess response to therapy, severity and prognostication in chronic HF patients. 
It has been shown in HF patients to be associated with mortality, hospitalisation and disease 
progression. In a study comparing 2441 chronic HF patients with NYHA class III/IV with 1863 
patients with NYHA class I/II it was demonstrated that those in NYHA III/IV had a hazard ratio of 
1.49 for HF related mortality (95% CI 1.20 to 1.84, p <0.0001) and 1.17 for HF related 
hospitalisation (95% CI 1.03 to 1.34, p = 0.017).51 
1.1.5 Current management 
The current management of HF consists primarily of pharmacotherapy. Other treatment options 
include device therapy and surgical therapy for selected patients.  Pharmacological therapy consists 
of drugs to relieve symptoms and drugs to attenuate the progression of the disease and reduce 
mortality and morbidity. The former group consists primarily of diuretics.  The main classes of 
diuretics used for symptom relief are loop diuretics and thiazide diuretics. Drugs to reduce 
mortality and attenuate disease progression include angiotensin converting enzyme inhibitors 
(ACEi) (or angiotensin receptor blockers-ARBs), beta blockers and aldosterone antagonists. ACEi (or 
ARBs) have been shown to improve LVEF, improve symptoms, reduce ventricular volumes and 
reduce the risk of mortality in systolic HF patients. 52, 53  In the CONSENSUS trial, enalapril reduced 
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mortality by 31% at 1 year compared to the control group in patients with HF, as well as a 
reduction in symptoms.52 
Table 1.3. New York Heart Association classification of heart failure symptoms 
NYHA class Symptoms 
I Symptoms only on strenuous activity. Asymptomatic with normal activity 
II Symptoms on prolonged or moderate exercise or exertion 
III Symptoms on doing activities of daily living, mild exertion. 
IV Symptoms at rest. Incapacitated. 
 
All patients, unless contraindicated, should be commenced on an ACEi (or ARB) as soon as a 
diagnosis of systolic HF is confirmed. Beta blockers have also been shown to improve LVEF (by as 
much as 5-10%), reduce hospitalisations, improve symptoms and reduce mortality. 41, 54, 55  In the 
MERIT-HF randomised controlled trial, metoprolol significantly reduced all-cause mortality in 
patients with HF compared to placebo.41 In patients with very symptomatic HF (NYHA III/IV), 
addition of an aldosterone antagonist, apart from improving symptoms, has also been shown to 
reduce hospitalisation and reduce mortality by almost 30%.56  Important trials of pharmacological 
agents in HF are presented in table 1.4.  
To aid in the diagnosis and assessment of HF and to guide decision making, measurement of 
biomarkers is often used. BNP (or NT-pro-BNP), as mentioned in section 1.1.2, has been an 
established biomarker in clinical HF practice for some time. BNP has been shown, not only to aid in 
the diagnosis of HF, but also to be an independent predictor of prognosis.57 Higher BNP levels are 
associated with adverse outcomes. Furthermore, recent trials have shown that serial measurement 
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of BNP aids in managing patients and that BNP-guided therapy is superior to clinical assessment 
guided therapy alone.58 Trials have shown reduction in BNP levels in patients on the RAS antagonist 
Valsartan in the Val-Heft study 59 and after biventricular pacing. 60 Furthermore, BNP reduction has 
been noted in association with reverse LV remodelling in HF patients. BNP (or NT pro-BNP) can be 
measured using commercially available assays. The cut-off for BNP and NT pro-BNP are different 
for the diagnosis of HF. A serum BNP level <100pg/ml or a NT pro-BNP level of <400pg/ml strongly 
suggests a diagnosis other than HF. The half- life of BNP is approximately 20 minutes while the half-
life of NT pro-BP is around 2 hours. Hence, BNP has to be processed reasonably quickly after 
collection compared to NT pro-BNP.   Serial BNP (or NT pro-BNP) levels measured in trials or clinical 
practice must be interpreted with caution. As much as 25% variability in measured values from one 
visit to another can be physiological. 61 
Selected patients with systolic LV impairment can be considered for device therapy. Around 50% of 
deaths in patients with systolic HF occur secondary to arrhythmias.62 In patients who have an LVEF 
≤35%, are symptomatic (NYHA II or III) despite optimal medical therapy and have a life expectancy 
of more than a year, implantation of an ICD (implantable cardioverter defibrillator) is 
recommended as primary prevention. Cardiac resynchronisation therapy (CRT), which involves 
implantation of a biventricular pacemaker with (CRT-D) or without (CRT-P) a defibrillator function, 
has been shown to improve symptoms, reduce hospitalisation with HF and prolong survival in 
patients with advanced HF. In the COMPANION trial, both CRT-P and CRT-D reduced all-cause 
mortality in patients with advanced HF by 24% and 36% respectively when compared to optimal 
pharmacotherapy alone. 63 In the MADIT-2 trial, implantation of an ICD in post MI patients with 
significant LV dysfunction (LVEF<30%) significantly reduced the risk of mortality in patients who 
received an ICD when compared to optimal medical therapy. 64 The aim of the CRT is to reduce the 
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interventricular dyssynchrony and thus optimise ventricular stroke volume.  In the CARE-HF trial, 
LVEF increased by 3.4% at 3 months in the CRT group compared to the no CRT group.65 In the 
MIRACLE-HF trial, CRT increased LVEF by 3.6% at 6 months compared to 0.4% in the no CRT group. 
66 However, almost 20% of patients fail to respond to cardiac resynchronisation. 67  
Surgical treatment options are limited. Cardiac transplant selection criteria are strict and the 
availability of donors low.  This has led to the use of left ventricular assist devices (LVAD’s) as both 
destination and bridge therapy to transplant. However, these devices are still not widely available 
and are very expensive.  Very recently, a new class of drug, known as neprilysin inhibitors, has 
shown promise in a phase III trial. The drug LCZ696 was compared against standard ACE inhibitor 
therapy with enalapril. LCZ696 was found to reduce both mortality and hospitalisation from heart 
failure compared to enalapril. 68 Gene therapy has also shown promise in preliminary trials. A key 
target for gene therapy has been SERCA2a (Sarcoendoplasmic reticulum calcium ATPase), a protein 
involved in calcium transport. SERCA2a levels and activity are reduced in advanced heart failure 
and leads to reduced systolic calcium release. In the phase I and II CUPID trials, (Calcium 
Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) adeno-
associated virus type 1 (AAV-1) vectors were used to deliver SERCA2a gene to patients with 
advanced heart failure via the intracoronary route with the aim of restoring SERCA2a levels in these 
patients. The trial demonstrated improvements in patient symptoms (NYHA and QOL 
questionnaire), LVEF, LVESV, BNP and functional parameters (6-min walk test and MVO2) at 6 
months.69 However, the advent of novel therapies in heart failure are slow in coming and the 
prognosis remains poor despite the current evidence based treatment of HF. 
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1.1.6 Prognosis 
 
Both LVEF and LV volumes have been linked closely to mortality and morbidity in patients with HF.  
The lower the LVEF, the higher is the risk of mortality. The DIG trial was a randomised clinical trial 
to investigate the effect of digoxin on mortality and hospitalisation in patients with heart failure.  In 
the DIG study, LVEF lower than 45% was associated with an almost linear increase in mortality risk 
across successive LVEF deciles (figure 1.2).70, 71 Apart from prognostic information, the assessment 
of these parameters aids in the management of these patients in terms of monitoring and decision 
making on device therapy for advanced HF patients (i.e. cardiac resynchronisation therapy). 
Although LVEF and volumes are both prognostic markers in HF patients, they do not always 
correlate with HF symptoms or exercise capacity.72   
Treatment for HF in developed countries is mostly based on existing European Society of 
Cardiology, American Heart Association or national guidelines. These guidelines are based on 
extensive evidence from numerous trials, as highlighted in section 1.1.5. Several classes of drugs, 
most notably ACEi and beta-blockers, as well as cardiac resynchronization therapy and ICD 
implantation have shown mortality benefit. However, the epidemiological perspective suggests 
these treatments have only had a modest effect on HF prognosis. 
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Figure 1.2. Survival and LVEF. Survival curves from the DIG trial showing the relationship between 
baseline left ventricular ejection fraction (LVEF) and survival. (From Curtis JP, Sokol SI, Wang Y, et 
al. Journal of the American College of Cardiology 71) 
 
  Although ACEi have shown significant reductions in the relative risk of mortality, the absolute risk 
reduction has been small, as highlighted in the paper by V L Roger.73 In the study by MacIntyre et 
al. from Scotland, where they looked at event rates in more than 65000 patients with a primary 
diagnosis of HF, they noted an improvement in median survival from 1.2 to 1.6 years.74 However, 
VL Roger notes, that this rise is modest and that, although statistically significant, considering the 
large sample size, the improvements are not clinically significant. This fact is reiterated by the 
authors of the study, who in the conclusion of the paper, write “…….there is still much room for 
improvement”.  This is reflected by the fact that the current prognosis for patients who are 
admitted to hospital with HF remains very poor. Almost all other fields in cardiology, apart from HF, 
have seen dramatic improvements in prognosis. Yet, only half the patients with HF survive at 5 
years and the 10 year survival is only 10%. 74, 75 The increasing prevalence of HF poses a significant 
burden to patients, practitioners, and healthcare systems and highlights the clear need for 
alternative therapies.  
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Table 1.4. Landmark trials forming the basis for current medical therapy in heart failure (adapted from 
McMurray J, Pfeffer M. Heart failure 62) RR-Relative risk 
Trial N Severity of HF Drug Primary 
endpoint 
Primary outcome 
 
ACE inhibitors      
CONSENSUS 253 End-stage Enalapril 20mg BD Death 40%  RR reduction 
SOLVD-T 2569 Mild-severe Enalapril 10 BD Death 16% RR  
Reduction 
Beta-blockers      
CIBIS-2 2647 Mod-severe Bisoprolol 10mg 
OD 
Death 34%  RR  
reduction 
COPERNICUS 2289 Severe Carvedilol 25mg BD 
 
Death 35% RR  
reduction 
MERIT-HF 3991 Mild-severe Metoprolol XL/CR 
200mg OD 
Death 34% RR  
Reduction 
Angiotensin 
receptor blockers 
     
Val-HeFT  5001 Mild-severe Valsartan 160mg 
BD 
Death or morbidity 13% RR  
Reduction 
CHARM-alternative 2028 Mild-severe Candesartan 
32mg OD 
Cardiovascular 
death or HF 
hospitalisation 
23% RR  
Reduction 
CHARM-added 2548 Mod-severe Candesartan 
32mg OD 
Cardiovascular 
death or HF 
hospitalisation 
15% RR  
Reduction 
Aldosterone 
antagonists 
     
RALES  Severe Spironolactone 25-
50mg OD 
Death 30% RR  
Reduction  
EMPHASIS-HF 2737 Mild-mod Eplerenone (up to 
50mg OD) 
Cardiovascular 
death or HF 
hospitalisation 
HR 0.69 (18.3% in 
eplerenone group v 
25.9% in placebo) 
Digitalis      
DIG 6800 Mild-severe Digoxin Death No effect 
Cardiac 
resynchronisation 
therapy (CRT-P) 
     
COMPANION 925 Mod-severe CRT-P Death or any 
hospital admission 
19% RR  
Reduction 
CARE-HF 813 Mod-severe CRT-P Death or any 
cardiovascular 
hospital admission 
37% RR  
Reduction 
Cardiac 
resynchronisation 
therapy plus 
defibrillator (CRT-
D) 
     
COMPANION 903 Mod-severe CRT-D Death or any 
hospital admission 
20% RR  
Reduction 
 
Implantable 
cardioverter 
defibrillator (ICD) 
     
SCD-HeFT 1676 Mild-severe ICD Death 23% RR  
Reduction 
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1.2 Regenerative medicine 
 
1.2.1 Introduction 
 
Despite the enormous improvements in cardiovascular therapy, the morbidity and mortality from 
heart failure remains significant resulting in a need for additional, novel therapeutic approaches. 
Stem cells as a form of regenerative medicine have emerged as a potential solution to the problem. 
Cardiac regenerative medicine came to the forefront of medical research more than a decade ago 
with the goal of regenerating cells in the damaged heart. However the concept of organ 
regeneration existed long before the term regenerative medicine was coined. Back in the 8th 
century BC, Greek mythology described the story of Prometheus. Legend has it that the Titan God 
Prometheus offended Zeus by stealing fire from Mount Olympus for the benefit of mankind.76 As 
punishment, he was banished to the Carpathian Mountains and chained to a rock to be tortured by 
the eagle Ethos. Despite Ethos pecking away part of his liver every night, Prometheus’ liver would 
regenerate everyday only to be pecked on the next night. Hence, the Greeks named the liver from 
the word “hepanomai” meaning to “repair oneself”.  
1.2.2 Stem cells 
 
Stem cells are cells that possess the unique ability to divide into multiple different cell types. These 
cells are present in the human embryo-human embryonic stem cells- and are the cells that give rise 
to all the cell types and resultant organs that form the complete organism. The adult human also 
has a reservoir of stem cells- non-embryonic or adult stem cells- in various locations in the body 
e.g. bone marrow, adipose tissue, umbilical cord, gut and heart. In tissues, such as the gut and liver, 
these cells repair and replace damaged tissue on a regular basis. In the heart, these cells do exist, 
and are the focus of much research into their role in cardiac repair. The key feature of stem cells is 
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that they are undifferentiated cells. The cells resulting from the proliferation of stem cells can 
either differentiate and commit themselves to a certain cell lineage or form new stem cells.   The 
words “stem” and “progenitor” cells are sometimes, inappropriately, used interchangeably. The 
definitions of stem and progenitor cells are as follows: stem cells are characterised by their ability 
to divide indefinitely and into multiple, mature cell types. This ability of stem cells to divide into 
multiple, mature cell types is defined by varying degrees of potency-multipotence, pluripotence, 
totipotence- compared to progenitor cells which are characterised by their lack of ability to divide 
indefinitely and are usually unipotent.77  Table 1.5 shows the definition of the levels of potency. 
The adult bone marrow is composed of a mix of stem and progenitor cells i.e. pluripotent and 
multipotent cells as well as more mature, differentiated cells and has been the most widely used 
source of stem cells in cardiac research.  
 
Table 1.5. Levels of cell potency and definitions  
Totipotent Able to form all differentiated cells in the organism 
and trophoblastic cells of the placenta 
Pluripotent Able to form cells from all three germ layers but not the placenta or 
supporting structures 
Multipotent Able to form multiple but limited cell types  
Unipotent Able to differentiate into only one cell type 
  
1.2.3 The concept of cardiac regeneration 
For a long time, the adult human heart has been considered a post-mitotic organ. As mentioned in 
section 1.1.2, an AMI can result in the loss of a billion cardiomyocytes and the human heart lacks 
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the ability to regenerate cells to the degree required to replace such a large number of damaged 
cells. The subsequent replacement of the injured tissue by scar results in impairment of cardiac 
function and results in HF. The target of regenerative practitioners is to deliver stem and progenitor 
cells to the affected area, which would proliferate into mature cardiomyocytes and electrically 
couple with the host cardiomyocytes to replace the scar tissue with functional cardiac tissue. This 
in turn would improve cardiac function. Studies back in the 1970’s by Rumyantsev and others in 
lower vertebrates, e.g. amphibians, suggested that the heart had regenerative capacity. 78 The 
zebrafish, a lower vertebrate, has been a popular animal model of cardiac regenerative studies. 
More than a decade ago, Poss et al. demonstrated that resection of 20% of the adult zebrafish 
heart resulted in replacement of the excised tissue by new cardiac muscle within a few weeks. 79 To 
mimic cardiac ischaemic injury rather than direct physical injury through excision, groups have used 
cryoinjury to create areas of myocardial necrosis in zebrafish models. Again, replacement with new 
cardiac muscle was evident. 80 However, unlike the zebrafish, the mammalian heart does not have 
the ability for such large scale cardiac regeneration although the initial concept that the adult 
human heart is totally post-mitotic has been challenged. In a study by Bergmann et al., they used 
14C carbon dating in individuals exposed to nuclear bomb tests during the Cold War to calculate the 
age of cardiomyocytes and found that cardiomyocytes renew over the course of an individual’s 
lifetime. The turnover decreases gradually with age with a 1% turnover annually at age 25 and 
0.45% at age 75.81 Other evidence for cardiac regeneration comes from chimerism studies where 
post-mortem examination of cardiac tissue from male patients who had received heart transplants 
from female donors showed evidence of Y-chromosome positive cardiomyocytes suggesting 
cardiac regeneration or some form of integration with the recipient tissue. 82 Although the above 
demonstrate that there is some regenerative capacity in the adult heart, this is by no means on a 
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scale that would be therapeutically meaningful. However, a key goal of regenerative medicine is to 
try and revive this innate regenerative property. Furthermore, improvements in cardiac function 
have been observed in clinical trials using cell therapy but without clear evidence of myocardial 
regeneration. This has led to the key goal of “regenerative” medicine moving from achieving 
myocardial regeneration to myocardial repair instead. 
1.2.4 Introduction to cell types  
 
Several clinical trials have looked at stem and progenitor cell therapy in both acute MI and chronic 
ischaemic cardiomyopathy. So what are the attributes of the ideal cell type?  The ideal cell type 
would have to be: 
• Safe 
• Improve cardiac function and hence symptoms/prognosis 
• Able to create new, functional cardiac tissue which integrates well with host tissue 
• No immunogenicity 
• Easy to deliver 
• “Off the shelf” availability of allogeneic products 
• No socio-ethical problems 
• Ease of availability 
 
Prime among the above attributes are safety, ease of availability and lack of immunogenicity.  
 
To date, several different cell types and sources have been identified and used in pre-clinical and 
clinical trials.  Human stem cell sources can be broadly divided into three different categories: a) 
embryonic/foetal derived stem cells, b) adult or non-embryonic stem cells and c) adult somatic cells 
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which have been transformed into stem cells (induced pluripotent stem cells-iPSC). Autologous 
bone marrow cells (BMC) have been the most widely used in clinical trials due to the extensive 
experience of using these cells in haematology and the ease of availability and will be discussed in 
detail in section 1.2.5. Other cell types used in cardiac research are the following:  
a) Embryonic stem cell 
 
Theoretically, this is the most attractive cell type in view of its pluripotent nature. Embryonic stem 
cells (ESC) are obtained from the inner layer of the blastocyst stage of the human embryo. Human 
ESC lines were first described by Thomson et al.83  In preclinical studies, ESCs have been found to 
differentiate into cardiomyocytes which integrate into host tissue in small animal models. In the 
study by Caspi et al, they injected human ESCs to rat chronic myocardial infarction models and 
demonstrated an improvement in LV function. 84 However, the use of this cell type has been limited 
by the risk of tumorigenicity, the immunogenicity due to their allogeneic nature and the ethical 
concerns in using cells from human embryos. Tumorigenicity was demonstrated at high ESC doses 
in animal models in a study by Behfar et al.85 Therefore, clinical trials using ESC in cardiac research 
are still some way off.  Recently, Murry et al. in Nature describe a study where they delivered 1x109   
cryopreserved, human embryonic derived cardiomyocytes (hESC-CM) intramyocardially to monkeys 
that had been artificially induced to undergo myocardial infarction and subsequent reperfusion.86 
They report good engraftment of the cells into the native myocardium with good contractile 
activity and perfusion of the grafts by native vasculature. On the downside, all the hESC-CM 
monkeys had arrhythmias. This large scale delivery of hESC-CM into a large animal model renews 
the concept that hESC’s might be a realistic prospect in human cardiac regenerative trials in the 
future although the risk of teratoma formation and arrhythmias remain major obstacles.  
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b) Adult stem cells 
 
1. Skeletal myoblasts  
 
Skeletal myoblasts (SM) are progenitor cells that regenerate into myotubes and striated muscle 
fibres. These multipotent cells were attractive candidates for cardiac regeneration in view of the 
ease of availability from muscle biopsies, their contractile nature, their resistance to hypoxic 
conditions and their rapid expansion in vitro. Preclinical studies in small and large animal models 
were quite encouraging with several studies reporting improvements in LVEF and reverse 
remodelling.87-89  
However, of note, in experimental studies, skeletal myoblasts implanted into the myocardium 
differentiated into skeletal i.e. striated muscle fibres rather than cardiomyocytes90. It appears that 
the newly formed myotubes fail to integrate electromechanically with the host cardiomyocytes as a 
result of failure of expression of key gap junction proteins, like connexion-43 or N-cadherin. This 
creates “islands of conduction block” which appear to provide a substrate for the arrhythmias.   In a 
study by Roell et al. published in Nature, SM from transgenic mice which were overexpressing 
connexin-43 showed a reduction in the incidence of ventricular tachycardia when compared to 
normal SM.91 
In 2001, SM became the first cell type to be used in stem cell clinical trials in cardiac research by 
Menasche et al. in a small, non-randomised, uncontrolled study. However, SM have been limited in 
their use in clinical trials due to the risk of potentially fatal arrhythmias.  In the phase II, 
randomised-controlled MAGIC trial, SM showed no improvement in LVEF compared to controls, 
with a higher incidence of ventricular arrhythmias in the cell treated group.92 Similarly, in the 
SEISMIC phase II, open-labelled, randomised trial, SM injected intramyocardially in patients with HF 
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showed no improvement in LVEF at 6 months.93 The prematurely terminated MARVEL-1 trial 
suggested improvements in the 6 minute walk test (6MWT) at 6 months in cell treated patients. 
However, ventricular tachycardia was more frequent in this group.94 Given the adverse effects 
observed with SM, likely a result of the lack of integration of these cells with the host tissue, in a 
population already at a higher risk of significant arrhythmias, the future of this cell type in HF 
patients is questionable.   
2. Mesenchymal stem cells 
 
Mesenchymal stem cells (MSC) are available from a wide range of tissues. Their most abundant 
source is the bone marrow. Other sources of MSC’s include adipose tissue, umbilical cord and 
peripheral blood.  These multipotent stem cells have the ability to commit themselves down 
mesodermal (chondrocytes, adipocytes and osteoblasts) and non-mesodermal lineages. These non-
haematopoietic cells are defined in vitro by their ability to adhere to plastic surfaces (“plastic 
adherence”). There are no specific cell surface markers for MSC’s although they are usually 
accepted to express CD105, CD90 and CD 73 and are negative for haematopoietic markers CD34, 
CD45 and CD14. In large and small animal models, MSC’s have been shown to exert a beneficial 
effect on cardiac function including improvement in LV ejection fraction, reduction in infarct size, 
neoangiogenesis and reduction in mortality. 95    Convincing evidence for transdifferentiation into 
cardiomyocytes on a scale sufficient to explain these improvements is lacking.96 MSC’s have 
properties which make them attractive candidates in cell therapy. They lack human leukocyte 
antigen (HLA) class II molecules and thus, do not induce immunogenic reactions and hence are 
attractive from a safety perspective. Furthermore, this lack of immunogenicity makes them 
attractive as allogeneic cell products. The main sources of MSCs used in cardiac regenerative 
medicine are discussed below. 
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Bone marrow derived mesenchymal stem cells 
 
In the bone marrow, mesenchymal stem cells (MSC) reside in the bone marrow stroma. They were 
first described by Friedenstein et al. in the 1970’s. 97 MSCs only make up 0.001% to 0.01% of the 
mononuclear cell fraction. Makino et al. were the first group to show differentiation of BM derived 
MSC into cardiomyocytes in vitro using mice cells98 followed by the demonstration of 
differentiation of MSC into cardiomyocytes in vivo by Toma et al.99 However, a number of the 
experiments used genetic manipulation to induce transdifferentiation into cardiomyocytes-like 
cells. In Makino’s study, epigenetic modulation with DNA methylation was used. Although, 
experimentally successful, this approach is not clinically practicable. Whether unmodulated MSCs 
differentiate into functional cardiomyocytes in vitro is controversial but animal studies have shown 
that MSCs do differentiate into vascular smooth muscle cells and endothelial cells and do improve 
cardiac function. Thus, it appears that the beneficial effect is likely mediated by mechanisms, other 
than direct cardiomyocytes differentiation, including proangiogenic differentiation and secretion of 
paracrine factors, which prolong cell survival, homing and angiogenesis amongst other functions 
and also possibly by stimulating and mobilising resident cardiac stem cells from their intracardiac 
niches (see under “Mechanism of action”-section 1.2.9).  Clinical trials using bone marrow derived 
MSCs are discussed together in the section on trials using bone marrow derived cells (section 
1.2.5). 
Adipose tissue derived mesenchymal stem cells 
 
 Adipose tissue is abundant. With increasing liposuction and the low immunogenicity of adipose 
derived stem cells, these cells are also a potential, attractive allogeneic product.  Adipose derived 
cells have been given various names including adipose derived stromal cells (ADSC), adipose 
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derived adult stem cells (ADAS) and adipose derived mesenchymal stem cells (AdMSC) to name a 
few. The current consensus is to call these cells adipose derived stem cells (ASC) to avoid confusion. 
These cells are multipotent, plastic-adherent stem cells, very similar to bone marrow derived 
MSC’s. Whether these cells are actually MSC’s derived from adipose tissue or cells which are just 
MSC-like cells remains unclear. In one study, ASC and MSC when compared were 
immunophenotypically >90% identical.100 However, there were some differences e.g. CD106 
expression on MSC but absence on ASC.  Although whether or not ASC are the same as MSC’s is still 
unclear, what is clear is that adipose tissue contains a potential, widely available source of stem 
cells. In fact, adipose tissue is reported to contain more than 2000 times the number of MSC-like 
cells compared to fresh bone-marrow, thus minimising the time needed to culture expand these 
cells as is necessary when using BM-derived MSCs.   In animal studies, ASC transplantation has 
been shown to improve cardiac function, reduce infarct size and myocardial fibrosis in post-MI 
models. 101, 102 In the study by Wang et al, ASC were injected intramyocardially into the peri-infarct 
zone in female Lewis rat hearts 1 week after an MI. Using cardiac MRI at 1 week and 4 weeks after 
the cell transplantation and immunofluorescence studies, the group showed a significant 
improvement in LVEF and as well as an increase in capillary density in the peri-infarct area. 
However, there was no evidence of differentiation into cardiomyocytes on a scale that would be 
sufficient to explain the improvements seen.102 In the preliminary results of the PRECISE 
(Randomised Clinical Trial of Adipose-Derived Stem Cells in Treatment of Non Revascularisable 
Ischaemic Myocardium) double-blind, placebo-controlled  trial in patients with chronic HF and no 
revascularisation options, a reduction in infarct size at 6 months and improvement in functional 
outcomes as demonstrated by an increase in MVO2 and metabolic equivalents at 18 months in the 
treatment group were seen.103  However, LVEF deteriorated in the treatment arm at 6 months 
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compared to control (45 versus 48%). These mixed findings highlight the need for larger trials using 
ASC to clarify the potential role of ASC’s in the treatment of patients with ischaemic 
cardiomyopathy.  A slightly larger, phase II, randomised, placebo-controlled trial using 
intramyocardial injection of ASC in patients with chronic ischaemic cardiomyopathy is underway in 
the USA (ATHENA trial; NCT 01556022) 
Umbilical cord derived mesenchymal stem cells 
 
 The umbilical cord (UC) is a rich source of almost all the stem cells found in the bone marrow. 
These include CD34+ cells as well as mesenchymal stem cells (UC-MSCs). The advantage of using UC 
is that it is a waste product after baby delivery and so does not pose ethical concerns. Another 
potential advantage is that these cells could be stored for future use and serve as an autologous 
storage bank of cells for the individual. However, the disadvantage is that they can only be 
obtained from delivering mothers which restricts their source.  UC-MSCs possess the same qualities 
as their BM-MSC counterparts in that they are multipotent, have immunomodulatory properties 
and can be expanded ex vivo. UC-MSCs can be obtained from the whole UC, umbilical vessels, the 
umbilical lining or the periumbilical vessels.104 Animal studies with cord blood cells have shown 
promising results. In mice models of artificially induced MI, there was evidence of increased 
angiogenesis in the peri-infarct area after receiving UC-MSC’s. 105  A few clinical trials are underway 
or planned using UC-MSC in HF. One of the planned studies is in China where the investigators plan 
to inject UC-MSC intramyocardially into patients with ischaemic cardiomyopathy (LVEF <45%) 
(NCT01946048). Their primary endpoint is change in LVEF as measured using echocardiography.  
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3. Cardiac stem cells 
 
The concept of the heart as a post-mitotic organ has been modified as discussed above. It has 
increasingly come to the attention of the scientific community that there exists a heterogenous 
population of resident cardiac stem cells (CSC). These are multipotent and can give rise to 
cardiomyocytes, smooth muscle and endothelial cells.106  CSCs include c-kit+ (c-kit is a receptor 
tyrosine kinase for the cytokine stem cell factor, which is involved in haematopoiesis) stem cells, 
cardiosphere-derived cardiac stem cells (CDC), Sca-1 (a murine stem cell marker) cells, side 
population cells and islet-1+ cells. Beltrami et al. in 2003 identified resident c-kit+ cells in rat hearts. 
107 In 2007, Anversa’s group identified c-kit+ cells from the human heart. 108  CDC’s are cardiac cells 
which when isolated and grown in culture form spherical clusters, which Messina et al. labelled 
cardiospheres after identifying these cells in 2004. 106 The problem with the original cardiospheres 
were that there were concerns the cell clusters were too large to safely infuse through the 
intracoronary route. Marban et al. subsequently refined the process of CDC isolation and expansion 
so that not only were the cells more compact and thus safely deliverable via the intracoronary 
route but also could be harvested from percutaneous endomyocardial biopsies, thus obviating the 
need for surgical procedures. Furthermore, the whole process of isolation to expansion takes 4-6 
weeks which is not a considerable length of time considering the chronicity of the patients’ 
condition. The two most relevant cell populations to human studies are the c-kit+ and CDC 
populations as there is most clinical data on these cell types.  CSC are present in a very low 
frequency in the adult heart at ~1 per 10000 cardiomyocytes. 107 However, the advantage of CSC is 
that they can be isolated from cardiac tissue and then expanded ex vivo before being transplanted 
back into the patient. In several animal studies, using small and large animal models and models of 
acute and chronic ischaemia, CSC’s have been shown to have a range of beneficial effects including 
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improvement in cardiac function, reduction in fibrosis, reduction in infarct size and reverse 
remodelling.109-111 In a chronic ischaemic cardiomyopathy animal model, c-kit+ cells were infused 
using the intracoronary route  to pigs 90 days post-MI and were found to have improved LVEF, 
reverse remodelling and evidence of neoangiogenesis. 112 Marban et al. also did a head-to-head 
study using CDC, bone marrow mononuclear cells, BM-MSC and ASC in a post-MI animal model and 
demonstrated superiority of CDC over the other cell types in terms of improvement in cardiac 
function and reverse remodelling.113  
Clinical trials, so far, have been encouraging. The SCIPIO trial, a phase I trial, used CSCs in ischaemic 
cardiomyopathy patients undergoing coronary artery bypass graft surgery (CABG). 114 Apart from 
confirming CSC therapy safety and feasibility, the interim CMR results of the trial showed a 
significant increase in LVEF (27.5±1.6% to 41.2±4.5%; p=0.013) and reduction in infarct size (-
9.8±3.5g, p=0.039) at 12 months. The authors also noted improvements in regional contractility. 
Interestingly, the functional improvement was greatest in segments with the most myocardial 
dysfunction. Also noted was an increase in viable muscle mass, indirectly suggesting muscle 
regeneration.  However, there has been significant criticism with the way the data was handled and 
some of the claims could be exaggerated. The publication is under review by the research conduct 
standards authority at Harvard.115 In the proof-of-concept, CADUCEUS trial, CSC were administered 
via intracoronary route to patients with a recent MI. Although no improvement in LVEF was noted, 
a significant reduction in scar size, increase in tissue viability and regional contractility were 
observed.116 This trial has shown safety and feasibility and forms the basis of future trials using this 
cell type.  
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4. Epicardial stem cells 
 
The embryonic epicardium contains epithelial cells, which have been shown to contribute to the 
development of the coronary vasculature and myocardium.  For this to happen, the epicardial 
derived stem cells (EPDC) change from epithelial cells to mesenchymal-like cells, the “epithelial-to-
mesenchymal transition”, and then migrate to the subepicardial layers to contribute in cardiac 
development. However, over the course of embryonic development, this tissue generative capacity 
declines and by the time to adulthood, the “stemness” of the cells becomes dormant. However, 
some groups have suggested that it might be chemically possible to reactivate the stemness in 
these cells to regenerate adult cardiac tissue. One such chemical messenger implicated in this 
process is thymosin β4 (Tβ4). Tβ4 is an actin monomer-binding protein that can “re-awaken” these 
dormant EPDC’s from the adult epicardium117. Exactly how it does this is not clear.  In experimental 
animal studies, injection of human EPDCs into mice post-MI hearts showed improvement in cardiac 
function.118 
c) Adult somatic cells 
 
 Induced pluripotent stem cells 
 
 Takahashi and Yamanaka, in 2006, transduced mouse fibroblasts with four different transcription 
factors- Oct3/4, Sox2, c-Myc, and Klf4, to yield  pluripotent stem cells as a result of reprogramming 
“stemness” into the cells. These cells were similar to mouse ESCs. A year later, the same group 
transformed human adult somatic cells into pluripotent stem cells by transducing human dermal 
fibroblasts with the same four transcription factors using retroviral vectors. These transformed 
somatic cells, termed induced pluripotent stem cells (iPSC), do not have the same ethical issues as 
ESCs. Differentiation of iPSCs into functioning and morphological cardiomyocytes, as well as direct 
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programming of somatic cells into cardiomyocytes bypassing the pluripotent stage, has been 
demonstrated using animal and human cells.119-121 Of particular relevance to the HF population, 
Zwi- Dantsis et al. have derived cardiomyocytes from human iPSCs isolated from HF patients.122 
However, iPSC development has several hurdles to overcome. A potential concern with iPSC is their 
low and inefficient reprogramming efficiency. The genome stability of iPSCs is low and thus poses 
the risk of tumorigenicity. Human studies are, therefore, some way from starting. Table 1.6 below 
shows the advantages and disadvantages of the various autologous cell types. 
Table 1.6. Cell types and their advantages and disadvantages. + Advantages - Disadvantages 
 ESC BMC MSC EPC SM CDC IPSC 
 
+ 
Pluripotent Ease of 
availability 
Excellent safety 
and feasibility 
profile 
Autologous 
(and allogeneic 
trials ongoing) 
Low 
immunogenicity 
Widespread 
availability 
Multipotent 
Available from 
bone marrow and 
peripheral blood 
Pro-angiogenic 
Resistant to 
ischaemic stress 
Autologous i.e. no 
immunogenicity 
Ease of availability 
 
Resident cardiac 
cells 
Low 
tumourigenicity 
Autologous 
Transdifferentiatio
n 
 
Pluripotent 
No ethical 
issues 
Autologous 
 
- 
Tumorigenicity 
Ethical hurdles 
Isolation 
Immunogenicity 
Transdifferentiati-
on debatable 
Unclear which cell 
subset beneficial 
Bone marrow 
aspiration 
uncomfortable 
 
Difficult to isolate 
as low yield 
Need to expand in 
vitro 
Heterogeneity 
Low 
transdifferentiatio
n capacity  
No myocardial 
transdifferentiatio
n 
Phenotypic 
definition unclear 
No 
transdifferentiatio
n or integration 
Arrhythmogenic 
potential 
Discouraging trial 
results 
Need biopsy to 
obtain cells 
Low yield 
Need lengthy 
preparation 
 
Low 
reprogram
ming rates 
Poor 
engraftment 
Tumourigen
icity 
 
1.2.5. Bone marrow derived cells (BMC) 
 
The bone marrow contains a heterogeneous mixture of stem, progenitor and mature cells. The 
stem and progenitor population make up a very small proportion of the unprocessed cellular 
component of the bone marrow. The principal stem and progenitor cell components are 
haematopoietic stem cells (HSC), mesenchymal stem cells (MSC) and endothelial progenitor cells 
(EPCs)-henceforth, collectively referred to as bone marrow derived cells (BMC). BMC have been by 
far the most widely used stem cells in the field of cardiac regenerative medicine. The main reasons 
for this widespread use include ease of availability, high yield of cells thus not necessitating in vitro 
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expansion and the extensive experience of using these cells in haematology and haemato-
oncology. However, a downside of using these cells is the invasive and “uncomfortable” nature of 
bone marrow aspiration to obtain the cells. The procedure is, however, safe. In a retrospective 
study by Bain et al. looking at bone marrow biopsy complications over a 7-year period, they found a 
0.05% incidence of adverse events out of almost 55000 biopsies123. The key side effects reported 
were haemorrhage, needle breakage and infections. In another study, this time a prospective 
study, again by Bain et al, they found a 0.07% rate of adverse events over a 1 year period124. A 
common side effect from this procedure is bone pain which is usually transient. Despite these 
minor side effects, the majority of trials have used BMC. The stem and progenitor cells reside in a 
heterogeneous mixture of cells in the unfractionated bone marrow mononuclear cell component of 
the bone marrow. 
1.2.5.1 Unfractionated bone marrow mononuclear cells  
 
 The bone marrow mononuclear cells are a heterogeneous mixture of BMCs, characterised by the 
presence of unilobulated, mononuclear cells that lack granules in the cytoplasm. These cells are of 
similar density and morphology and can thus be separated out by means of density gradient 
centrifugation. The key  stem and progenitor cells of the bone marrow reside in this unfractionated 
bone marrow mononuclear fraction   However, the stem and progenitor cell population only make 
up a small fraction of the mononuclear cell population with mature, committed cells making up the 
remainder of the cells. The commonest way of separating out the mononuclear cell fraction 
involves, amongst other methods, adding Ficoll medium to the fresh bone marrow sample and 
centrifuging at room temperature to obtain the “buffy” layer (more details in methods chapter-
chapter 2).  
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The key bone marrow mononuclear stem cell populations includes haematopoietic stem cells, 
mesenchymal stem cells and endothelial progenitor cells. Other cell types include side population 
cells 125 and very small embryonic-like stem cells (in mice bone marrow). MSC’s have already been 
discussed in section 1.2.4. HSC and EPC make up only 2-4% of the mononuclear cell population in 
the bone marrow. 
The HSC’s give rise to haematopoietic lineages-both myeloid and lymphoid.  The identity and 
isolation of HSC’s has been the focus of much research. The HSCs are isolated by means of 
identifying a certain combination of cell surface proteins or “cell-surface markers” characteristic of 
HSCs. CD34+ is widely used as a marker of HSC. However, CD34 is not specific to HSCs and HSCs 
make up a small proportion of CD34+ cells. As the stem and progenitor cells mature into more 
committed, differentiated lineages, they tend to lose CD34 expression. To increase specificity of 
purification of HSC’s further, some additional cell surface markers have been identified. HSC’s do 
not express the Lin antigen on their cell surface, antigens which are present on mature cells. 
Furthermore, in humans, HSCs tend to express low levels of or no CD38 and CD45RA and higher 
levels (compared to differentiated cells) of CD90.  HSCs are not exquisitely found in the bone 
marrow but also in the circulation.  Peripheral blood HSC when injected into MI mice models 
showed transdifferentiation into cardiomyocytes. 126 However, whether human HSCs 
transdifferentiate into cardiomyocytes in real life, non-laboratory conditions is controversial with 
some groups showing evidence of transdifferentiation whereas other groups have failed to do so. 
126, 127 128  
 A subset of the haematopoietic stem cell progeny can differentiate into an endothelial phenotype 
ex vivo and these progenitor cells are termed endothelial progenitor cells. EPCs derived from bone 
marrow were first described by Asahara et al. in 1997,129 although there is still considerable debate 
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and controversy regarding the correct cellular definition of EPC identity.130 It is generally accepted 
that cells bearing the cell surface markers CD34+, CD133+ and the endothelial cell surface marker 
VEGFR2131 represent EPC’s. EPC in bone marrow are derived from HSC and induce re-
endothelialisation and neovascularisation by either directly differentiating into endothelial cells or 
by secreting paracrine pro-angiogenic factors. EPCs also circulate in the bloodstream (known as 
circulating endothelial progenitor cells-CEPC). The exact identity and origin of CEPC are also 
debated.130, 131 EPCs and HSCs are mobilised from the bone marrow to peripheral blood in response 
to cytokines such as granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony 
stimulating factor (GM-CSF)132 as well as hypoxic injury e.g. myocardial infarction or other forms of 
stress.133 Low CEPC levels have been correlated with the severity of ischaemic HF in a study by 
Berezin et al. 134 In pre-clinical studies, human EPCs, injected into mice models of hindlimb 
ischaemia,  showed significant improvement in blood supply and capillary density.135 Kawamoto et 
al. culture expanded human CEPC and injected them intravenously into rat MI models and showed 
the incorporation of these cells into areas of neovascularisation as well as preservation of LV 
function. 136  
1.2.5.4 The transition from pre-clinical to clinical trials using bone marrow-derived cells 
 
Preclinical studies using BMC have shown mixed results with some showing encouraging results.137, 
138 Tomita et al. showed an improvement in myocardial function and evidence of increased 
angiogenesis with intramyocardial injection of BMCs in rat models of chronic myocardial infarction. 
In 2001, Orlic et al., published the results of a “defining but controversial” point in the field of 
cardiac stem cell research.139 In their article in Nature, Orlic reported transdifferentiation of BMCs 
into neo-myocardium when injected into transgenic mice models of myocardial infarction. Within a 
few months of the publication of Orlic’s report, the first human study was underway. Very rarely in 
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medical science is a shift from bench to bedside seen so quickly and so prematurely. Ironically, a 
few other groups subsequently failed to reproduce the evidence of transdifferentiation into neo-
myocardium as had been demonstrated by Orlic et al.127 In the study by Murry et al, they injected 
haematopoietic stem cells into adult normal and injured mouse hearts and then used genetic 
techniques to track cardiomyocytes specific transgenes and found no evidence of 
transdifferentiation into cardiomyocytes.  In the clinical setting, fewer studies using BMCs or 
subsets have been undertaken in the chronic HF setting when compared to trials in acute 
myocardial infarction patients. The results have been mixed. The premature translation of 
preclinical studies to clinical research is probably partly to blame for the lack of clarification on a 
number of factors which introduce heterogeneity in trial design including route of delivery, dosing 
of cells, cell preparation techniques, superiority of cell type and cell functional characteristics. 
These are likely to have played a part in generating these mixed results. Clinical trials using BMCs 
are discussed in detail next.   
1.2.5.5 Clinical trials of BMC therapy in heart failure 
 
Encouraging results from preclinical trials of cell therapy in HF led to a rapid transition to clinical 
research. The vast majority of trials to date have been small scale, phase II trials using BMCs with 
the aim of testing safety and efficacy. The trials have not raised any significant safety concerns. 
However, the efficacy results have been mixed with some trials suggesting improvement in LVEF 
whereas others have failed to do demonstrate this.  
Perin et al., injected bone marrow mononuclear cells intramyocardially in 14 patients with chronic 
HF in a prospective, open-labelled, non-randomised study in 2003. They found a 9% improvement 
in LVEF, measured using echocardiography, in the cell treated group. 140 They also showed 
significant improvement in myocardial perfusion and functional capacity at 6 and 12 months 
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follow-up. 141 In 2005, Strauer et al, reported the results of the open-labelled, controlled IACT 
study, where they infused autologous, bone marrow mononuclear cells via the intracoronary route 
into 18 patients with ischaemic cardiomyopathy. They reported a 15% improvement in LVEF at 3 
months along with a 30% reduction in infarct size. 142 The same author reported the results of the 
STAR-HEART study in 2010, an open label, non-randomised trial, and showed a significant 
improvement in LVEF at 5 years in 191 patients with HF who had received intracoronary BMC. 143 
However, questions have been raised regarding the validity of this trial.144  Two of the more recent 
trials - FOCUS-HF and FOCUS-CCTRN, both from the US, have failed to show any benefit in HF 
patients treated with intramyocardial, autologous BMC therapy.145, 146 FOCUS-HF was a small 
single-blinded, placebo-controlled trial (n=30). The FOCUS-CCTRN trial was a larger (n=92), phase II, 
randomised, double blinded study. Both trials demonstrated no safety concerns. However, neither 
trial showed an improvement in the primary efficacy end-points {LVEF, MVO2 (peak oxygen 
consumption on cardiopulmonary exercise testing) in FOCUS-HF and left ventricular end systolic 
volume-LVESV index or reversible perfusion defect in FOCUS-CCTRN}.  In FOCUS-HF, although there 
was no improvement in the primary end-point, younger patients (≤60 years) were noted to have a 
higher BMC proliferative capacity and significant improvement in MVO2. Similarly, in the FOCUS-
CCTRN trial, the increase in LVEF was greater in patients with higher BMC counts. Both these trials 
suggest a mechanistic link between cell numbers and proliferative capacity and trial outcomes and 
emphasise the need for further studies.  
The TAC-HFT 147 study was a phase 1 and 2 randomised, blinded, placebo-controlled study looking 
at transendocardial injection of MSC or BMC as compared to placebo in a total of 65 patients with 
ischaemic cardiomyopathy. The study found no safety concerns. In both cell treated groups, the 
quality of life improved as assessed using Minnesota Living with HF questionnaire. Functional 
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improvements were noted in the MSC treated groups with significant improvement in the 6 minute 
walk test (6MWT) distance. However, no significant change in LVEF or LV volumes were detected.   
Preclinical and clinical trials with MSCs have been encouraging. The results of the first double-
blinded placebo controlled trial with transendocardially injected autologous MSC in HF (MSC HF 
trial) has been presented at the ACC scientific sessions.148 The trial showed a significant reduction 
in LVESV (-8.2±14.2ml) (the primary endpoint) and increase in LVEF (5.5±3.8%) in the cell treated 
group and there was functional improvement in the cell treated group, although a similar 
functional improvement was also noted in the placebo group.  This raises the question of how 
important these cardiac functional endpoint improvements are, if they do not translate to well-
defined improvements in patients’ clinical wellbeing. 
Other ongoing clinical trials include the randomised, phase I/II ASSURANCE trial looking at direct 
intramyocardial injection of BMC in patients undergoing left ventricular assist devices for severe 
heart failure (NCT00869024). 149 The REPEAT trial, led by Prof Zeiher and team from Frankfurt,  is a 
phase II/III trial investigating whether repeat IC or single IC autologous bone marrow mononuclear 
cells is more effective  in reducing mortality (NCT01693042).150 
Most trials to date have studied the effect of BMC therapy on systolic function and LV volumes as 
well as patients’ functional status but not on diastolic function. Yao et al. looked at the effect of 
intracoronary delivery of autologous BMC on systolic and diastolic function and found that BMC 
improved diastolic function but not systolic function.151 Further studies are necessary to study the 
effect of cell therapy on diastolic function.  
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1.2.6 Use of adjunctive therapy and allogeneic cells 
 
1.2.6.1 Adjunctive therapy 
 
Novel approaches are being used to “manipulate” cells before administration. In the C-CURE trial, 
autologous bone-marrow derived mesenchymal cells were exposed to a 'cardiopoietic cocktail' 
(exact ingredients unknown) that enhanced differentiation into cardiac progenitor cells which were 
then injected intramyocardially. It showed improved LVEF and LVESV as well as increased 6MWT 
distance.152 In another approach, extracorporeal cardiac shock wave was administered prior to 
BMC therapy in the CELLWAVE trial. They demonstrated a significant improvement in LVEF in the 
shockwave-treated BMC group compared to the group receiving shockwave and placebo infusion 
only.153 . Granulocyte colony stimulating factor (G-CSF) is a potent haematopoietic cytokine used as 
an adjunct as well as on it’s own in a few clinical trials to mobilise BMC from the bone marrow and 
is discussed in more detail in section 1.2.7. 
1.2.6.2 Allogeneic cells 
 
Allogeneic products are appealing for at least two reasons: the availability as “off the shelf” 
products thus obviating the need for invasive bone marrow aspiration in the patient as well as the 
possibility of using these cells when the autologous cells are found to be dysfunctional. It is known 
that in HF and with age, stem cell functional characteristics decline. 154 It is not clear how this 
decline relates to clinical potency for cardiac repair. The key concern regarding the use of 
allogeneic cells has been the risk of immunogenicity. In the phase 1/2 randomised, but not 
controlled, POSEIDON trial, which compared autologous and allogeneic mesenchymal stem cells, 
delivered transendocardially, in patients with ischaemic cardiomyopathy155, there were no findings 
suggestive of significant safety concerns. However, although the autologous group showed 
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improvements in some patient functional outcomes (quality of life questionnaires, 6 minute walk 
test) and the allogeneic group showed a reduction in LVEDV, no overall improvement in LVEF was 
seen. The trial demonstrated an inverse relationship between efficacy and number of cells injected 
as well as a reduction in scar size with cell therapy. However, more definitive phase III studies will 
be necessary before reaching a conclusion regarding efficacy. The ongoing ALLSTAR trial will look 
into allogeneic CSC transplantation (NCT01458405 clinicaltrials.gov).  
1.2.7 G-CSF in stem cell trials 
 
G-CSF is a potent cytokine known to mobilise haematopoietic cells as well as mesenchymal stem 
cells.156, 157 It is commonly used in daily haematological practice and this extensive experience from 
haematology suggests that it is safe to use in the vast majority of patients. The most commonly 
reported adverse effects from G-CSF administration include bone pain and headache. In a study by 
Anderlini et al, of 341 patients receiving G-CSF, 84% complained of bone pain, 54% of headache 
and 31% of fatigue.158 In animal studies, G-CSF has been shown to improve cardiac function and 
survival after myocardial infarction.159, 160 G-CSF mobilises HSC from the bone marrow by 
modulating the SDF-1/CXCR-4 axis. SDF-1 or stromal cell derived factor-1, a chemotactic 
chemokine, and CXCR-4, its receptor, appear to play a critical role in retaining HSC in the bone 
marrow.  The gradient between bone marrow SDF-1 and peripheral blood SDF-1 controls the 
retention of HSC in the bone marrow. Disruption of this gradient results in mobilisation of stem 
cells into the peripheral blood.  Administration of G-CSF results in the production of a proteolytic 
environment in the bone marrow with increased levels of metalloproteinase-9, neutrophil elastase 
and cathepsin G, which appear to degrade and disrupt the SDF-1/CXCR4 axis. 161  In the study by 
Fukuhara et al on mice, administration of G-CSF before and after artificially inducing an infarct, 
resulted in significant numbers of BMCs in the peri-infarct area compared to those mice that didn’t 
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receive G-CSF. Furthermore, some of these bone marrow derived cells were found to express 
markers suggesting differentiation into cardiomyocytes159. Other studies have suggested that G-CSF 
might have a direct effect on cardiomyocytes. In the study by Harada et al., published in Nature 
Medicine, they showed that G-CSF resulted in activation of anti-apoptotic signalling via the JAK-
STAT pathway and thus conferred a survival advantage on the cardiomyocytes.162  Human trials 
have looked at whether treatment with G-CSF, either by virtue of cell mobilisation or as a paracrine 
factor, leads to improvement in cardiac function, either alone or in combination with stem cell 
administration. However, most of these trials have been small and non-randomised, non- 
controlled and results have been mixed. 156, 157, 163-166 Some have suggested an associated 
improvement in LVEF 165 although most of the other studies have shown a lack of improvement in 
LVEF in both ischaemic cardiomyopathy  164 and in subjects with coronary artery disease.156, 157A 
few trials have raised concerns as to whether G-CSF increases the rate of in-stent restenosis in 
patients with previous PCI 167 although other subsequent trials have not borne this out. 168  Table 
1.8 lists cell therapy trials in HF, including trials that have used G-CSF as adjunctive therapy.  
1.2.8 Summary of cell therapy trials in HF 
 
The phase II trials of cell therapy have shown mixed signals of effect. The trials have, however, 
demonstrated that BMC therapy as well as cardiac stem cell therapy appear to be safe. There are 
several possible reasons for the lack of translation of the beneficial effects seen in preclinical 
models into clinical research (Table 1.7). The positive and negative signals of effect, bearing in mind 
the heterogeneity of methods and endpoints in the trials, paves the way, using the experience from 
these trials, for further phase II trials with modification of method/endpoints as well as, most 
importantly, phase III trials.  
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1.2.9 Mechanisms of action 
 
The proposed mechanism of action of stem and progenitor cells is unclear and remains a matter of 
significant debate. There are several postulated mechanisms and it is likely that they are not 
mutually exclusive (figure 1.3). They include 1. Transdifferentiation of stem and progenitor cells 
into cardiomyocytes 2. Transdifferentiation of stem and progenitor cells into blood vessels 3. Cell 
fusion and 4. Paracrine hypothesis. The original work by Orlic et al. suggested that the primary 
mechanism of action of cell therapy was transdifferentiation.139 However since then, numerous 
studies have demonstrated conflicting results with some animal studies supporting 
transdifferentiation 137, 169 yet others showing no evidence in favour of transdifferentiation. 127, 170  
It is now clear that transdifferentiation does not occur to the extent that would explain the 
observed improvements in cardiac function seen in clinical and pre-clinical work. Differentiation of 
stem and progenitor cells into endothelial phenotype cells has been demonstrated in previous 
studies. In the study by Wang et al., they injected human CD34+ cells in immunodeficient mice 
models of MI and noted differentiation of the CD34+ cells into human-derived endothelial 
phenotype cells171. In the study by Tillmanns et al, they demonstrated the formation of de novo 
coronary artery like structures after injection of cardiac progenitor cells into rat models of coronary 
occlusion.172 This latter point is particularly relevant, i.e. the presence of total coronary occlusion or 
flow limiting disease, as this mechanism of action is likely to be beneficial and important to patients 
with such disease. In patients without occlusive or flow limiting coronary disease, this mechanism is 
unlikely to explain the majority of benefit in cardiac function, although it is likely to be an important 
contributory element in the cardiac improvement.  The evidence for cell fusion between stem cells 
and endogenous cardiomyocytes comes from a few studies. 181-183 However, the observed level of 
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fusion was too low to adequately explain any improvement in cardiac function. This postulated 
mechanism of action has fallen out of favour.  
 
Table 1.7. Potential reasons why results of preclinical stem cell research fail to translate 
(Adapted from 173 Choudhury T, Mathur A. The birth of regenerative pharmacology. 2012) 
  
 Not enough cells injected in human trials compared to animal studies 
 Timing of cell injection – different time course of remodelling in animals 
compared to humans 
 Cell characteristics- difference in cell characteristics between animals and 
humans 
 Delivery method-concentration of cells at target lower in humans than in animals 
due to low retention 
 Animal heart failure models not very representative of human heart failure and 
hence dissimilar results 
 Low regenerative potential in cells from elderly patients and patients with heart 
failure  
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Table 1.8 Clinical trials using bone marrow derived cells in ischaemic cardiomyopathy. IC-intracoronary; IM-
intramyocardial; BMMNC-bone marrow mononuclear cells; CABG-coronary artery bypass graft surgery; MRI-magnetic resonance 
imaging ; SPECT-single photon emission computed tomography; QLV-quantitative left ventriculography; CPC-circulating endothelial 
progenitor cells 
TRIAL Cell type? G-
CSF 
Randomised Placebo-controlled Double 
blinded 
Route(s) Co-intervention Imaging 
modality 
Main outcomes 
Patel 2005
174
 CD34 No Yes No placebo control No Subepicardial 
injection 
CABG Echo, 
SPECT, 
angio 
Improved LVEF 
Hu 2011
175
 BMMNC No Yes Yes Yes IM CABG MRI Improved LVEF, LVESVI 
and WMSI 
FOCUS-HF
146
 BMMNC  No Yes Yes but placebo was 
mock injection 
procedure only 
No IM No Echo, 
SPECT 
No change in LVEF 
CCS and QoL improved 
FOCUS-CCTRN
145
 BMMNC No Yes yes Yes IM No Echo, 
SPECT 
No change in LVESV 
index, maximal oxygen 
consumption 
Pokushalov 2010
176
- BMMNC No Yes No-optimal medical 
therapy 
No IM No Echo, 
SPECT 
Improved LVEF, CCS 
and NYHA 
Zhao 2008
177
 BMMNC No Yes Yes ?No IM CABG Echo, 
SPECT 
Improved LVEF, CCS, 
perfusion 
Perin 2003
140
 BMMNC No No Yes No IM No Echo, 
SPECT 
LVEF up 
LVESV and LVEDV down 
Assmus 2006-
TOPCARE-CHD
178
 
BMMNC or 
CPC 
No Yes Control=no cell 
infusion; was a 
crossover study 
No IC No Echo, 
SPECT, 
MRI 
LVEF up and NYHA 
down (BMMNC only) 
Assmus 2012-
CELLWAVE
153
 
BMMNC No Yes Yes Yes-in 
second 
phase 
IC Shockwave QLV, MRI Improved LVEF 
Assmus 2012-
TOPCARE-G-CSF
164
 
CPC Yes Yes No No SC (G-CSF) /IC 
(cells) 
No QLV, MRI No significant effect on 
LVEF 
Gao 2006
179
 BMMNC No Yes No placebo infusion-
control group had 
standard medical 
care 
No IC No  Echo Improved LVEF; LVESV, 
BNP decreased 
Ang 
2008
180
 
BMMNC No Yes No-CABG only as 
control 
- IC (via graft) AND 
IM-directly into 
scar not peri-scar 
CABG DSE No change in LVEF, LV 
volumes or infarct size 
STAR-HEART
143
 BMMNC No No No No IC No SPECT, 
QLV 
Improved LVEF 
 
63 
 
The mechanism that has gained increasing support and is currently the most accepted is the 
paracrine hypothesis. Several studies have shown that administered stem cells secrete numerous 
cytokines, chemokines and   growth factors that can exert beneficial effects. These ‘paracrine’ 
effects include but are not limited to anti-apoptotic cell signalling, stimulation of cell homing and 
induction of neo-angiogenesis (table 1.9). Gnecchi et al demonstrated a reduction in apoptosis of 
ischaemic rat cardiomyocytes exposed to conditioned medium from MSC exposed to hypoxic 
stress.  The same group overexpressed Akt, a protein kinase that inhibits cellular apoptosis, in 
MSC’s and then administered conditioned medium from these cells to animal infarct models and 
demonstrated significant reduction in apoptosis and infarct size. 184, 185 MSCs have also been shown 
to exert a wide array of proangiogenic cytokines including VEGF (vascular endothelial growth 
factor) and bFGF (basic fibroblast growth factor).186 Work on bone marrow mononuclear cells has 
also suggested a paracrine mechanism. In the study by Kamihata et al using rat ischaemic models, 
they showed significant increase in the levels of proangiogenic cytokines after injection of bone 
marrow mononuclear cells into ischaemic myocardium.187 Takahashi et al. cultured rat bone 
marrow mononuclear cells and then analysed the supernatant culture medium. They found various 
cytokines including VEGF and IGF-1 (insulin like growth factor-1) in the supernatant. In vitro, this 
supernatant inhibited cardiomyocyte apoptosis and maintained cell contractility.  They then 
injected the supernatant into rat ischaemia models which resulted in increased angiogenesis, 
reduction in scar size and significant improvement in cardiac function.188 Other paracrine effects 
include stimulation of endogenous stem cells by paracrine mediators and modulation of the 
extracellular matrix. There is evidence that administered stem cells might work by stimulating and 
recruiting endogenous cardiac stem cells from their ‘niches’. The work by Hatzistergos et al. 
showed that MSC injected in swine models resulted in engrafted and well integrated MSCs, 
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endogenous CSC’s and adult cardiomyocytes on histological examination of the heart tissue.96 CSC 
and SM have been shown to have beneficial effects on the extracellular matrix by modulating levels 
of matrix metalloproteinases and their inhibitors, tissue inhibitor of metalloproteinase (TIMP), both 
important mediators of extracellular remodelling189, 190. To date, several factors have been 
identified as paracrine mediators of stem cell action (table 1.9).  
 
Figure 1.3. Mechanisms of action for cell therapy. Multiple mechanisms of action of stem and progenitor cells in cardiac 
repair have been postulated. The paracrine effect has gained most support. 
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Table 1.9. Paracrine effectors of stem and progenitor cells 
  
 1.2.10 Cell delivery methods 
 
Several cell delivery methods have been used in clinical trials so far. No direct comparison between 
all the delivery methods has yet been carried out in ischaemic cardiomyopathy patients although 
meta-analysis191 suggests that the intramyocardial (IM) route of delivery is superior in HF patients 
in terms of improvement in LV function. The various routes of cell delivery are discussed in the 
following section (figure 1.4). 
a) Transcatheter intramyocardial injection 
 
 The procedure involves administration of the cells via injection directly into the myocardium using 
a catheter based approach. There are several catheter systems in use, including the Helix, Myostar 
and Stilletto systems. The operator uses imaging (e.g. MRI guidance) or electromechanical mapping 
(EMM) guidance to detect areas of infarction and thus helps localise the target areas of injection in 
the peri-infarct area. The NOGA® electromechanical mapping system is commonly used for the 
purpose of EMM. It measures transmembrane voltage, a reflection of viability, and linear local 
shortening, a measure of contractility, to map out areas of infarction and viable tissue. The IM 
PARACRINE EFFECTS PARACRINE EFFECTORS 
Cell survival SDF-1, bFGF, HGF, VEGF, IGF-1, MCP-1, SFRP-2, IL-10 
Induction of neoangiogenesis VEGF, SDF-1, bFGF, IGF-1, MCP-1, HGF, IL-1β, Angiopoietin  
1 and 2  
Stimulation of cell homing/migration SDF-1, TNF-α, TIMP 1 and 2, MIP 1α, IGF-1 
Remodelling of extracellular matrix IL-10, thymosin β4, TIMP 1 and 2, HGF, MCP-1 
Cell differentiation VEGF, IGF-1, HGF, TNF-α 
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route has advantages including the option of directly injecting cells into the target area of 
myocardium. Furthermore, patients with chronic ischaemic heart disease may not have patent 
coronary arteries supplying the myocardial region of interest and hence, the IM route offers an 
alternative. The procedure does not require open surgical intervention. However, the procedure is 
not without its risks. Significant risks include myocardial perforation and significant, ventricular 
arrhythmias.  Furthermore, the retention of cells at the site of interest, although better than the 
intracoronary route, is still quite poor. Hou et al. looked at cell retention after cell administration 
via 3 different routes in swine ischaemic models and found that the IM route had the most 
retention at 11+/-3% when compared to intracoronary delivery where the retention was 2.6+/-
0.3%.192  
 
 
b) Intracoronary  injection 
 
 The intracoronary (IC) route has been the most widely used route in clinical trials for obvious 
reasons- it can be easily used by interventional cardiologists and does not require any extra 
training. Furthermore, the procedure can be done at the time of PCI and is safe to do after AMI. 
Another advantage of this route is that the cells are distributed more evenly over the area of 
interest. However, as mentioned above, the retention of cells is very low. The most commonly used 
method of IC infusion of cells involves transient occlusion of the artery.  A standard, 0.014” over-
the-wire balloon is used and the cell suspension/placebo infused distal to the occluding balloon 
using a stop-flow technique as previously described by Assmus et al. 193 The reasoning behind this 
technique is that transient occlusion of the artery proximal to the cells will maximise retention of 
the cells. The other approach is to infuse the cells while maintaining coronary flow.  Most of the 
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trials using IC delivery show that it is a safe procedure. In a recent retrospective study by Assmus et 
al., looking at 775 procedures involving IC cell administration using the stop-flow technique, they 
demonstrated that IC cell delivery posed no additional risk to that of a conventional angiogram.194 
However, the efficacy of this route in terms of improvement in cardiac function is not so clear. In a 
review article by Sheng et al, they looked at 30 studies since 2002 that used IC cell delivery and 
questioned the actual effect of IC cell delivery on cardiac function 195.  Furthermore, Dib et al. 
studied the viability of MSCs before and after passage through a standard, OTW balloon catheter. 
They noted that the inner lumen of the catheter partially collapses during balloon inflation. Cell 
viability was reduced at both low and high flow rates and with a range of inflation pressures 
suggesting that use of standard OTW balloon catheters might affect cell viability and thus efficacy 
outcome.196  
c) Surgical intramyocardial injection 
 
 In contrast to transcatheter IM injections, this involves a direct, surgical approach, necessitating 
open-heart surgery or lateral thoracotomies.  As a result, this route is more prone to significant 
complications associated with the invasive nature of the procedure as well as the risk of myocardial 
perforation and ventricular arrhythmias associated with IM injection. The advantage of this route is 
the direct visualisation and injection of cells into the peri-infarct area. However, as with other 
routes, the retention of cells is also a problem as cells have been shown to leak out of the injection 
site. In a study by Grossman et al., they injected 15 pigs via transcatheter IM approach as well as a 
direct, open-chest surgical approach and found a lower retention in the direct surgical approach 
pigs as compared to the transcatheter approach pigs (15% v 43%; p<0.01).197 The other 
disadvantage is that this route is usually reserved for patients who are due to undergo 
cardiothoracic surgery and not an ideal route across the spectrum of cardiac patients.  
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d) Venous approaches 
 
Intravenous: The intravenous route is obviously the least invasive route and one that can be used 
across centres as it requires minimal training. However, it has the distinct disadvantage of not 
delivering cells directly either into the myocardium or into the coronary circulation. As a result, the 
success of the procedure relies on the ability of the cells to home to the target of interest i.e., the 
heart. However, in chronic HF patients, the migratory capacity of the cells may be impaired as may 
the trophic signals from the heart and as a result this route of delivery is unlikely to be very 
successful in ischaemic cardiomyopathy patients.  In a pre-clinical study by Barbash et al, they 
found that intravenous delivery of bone marrow derived mesenchymal stem cells to post-MI rats 
had a significant reduction in cell delivery to the heart due to entrapment in the lungs198.  
 
Coronary sinus and coronary veins: Retrograde cell injection via the coronary sinus has also been 
used. This allows retrograde delivery of the cells where the coronary arteries of interest are 
occluded. However, in ischaemic cardiomyopathy patients, a significant number have biventricular 
pacemakers which involve passing a lead via the coronary sinus. Hence, in these patients, this route 
cannot be used. Furthermore, the success of the procedure is reliant on the venous anatomy and in 
patients with complex venous anatomy this can be a problem.   
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1.2.11 Meta-analyses of BMC therapy trials in HF 
 
To gauge some sort of conclusion regarding the efficacy of BMC therapy and the best route of cell 
delivery in heart failure, one has to look at meta-analyses. In a recent meta-analysis, by Fisher et 
al., of autologous BMC in chronic heart disease, a +5.95% mean difference in LVEF in the sub-set of 
patients with heart failure receiving cell therapy when compared to controls was observed. 
Furthermore, a +5.30% mean difference in the intramyocardial (IM) cell therapy group (which was 
statistically significant when compared to the 3.19% improvement in the intracoronary (IC) group) 
was noted, suggesting superiority of the IM route. The findings are also in agreement with three 
INTRACORONARY 
TRANSVENOUS-
intravenous or 
coronary sinus 
INTRAMYOCARDIAL
-percutaneous or 
surgical 
Figure 1.4. Routes of cell delivery. 
Figure showing the various routes of 
delivering stem and progenitor cells to the 
heart. 
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other  meta-analyses of cell therapy and heart failure: Kandala et al. (5.13% via IM route) 199, 
Jeevanantham et al. (3.96%; not route specific) 200  and Fisher et al. (3.47%; 8 of 9 trials via IM 
route).201 The evidence for using G-CSF as a pharmacological agent in HF comes from small, non-
randomised trials and has been mixed with most trials showing no improvement in LVEF as 
discussed above.  Thus the overall conclusion from meta-analyses is that cell therapy does improve 
cardiac function, albeit modestly, and that the intramyocardial route appears to be superior to the 
alternative available routes, although no direct trial evidence of this is available in ischaemic 
cardiomyopathy patients.  
1.2.12 Unanswered questions 
 
Firstly, the effects of G-CSF in ischaemic cardiomyopathy have been mixed with a number of 
studies showing no benefit of G-CSF, with some studies actually suggesting a possible deleterious 
effect with respect to LVEF and increased rate of restenosis in patients. However, the theoretical 
attraction of G-CSF, in terms of enhanced cell mobilisation and aid in cell homing, remains. This 
together with the positive results from pre-clinical studies, means that further research using this 
cytokine is imperative. Secondly, although G-CSF itself has been used in several trials as a solo 
“therapeutic” agent, the full benefit may require the delivery of autologous BMC to the heart to be 
seen. So far, no study has compared the effects of G-CSF alone and in combination with BMC in 
ischaemic cardiomyopathy patients. Thirdly, the optimal route of cell delivery is still unclear. As 
discussed in detail in section 1.2.10, the intracoronary and the intramyocardial routes have been 
the most widely used routes in clinical trials. However, to date, no single trial in ischaemic 
cardiomyopathy patients using autologous BMC has compared the intracoronary to the 
intramyocardial route. As discussed in section 1.2.5, to date, several trials have looked at the effect 
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of BMC on cardiac function but quite a few have lacked true placebo-control arms (table 1.7). There 
is therefore a need for a study assessing whether G-CSF administration alone or in combination 
with either the IC or targeted IM injection of autologous bone marrow derived cells (BMC) leads to 
an additional benefit on cardiac function compared to placebo controls. The vast majority of 
studies to date have concentrated on systolic cardiac function as the key outcome. However, there 
are few studies looking at the effect of G-CSF and cell therapy on diastolic function. The prevalence 
of heart failure with preserved ejection fraction is estimated to be up to 50% of the heart failure 
population.18 Thus, studying the effect of G-CSF and BMC on diastolic function would be highly 
relevant to heart failure therapy. There is also a paucity of studies looking at the effect of G-CSF 
and cell therapy on the levels of various cytokines involved in heart failure (discussed in section 
1.1.2.3) and their association with effects on cardiac function.  
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1.3 Hypothesis and aims  
 
The main aim of this thesis is to test the hypothesis that subcutaneous G-CSF alone, or in 
combination with autologous bone marrow derived stem cells, improves cardiac function in 
patients with ischaemic cardiomyopathy.   
 
Specific aims 
 
1. To determine whether G-CSF administration alone or in combination with bone marrow-
derived cells is safe and results in an improvement in left ventricular function in patients 
with ischaemic cardiomyopathy  
2. To determine the optimal route of delivery for therapy: specifically testing whether the 
intracoronary or the intramyocardial route is superior in terms of efficacy 
3. To assess the mechanisms by which improvements in LVEF and/or symptoms may have 
occurred specifically assessing cytokine levels, myocardial scar size and diastolic 
function.  
4. To assess the relationship between cell characteristics and change in LVEF e.g. numbers 
of cells delivered and CFU-GM colonies  
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Chapter 2 Methods 
 
2.1 THE REGENERATE IHD trial 
 
2.1.1 Introduction  
 
The MDRes thesis is based on the results of the REGENERATE-IHD trial primary and secondary 
outcomes as well as sub-studies designed to gain mechanistic insights into the action of G-CSF and 
BMC therapy. The REGENERATE-IHD trial was an investigator-initiated, randomised, placebo-
controlled, single-centre trial. The trial was designed to fill certain unexplored gaps in knowledge 
on the effects of G-CSF and BMC therapy in ischaemic HF, as discussed in section 1.2.12. The trial 
attempted to address this by being a unique clinical trial that 1. investigated the effects of G-CSF 
alone 2. investigated the effects of G-CSF in combination with autologous BMC 3.  administered cell 
therapy via the intracoronary (IC) and targeted intramyocardial (IM) routes 4. had appropriate 
comparator groups for each arm of the trial. The trial assessed whether G-CSF administration alone 
or in combination with either the IC or targeted IM injection of autologous bone marrow derived 
cells leads to an additional benefit on cardiac function compared to placebo controls (serum). The  
trial was initiated following a pilot study to address safety and feasibility.202  
 
Ethics and trial registration 
 
The Local Research Ethics Committee approved the protocol (REC no. 04/Q0603/13). The trial was 
registered with www.clinicaltrials.gov (NCT00747708) and the European Clinical Trials register 
(EudraCT no. 2005-002706-27). Approval was obtained from the MHRA. The trial was conducted in 
accordance with the Declaration of Helsinki and was in agreement with the revised Declaration of 
Helsinki (October 2013, Fortaleza, Brazil).  
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2.1.2 Trial design 
 
The trial was designed to assess the efficacy of G-CSF alone and in combination with autologous 
BMC via two different routes of cell delivery. Thus, there were three separate arms in the study, 
namely peripheral, intracoronary and intramyocardial. Each arm had an appropriate comparator or 
control group. The peripheral arm was designed to test the efficacy of G-CSF alone with the control 
group being subcutaneous saline. In the intracoronary arm, the participants were designated to 
either receive G-CSF and intracoronary cells or G-CSF and intracoronary placebo (autologous 
serum). The third arm-the intramyocardial arm- was designed to test the efficacy of G-CSF with 
intramyocardial cell therapy (active group) as compared to G-CSF and intramyocardial placebo 
(autologous serum).  The primary end-point was chosen as change in left ventricular ejection 
fraction (LVEF) as measured using advanced cardiac imaging. The vast majority of cell therapy trials 
to date have assessed change in LVEF as one of the main outcomes. LVEF is associated with 
prognosis in heart failure patients. Furthermore, advanced cardiac imaging with cardiac magnetic 
resonance (CMR) is now recognised as the most accurate way of assessment of LVEF. 203 Hence, it 
was decided to use LVEF as the primary endpoint in the trial-to enable comparison with other 
studies and due to availability of advanced cardiac imaging. 
Power calculation 
Following a pilot study, as requested by the ethics committee, the study was powered to detect a 
3·5% within group improvement in the primary endpoint i.e. change in LVEF at twelve months 
based on changes seen in a contemporary review of cell therapy.204  Based on a power of 90%, a 
significance level of 5% and an estimated within observation error of 4%, the calculated required 
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number of patients in each group was 11. It was estimated that an additional four per group would 
be needed in order to ensure that 11 patients reached the primary endpoint at 1 year, resulting in a 
size of 15 patients per treatment group.  
Statistical design 
A paired t-test was used to detect any statistical significance of within group changes in LVEF. For 
additional analyses using continuous variables, appropriate parametric (paired-t for paired and 
independent samples t-test for non-paired data, one-way ANOVA for multiple comparisons) and 
non-parametric (Wilcoxon signed –rank test for paired and Mann-Whitney for non-paired data) 
tests were used. Chi-squared or Fisher’s exact tests were used for categorical variables. Pearson’s 
linear regression was used for comparison between LVEF and cell function variables as well as 
cytokines. Values are quoted as mean ± SD unless otherwise stated. All p-values are two sided and 
p<0·05 considered to indicate statistical significance. Statistical analyses were performed using 
SPSS® version 21 (IBM Corp., Armonk, NY, USA) and graphs were produced using Graphpad Prism® 
version 6·0 (GraphPad Software, San Diego, CA).  
Study endpoints 
 
Primary endpoint 
 
The primary endpoint was the change in global left ventricular ejection fraction (LVEF) at 12 
months relative to baseline, measured by advanced cardiac imaging (CMR or cardiac CT where CMR 
contraindicated).   
Secondary endpoints 
 
Secondary Endpoints at 6 months 
Change in global LVEF measured by resting contrast echocardiography 
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Change in global LVEF measured by quantitative left ventriculography  
Change in NYHA class 
Change in serum levels of NT-proBNP 
Change in quality of life scores-using MacNew, EQ5D and SF-36 questionnaires 
Occurrence of major arrhythmias defined as ventricular tachycardia or survived sudden death 
Secondary Endpoints at 1 and 2 years 
The change in LVEF relative to baseline measured by resting contrast echocardiography  
Change in NYHA class compared to baseline 
Change in quality of life scores- assessed using MacNew, EQ5D and SF-36 questionnaires 
The occurrence of a Major Adverse Cardiac Event (MACE) - MACE defined as cardiac death, 
percutaneous coronary intervention (PCI), coronary bypass graft surgery (CABG) or myocardial 
infarction 
Patient selection 
 
Patients were referred to the trial with a confirmed diagnosis of HF from local HF clinics. Patients 
underwent screening by the research nurse or physician prior to inclusion in the study to ensure 
the inclusion criteria were met and that no exclusion criteria were present. All potential trial 
participants received detailed information regarding the objectives and methodology of the trial 
and the post-trial follow-up arrangements. A detailed patient information sheet (PIS) was provided 
to each patient by the research nurse. The potential participant was given ample time to think 
about the pros and cons of participating in the trial. Following this period, the research team 
answered any further questions raised by the patient. Once the patient was happy to go ahead, the 
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participant was asked to sign a consent form to indicate informed consent. The participant was 
informed of his/her right to change their mind at any point in the trial. The participant also 
consented to the use of his/her data gathered during the trial as well as any remaining bone 
marrow and stored blood sample for future trial related research.  
Inclusion and Exclusion criteria 
 
Inclusion criteria 
 Confirmed diagnosis of HF secondary to ischaemic heart disease  
 Established on optimal and stable medical therapy for at least 6 months 
 Documented impaired left ventricular ejection fraction (LVEF)  
 NYHA II-IV   
 No further treatment options. 
Exclusion criteria 
 Acute coronary syndrome within the preceding 6 months 
 Cardiogenic shock  
 Atrial fibrillation 
 Impaired renal function (serum creatinine >200µmol/l) 
 Serious concomitant illness with a life expectancy of <1 year 
 Contraindication to bone marrow aspiration 
 Chronic inflammatory disease  
 Active infection 
 Known infection with human immunodeficiency virus  
 Hepatitis B virus, hepatitis C virus, syphilis or Human T-cell lymphotropic virus.  
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Randomisation  
 
Patients were randomised to 1 of 3 arms: peripheral, intracoronary (IC) or intramyocardial (IM) 
(figure 2.1). The first 30 patients were allocated to the IM arm as the aim was to complete this arm 
first. This was done as treatment in this arm required the presence of expensive equipment for 
electromechanical mapping (NOGA®) as well the presence of senior clinicians and technical staff 
trained in the use of such equipment.   The remainder of the 60 patients were randomised in a 1:1 
manner to the other 2 arms (peripheral or IC), using a dedicated trial software system (HD Clinical, 
Bishops Stortford, Herts, UK).  
Once allocated to an arm, the patient was randomized in a 1:1 manner to receive either the active 
intervention or placebo. In the peripheral arm, patients received either subcutaneous G-CSF 
(active) or saline (placebo). In the IC arm, patients received either IC BMC (active) or IC autologous 
serum (placebo). In the IM arm, patients received targeted IM injection (with the aid of 
electromechanical mapping) of BMC (active) or autologous serum (placebo). 
 
Figure 2.1. Structure of the REGENERATE-IHD trial. Diagram showing the three arms of the trial. Each arm has 30 
participants divided into an active intervention and a placebo group. G-CSF-granulocyte colony stimulating factor 
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Treatment procedures 
 
Peripheral 
In the peripheral arm, the participant was admitted to the general cardiology ward for a period of 5 
days. All patients, apart from those in the peripheral placebo group, received their first dose of 
subcutaneous G-CSF (10µg/kg/day), which was continued for 5 days. Patients in the peripheral 
placebo group received their first dose of subcutaneous saline.  At the end of day 5, patients in the 
peripheral arm were discharged. 
Intra-myocardial and intra-coronary  
 
In the IC and IM arms, the participant was admitted to the hospital 6 days prior to the cell/placebo 
reinfusion. All patients received their first dose of subcutaneous G-CSF (10mcg/kg) on the day of 
admission and then daily for 5 days.  
On the morning of the procedure, all patients had 30mls of blood taken under strict aseptic 
techniques. This blood was used to obtain serum in which the BMC were suspended. Further blood 
was obtained for CD34+ count and clotting (if necessary) for patients on warfarin. Following the 
above, bone marrow aspiration was performed. The blood and bone marrow sample were then 
sent to the stem cell lab under sterile conditions. 
Bone marrow aspiration and cell processing  
 
Bone marrow aspiration 
Informed, written consent for the procedure was obtained on the day of the procedure. Under 
aseptic conditions and using local anaesthetic, 100mls of bone marrow was aspirated from the 
posterior iliac crest (figure 2.2). 205 5mls of aspirate was collected in each of 20 syringes. Each 
syringe was pre-rinsed with heparin and contained 1ml of heparin in it. The syringes were sent by 
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taxi in ice to the stem cell processing lab at the Royal London hospital, a fully compliant good 
manufacturing practice laboratory. The cells were suspended in autologous serum to make up a 
volume of 10mls (for the IC arm) and 2mls (for the IM arm) (see next section). The placebo (serum) 
was also prepared in identical sterile syringes. These were then transported to the cardiac 
catheterisation lab for the infusion procedure.   
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Figure 2.2. Bone marrow 
aspiration trolley and bone 
marrow aspiration being 
performed from posterior iliac 
crest 
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Cell processing 
The unprocessed bone marrow was transferred to a sterile, glass-shielded, stem cell laboratory. 
The 50mls of bone marrow harvest was pooled in a transfer bag and diluted with 0.9% saline in a 
1:2 ratio. The harvest was then passed through a 200µm filter. In each of four 50ml tubes, 15 ml of 
Ficoll was added. 30 ml of harvest was then carefully layered on top of the Ficoll in the first three 
tubes and 10ml in the last, making sure they do not mix. The tubes were centrifuged at 2500rpm 
for 30 minutes. The resultant “buffy” layer was pipetted out carefully and then resuspended in 
10ml of 0.9% saline and re-centrifuged at 2500rpm for 10 minutes (figure 2.3). This was repeated a 
further two times. The final cell pellet was suspended in 10 ml of autologous sera for the IC BMC 
group and 2ml of sera for the IM BMC group. For the placebo intervention groups, 10ml and 2ml of 
autologous sera were prepared for the IC placebo and IM placebo groups respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
                                                       Plasma 
layer 
 
 
Mononuclear “Buffy” layer 
 
 
                                                                           
Platelets/Erythrocytes 
Figure 2.3. Ficoll-Hypaque 
centrifugation of bone marrow. 
Component layers of bone marrow after 
centrifugation. The “buffy” layer is the 
mononuclear cell fraction. 
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Intracoronary and intramyocardial Interventions  
 
Intracoronary injection 
Coronary Angiography 
Premedication of diamorphine and diazemuls was given prior to the procedure and oxygen therapy 
at 2 litres per minute was administered throughout. A complete angiogram was recorded before 
and after the procedure. The angiogram was recorded in a standardised manner suitable for 
quantitative angiographic analysis. TIMI flow was recorded,206 as was the Rentrop classification for 
collaterals.207 The angiogram was used to confirm the diagnosis of ischaemic heart disease and also 
to allow decision-making regarding the vessels for injection. The aim was to infuse progenitor cells 
to as much of the left ventricle as possible utilising the coronary circulation. Ideally 3 suitable 
conduits (arterial as well as venous in the case of previous coronary bypass surgery) were identified 
that anatomically supplied the largest amount of left ventricular muscle. The progenitor cell 
suspension or placebo (serum) was divided equally and injected down all three conduits. A left 
ventriculogram was also acquired in 2 planes for quantification of left ventricular function.  
Weight adjusted bolus dose of heparin (100IU/kg) was given as per routine procedure. All patients 
were pre-treated with a loading dose of aspirin (300mg) and clopidogrel (600mg) and subsequently 
received a maintenance dose for 1 month (75mg). A 0.014-inch guide wire was passed into the 
target coronary artery. An over-the-wire compliant balloon catheter oversized by 0.5 mm, in 
comparison to the vessel diameter, was advanced into the proximal 1/3 of the target vessel and the 
wire removed. 
The balloon was inflated with low pressure (<4atms) to completely block blood flow for three 
minutes, while 3.3 ml of the progenitor cells suspension or placebo was infused distal to the 
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occluding balloon through the central port of the balloon catheter (in patients in whom there are 
only 2 target arteries, 5mls of progenitor cell suspension or placebo was infused). This procedure 
was then repeated in the remaining target vessels. After completion of the infusion, coronary 
angiography was repeated. 
Intramyocardial injection 
Patients underwent left ventricular electromechanical mapping using NOGA® XP Cardiac Navigation 
System and IM injection with the MyoStarTM catheter (Biologics Delivery Systems Group, Cordis 
Corporation, Diamond Bar, CA, USA) as previously described 208 209. The target areas for injection 
were the border zones around scar tissue based on voltage criteria obtained using the NOGA map 
as has been demonstrated previously by Perin et al 209. The total 2 ml volume of injectate was 
divided and delivered equally to 10 target areas at approximately 1cm intervals.  
 
Following either procedure, the patient was observed overnight and discharged the following 
morning.   
 
Details of baseline and follow-up visit investigations and other components 
 
Clinical assessment 
At admission, a full assessment was undertaken. The following points were specifically recorded: 
 NYHA class 
 CCS class 
 Presence of ICD/CRT (and if ICD, any shocks and date of last check) 
 Medications 
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 Fitness for procedure e.g. ability to lie flat for entire duration of procedure, if on warfarin, 
whether to be temporarily stopped 
 Details of physical examination with particular emphasis on cardiovascular examination 
 
At the follow-up visits, a full assessment was undertaken with special emphasis on the following 
points: 
 Change in cardiac symptoms since last visit i.e. progression, improvement or no change 
 NYHA class 
 CCS class 
 Any other symptoms i.e. non-cardiac 
 If ICD-any shocks and date of last check 
 Any hospital admission(s) since last visit and if so, details of admission 
 Any clinic visits  and outcome of visit, if available 
 Any change in medications since last visit and if so, details of name of medication, dose, 
frequency 
 Detailed cardiovascular examination with emphasis on any signs of fluid overload 
Advanced Cardiac imaging 
 
Cardiac magnetic resonance imaging 
 
Cardiac magnetic resonance (CMR) technology relies on magnetic alignment of the nuclei of 
hydrogen atoms when placed in a powerful magnetic field.  Radiofrequency signals are transmitted 
to excite the aligned atoms and the signal received from the tissue is received by receiver coils. 
Two different relaxation times- T1 (longitudinal relaxation time) and T2 (transverse relaxation time) 
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of the protons are used. The varying relaxation times of the protons as well as the varying proton 
density in different tissues are exploited to generate the contrast in image between tissues.  On T1 
weighted images the myocardium appears dark whereas on T2 weighted images the myocardium 
appears bright.  
 
For this study, imaging was performed on a 1.5 T Philips Achieva scanner with a cardiac 32-channel 
phased array coil. Each examination used cine-CMR for ventricular volumes and function. Cine CMR 
is considered the gold standard of the evaluation of cardiac volumes, mass, and systolic function 
since it does not apply geometric assumptions and has excellent reproducibility and accuracy 
(standard error for left ventricular ejection fraction, mass and volume is approximately 5%).  210, 211 
Thus CMR provides superior endo- and epi-cardial definition and thus allows accurate 
quantification of LVEF, LVEDV, LVESV and myocardial mass.  Not only can it demonstrate 
abnormalities in myocardial function, volumes and mass but it has a myriad of other applications 
including myocardial perfusion imaging, detection and quantification of myocardial scar tissue, and 
detection of non-ischaemic cardiomyopathies, cardiac masses or thrombi. A few trials have used 
CMR to look at changes in infarct size with cell therapy (Table 1.8).  The lack of radiation and the 
magnitude of information it provides makes it an attractive option over other imaging modalities. 
However, not all patients are suitable for CMR due to implanted, non-CMR safe, metallic devices 
e.g. pacemakers, which is a contraindication due to the magnetic field.  Hence, a significant number 
of HF patients have implanted devices which preclude them from undergoing CMR’s. In patients 
who were not suitable for CMR, cardiac computed tomography (CCT) was used as an alternative 
advanced imaging technique.  
87 
 
For scar imaging, gadolinium-chelated contrast agents are used. Gadolinium based agents tend to 
be retained for longer in scar tissue-late gadolinium enhancement (LGE)- compared to normal 
myocardium, secondary to reduced capillary density  and increased volume of distribution. By a 
pulsing sequence known as inversion-recovery using T1 weighted imaging, the normal myocardium 
is made to look very dark while the LGE myocardium looks bright i.e. hyper enhanced. CMR allows 
not only the detection but quantification of scar tissue as well. Various methods have been used to 
quantify scar tissue. These include quantifying as scar any myocardium that is a certain number of 
standard deviations above the intensity of the normal myocardium. Various SDs including 2, 3, 4, 5 
or 6 SD’s have been used. Manual quantification is also possible by tracing around the scar tissue of 
interest. The other commonly used method is the full width half max (FWHM) method which 
detects as scar any area of the myocardium that has an intensity more than half the maximal signal 
intensity of the scar. Unfortunately, there is no clear consensus on the best method to use. 
According to a paper by Bondarenko et al., the 5SD method was the most accurate when compared 
to visual (i.e. manual) analysis in patients with chronic HF. 212 Hence, the 5SD method was used for 
scar analysis in this study. T1 weighted inversion-recovery gradient images were acquired 10 min 
after injection of a dose of 0.2 mmol/kg of gadoterate meglumine (Dotarem) for late gadolinium 
enhancement. Inversion time was adjusted to null signal from healthy myocardium (voxel size 
2.07×2.16 mm, slice thickness 8 mm, FOV 300 mm). 
Endocardial and epicardial contours were manually traced for each of the slices in short axis LGE 
stack (Figure 2.4). The myocardial mass was then calculated. The 5SD semi-automatic method was 
then used to select areas of late gadolinium hyperenhancement (Figure 2.5). The 5SD method 
highlights as scar, myocardium that has a signal intensity more than 5 standard deviations above 
the normal myocardium. Any visible areas of scar not picked up by the software using the 5SD 
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method or any areas not compatible with scar formation were manually included or excluded 
respectively. The software was then used to calculate the actual mass (in grams) of the scar and the 
percentage (%) scar (calculated by expressing the scar mass as a % of the myocardial mass). Images 
were analysed in blinded fashion by 2 experienced operators. In case of discordance between 
operators, blinded review by a level III accredited CMR reader was performed. Analysis was 
performed using dedicated software (CVI42, Circle Cardiovascular Imaging Inc, Calgary, Alberta, 
Canada).  
 
                                    
Figure 2.5. Assessment of scar on CMR. Late gadolinium enhancement seen on image in left. 5SD method used to highlight 
area of scar (right) 
Figure 2.4. Endocardial (red) and 
epicardial (green) borders traced 
around short axis slices on CMR 
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Cardiac computed tomography  
 
Cardiac computed tomography (CCT) is an established imaging modality to quantify cardiac 
function and volumes. In a head-to-head comparison of 64-row CT, 2D echo, left cine 
ventriculogram (LCVG) and 3D echo with CMR, CT showed no significant over or underestimation of 
EF, end-diastolic volume (EDV) or end-systolic volume (ESV) compared to CMR. Furthermore, 
compared to the other three modalities (i.e. 2D and 3D echo and LCVG), CT was more accurate in 
assessing EF, EDV and ESV with CMR being the gold-standard. Of note, the study used a semi-
automated method of post processing similar to this study.213 A recent meta-analysis of 27 studies,  
comparing newer generation (64-row or more) CTs to CMR and 2D echo, lent further support to the 
previous study and  showed no significant difference between LVEF measured using CT and CMR or 
CT and echocardiography.214 To negate any effect of differences between imaging modality, a 
within group analysis was used to assess change in LVEF. Thus, for any single participant in the 
study, a single imaging modality was used at all follow-up timepoints.  
 The currently used multislice or multidetector (MDCT) scanners were introduced in the early 
1990’s.The MDCT consists of an X-ray source (s) and detector rows opposite the X-ray source both 
of which are loaded on a ring-like structure called a gantry. The patient is positioned within the ring 
on a table. The gantry rotates at a fixed, pre-specified speed. The X-ray beams emitted are 
captured by the detector arrays after traversing the patient.  The attenuation properties of tissue 
are detected by the software to reconstruct images of the heart and surrounding tissues.  Fast 
heart rates can reduce the temporal resolution and therefore, heart rate control with beta-blockers 
has been used to optimise imaging. One of the key factors affecting temporal resolution is the 
gantry rotation time-the time for the gantry to rotate 360º. To obtain complete cross-sectional 
views of the heart, a 180º is necessary. This equates to half the gantry rotation time. However, the 
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newer dual source CT’s (DSCT) have two x-ray sources emitting simultaneously. This reduces the 
time taken to acquire images to 1/4th the gantry rotation time. As a result, the temporal resolution 
has increased significantly to <80ms.  This high temporal resolution was one of the key factors 
favouring CT over other modalities, in patients not suitable for CMR. The other source of motion 
artefacts is that of breathing movements which necessitates breath-holds when acquiring images. 
As an example, with a 128 detector DSCT, each detector measures 0.625mm i.e. a total length of 
128x0.625=80mm. An average heart is around 120-150mm in length so the scan can be done with 
virtually one breath-hold thus minimising breathing artefacts. 
 
All patients in the trial were studied on a 64-slice spiral CT (Sensation 64, Siemens, Forchheim, 
Germany) scanner using retrospective gating to acquire the images. Intravenous B-Blockers were 
used in patients to achieve optimal pulse rate (<70), where needed, prior to initiation of the scan 
and all patients were on cardiac monitors during administration.  All scans were performed in the 
cranio-caudal direction.  An initial scouting x-ray (topogram) was performed to ensure correct 
alignment of the patient for the remainder of the scan.  The scan was initiated when contrast 
arrived within the ascending aorta. This was performed manually after test bolus arrived in the 
area of interest or using an automated CT triggering once the Hounsfield unit crossed a threshold in 
a set region of the aorta.  A total of 50 - 100 mls of contrast was used for the scan with the scan 
taking 10–15 minutes to complete.  Reconstruction algorithms were used to convert the raw data 
into interpretable images, which were then analyzed on specialist software. The data was 
reconstructed throughout the cardiac cycle and cine movie images were collected in 10 phases 
along the cardiac cycle and 10 levels. Analysis of LV volumes and function was performed using 
dedicated PC-based software Siemens (Forchheim, Germany) by using a semi-automatic method.  
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The end-systolic and end-diastolic phases were manually selected.  Once the end-systolic and end-
diastolic phases were selected, the software detected voxels (volumetric pixels) with an 
attenuation above a set threshold and based on this, delineated the epicardial and endocardial 
borders.  To activate the segmentation required the operator to define the mitral valve plane and 
mark a point on the anterior interventricular septum.  The hinge-to-hinge method was used to 
define the mitral valve plane to achieve greater consistency.215 This involves using the hinge points 
of the mitral and aortic valve leaflets closest to the ventricular wall as the two defining points for 
the mitral valve plane. A problem with this method, however, is that it excludes the left ventricular 
outflow tract (LVOT). To compensate for this, manual adjustment to the volumes to include the 
LVOT was carried out. Manual adjustment to the contours to exclude pacemaker artefacts and to 
include papillary muscles and trabeculae in the LV cavity was also performed. Further manual 
adjustments of contours were made where necessary.  
Transthoracic echocardiography 
 
A transthoracic echocardiogram (TTE) was performed on each patient at 6 months, 12 months and 
24 months. The following views were recorded: parasternal long axis view (PSLAX), parasternal 
short axis view (PSSAX), 4-chamber (4C) view, 3-chamber view and 2-chamber (2C) view. The scans 
were performed by accredited, practising echocardiographers. The following information was 
recorded: left ventricular dimensions, degree of valvular heart disease and forward flow velocities 
via the aortic, tricuspid and mitral valves. A commercially available contrast (Sonovue®) was 
injected via a peripheral cannula to enhance the definition of the endocardial borders. The contour 
of the LV in end-diastole and end-systole were traced in both the 4C and 2C views. The machine 
then calculated the global LVEF using the Simpson’s method whereby the end-systolic volume and 
end-diastolic volume are calculated by “stacking” together and adding the 2D “slices” or “discs” to 
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provide the 3D volume (Figure 2.6). The images were then analysed at a later date to assess LV 
systolic and diastolic function. 
 
   
Figure 2.6. Assessment of LVEF on contrast echocardiography. Endocardial definition delineated by used of contrast. 
Endocardial border traced in systole and diastole in both 4 chamber and 2 chamber views to yield LVEF. 
Assessment of diastolic function on echocardiography 
 
For the assessment of diastolic function, the following parameters were measured: mitral valve 
inflow E and A velocities, E:A ratio, Deceleration time (DT). Tissue Doppler imaging (TDI) was used 
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to measure E’ velocity (figure 2.7) and E:E’ ratio. Left atrial (LA) size was measured in the 
parasternal long-axis view.   
 
Figure 2.7 Tissue doppler imaging (TDI) on echocardiography. Measurement of E’ (+) using TDI imaging.  
Quantitative left ventriculography  
 
Quantitative left ventriculography (QLV) was performed at baseline and 6 months in the IC and IM 
arms. A pigtail catheter was placed into the LV cavity and 30mls contrast injected at a rate of 
10ml/second.  Image acquisition was carried out in two perpendicular planes- right anterior oblique 
(RAO) 30° and left anterior oblique (LAO) 60°. Left ventricular ejection fraction and volumes were 
calculated using the centreline method, using QXAngio 7.1® software (Medis Inc.). The analysis 
involved manually delineating the LV border in end-systole and end-diastole.  
Blood sampling 
 
Venous blood was obtained at admission, 6 months and 1 year. All bloods were processed at the 
hospital’s blood sciences laboratory apart from NT pro-BNP which was sent to a commercial blood 
sciences laboratory.   Peripheral blood was sent to the stem cell lab for CD34+ cell count, 
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mononuclear cell count (MNC) and circulating endothelial progenitor cell (EPC) count. Bloods were 
taken for the following: full blood count (FBC), urea and electrolytes (U&E), liver function tests 
(LFT’s), clotting screen and NT pro-BNP. An EDTA tube of additional blood was spun at 1600g for 
20mins and the supernatant serum stored at -80°C for further analysis.  
Quality of life (QoL) questionnaires 
 
In the trial on which this MDRes is based, the SF36 (short form 36), EQ-5D (EuroQol 5D) and the 
MacNew questionnaires were used. The three QoL questionnaires were filled in by participants in 
the trial at baseline, 6 months, 1 year and 2 years. Copies of each of the questionnaires are 
provided in Appendix 1.  
MacNew The questionnaire consists of 27 questions covering three domains-a 13 item physical 
domain scale, a 14 item emotional domain scale and a 13 item social wellbeing domain scale. A 
global score is obtained from the sum of the scores to the individual items. The scoring for each 
answer is from 1 (poor QoL) to 7 (good QoL). On average it takes 10 minutes to fill in. Missing 
responses do not contribute to the score. 216 A change in score of 0.5 or more in a domain or in the 
global score is taken as the minimal important difference.217 The questionnaire is available online 
and free to use. 
SF-36 The SF36 v2 questionnaire consists of 36 questions covering 8 domains- vitality, physical 
functioning, bodily pain, general health perceptions, physical role functioning, emotional role 
functioning, social role functioning and mental health.218 A low score indicates poor perception of 
health and vice versa. The raw scores are entered into using available SF36 v2 software which then 
transforms the score into a 0-100 scale (0-worst QoL and 100-best QoL). The software also 
generates two summary scores-the physical component summary (PCS) score and the mental 
health component summary (MCS) score. These two aggregate scores were standardised for the 
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UK population after analysing a large-scale data set of SF-36 responses from a random selection of 
the UK population. 219 A high score on the PCS or MCS indicates a high level of satisfaction with 
physical or mental health respectively and vice versa.  
EQ-5D The EQ-5D questionnaire consists of two parts- a Visual Analogue Scale (VAS) and the EQ-5D 
descriptive system.220 The VAS is a self-rated score using a 0-100 vertical ladder (0 being worst and 
100 being best imaginable health state) and taken as an overall indication of the quality of life. The 
EQ-5D descriptive system consists of 5 dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension has 3 options for the patient to choose 
from: no problems, some problems, extreme problems. Each of these options are weighted and 
when the raw data is entered from the EQ-5D descriptive system into EQ-5D software, a summary 
index score, based on the weighting, is provided which is taken as an overall measure of QoL in the 
individual.220  
2.2 Cytokine analysis 
 
Various cytokines including pro-inflammatory, anti-inflammatory and pro-angiogenic cytokines 
have been implicated in the pathogenesis of ischaemic cardiomyopathy as discussed in section 
1.1.2.3. However, no study has yet looked at the association between G-CSF and cell therapy and 
the levels of these cytokines or their association with the outcomes on cardiac function. As part of 
the MDRes, a selection of these cytokines was measured at baseline and at 1 year and analysed for 
any association with cell therapy and primary outcome. These were: IL-2, IL-4, IL-6, IL-8, IL-10, 
VEGF, IFN-γ, TNF-α, IL-1a, IL-1b and MCP-1. The reason why these cytokines were chosen was two-
fold. Firstly, as detailed in section 1.1.2.3, this selection of cytokines have been linked to the 
progression of heart failure and prognosis in heart failure patients. Secondly, the availability of a 
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multiplex assay to measure this collection of cytokines meant it was possible to obtain levels for 11 
different cytokines in one sample run.  
On the day of the cytokine analyses, the samples were left to thaw at room temperature. The 
cytokine analyses were performed using the Randox® Evidence Investigator™ by dedicated staff 
from Randox® Laboratories using their standard assay protocol detailed below. The Evidence 
Investigator™ Biochip Array was used to simultaneously detect multiple analytes from a single 
patient sample using ELISA (Enzyme Linked ImmunoSorbent Assay). The technology consists of a 
solid state device containing multiple regions of immobilised antibodies to the specific cytokines. 
Binding of horsedradish labelled antibody to the cytokines results in chemiluminescence and higher 
levels of cytokines results in increased levels of chemiluminescence i.e. using sandwich 
chemoluminescent immunoassay. The concentration of the analyte was calculated by measuring 
the light signal emitted from the chemoluminescent antibodies and compared to that of a standard 
calibration curve.  
Materials (all provided by Randox®) 
 Randox® Evidence Investigator™ 
 Cytokine High sensitivity Assay Diluent (1 x 14ml) 
 Cytokine High sensitivity Conjugate        (1 x 20 ml) 
 Cytokine High sensitivity Biochip             (54 biochips) 
 Cytokine High sensitivity Calibrator          (9 x 2ml) 
 Signal reagent EV805                                  (2 x 10ml) 
 Wash buffer concentrate                              (1 x 32ml) 
 Calibrator concentration disc and barcodes  
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 Biochip well cover slips 
 Cytokine high sensitivity control 
 Thermoshaker 
 
Detailed protocol 
The RANDOX® investigator machine was calibrated using standard calibration discs. The 
thermoshaker was equilibrated to +37ºC for 30 minutes before use. The following steps were then 
carried out (Figure 2.8). 
1) 200 µl of assay diluent was pipetted into each biochip well. 
2) 100 µl of sample was pipetted per well. See Figure 4.1. 
3) The biochips were incubated for 1 hour at +37 ºC and 370rpm. See Figure 4.2. 
4) The wells were covered and refrigerated at 2-8 ºC overnight. 
5) After overnight incubation, the reagents were discarded from the wells  
6) 2 quick wash cycles were carried out using 350µl of diluted wash buffer (32ml concentrate 
consisting of Tris buffered saline, pH7.4, with 968ml water)  into each well 
7) A further 4 wash cycles were carried out 
8) After the final wash and removal of all residual wash buffer, 300 µl  of conjugate (20mM Tris 
buffered saline, pH7.5, with assay specific antibodies labelled with horse radish peroxidase) and 
the wells incubated at 37 ºC  for 1 hour and 370 rpm 
9) Steps 6 and 7 were repeated after discarding conjugate 
10) The carriers were filled with wash buffer and left to soak till directly before imaging but for no 
more than 30 minutes. The carriers were protected from light 
11) The wash buffer was removed and 250 µl of the signal reagent immediately added.  
98 
 
12) After 2mins (±10s) the carriers were inserted into the Evidence Investigator™   
13) Images were captured and results processed by automated, dedicated software 
 
 
Figure 2.8 Randox Evidence Investigator™ Assay Steps (courtesy Mr Allen Huxley, Randox Laboratories) 
 
2.3 Cell Analysis 
 
Bone marrow mononuclear cell count was performed using an inverted, high powered microscope 
and a manual cell counter. Flow cytometry was used for quantitative analyses of CD34+ cells and 
EPC’s. A FACSCanto flow cytometer with BF FACSDiva v5.0.3 software (BD Biosciences) was used. 
HSC were identified by incubating the cells with fluorescein isothiocyanate (FITC)-labeled antibody 
against human CD45 (BD Biosciences, Erembodegem-AALST, Belgium) and phycoerythrin (PE) 
labeled antibody against human CD34 (BD Biosciences) for 15 minutes at room temperature.  
For EPC analysis, the bone marrow mononuclear cell sample was incubated with mouse serum IgG 
(Sigma, Dorset, UK) for 15 minutes at 4°C and a mix of the following antibodies-allophycocyanin 
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(APC)-labeled antibody to CD133 (Miltenyi Biotec, Surrey, UK) and PE labeled antibody to VEGFR-2 
(R&D Systems, Abingdon, UK) for positive selection of EPC’s and FITC-labeled antibodies to CD13, 
CD2 and CD22 to exclude non-EPCs. The resulting sample was then incubated with a PerCP-Cy5-
labeled 7AAD stain (BD biosciences) to check viability. The cells were then incubated with 2ml of 
PharmLyse™ buffer (BD Biosciences) for 15minutes at room temperature to lyse red blood cells. 
This was followed by a wash with PBS (Phosphate buffered saline). 20µl of Accucount flow 
cytometry beads (Saxon Europe, Kelso, UK) were then added prior to analysis using flow cytometry.  
Colony-forming unit granulocyte-monocyte (CFU GM) assays were performed on selective IC and 
IM bone marrow samples. The BMCs were plated out in triplicates on methylcellulose plates 
together with Methocult media, consisting of stem cell factor, granulocyte macrophage colony-
stimulating factor and Interleukin-3 (Stem Cell Technologies). The plates were left in the incubator 
for 14 days. Using phase contrast microscopy, CFU-GM were counted on day 14 (colony>50cells). 
The mean of the triplicate was taken as the final result.   
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Chapter 3  The safety and efficacy of G-CSF and autologous bone marrow derived cells in 
ischaemic cardiomyopathy 
 
3.1 Background 
 
Trials assessing the therapeutic effectiveness of G-CSF in ischaemic cardiomyopathy have 
demonstrated mixed results as have similar studies assessing the effects of autologous BMC. As 
detailed in section 1.2.12, no single study has yet looked at the effect of G-CSF alone and in 
combination with autologous BMC in ischaemic cardiomyopathy patients. Furthermore, the 
optimal route of delivery of cells is still unclear as no single trial has compared routes of delivery, 
although meta-analyses suggest the intramyocardial route is superior.  The majority of trials that 
have looked at the effect of G-CSF or autologous BMC have been small in size and have often 
lacked appropriate placebo-control arms. The REGENERATE-IHD trial was designed with the aim of 
addressing the above limitations. This phase II, randomised, placebo-controlled trial assessed the 
safety and efficacy of G-CSF alone and in combination with autologous bone marrow derived cell 
therapy, delivered either via the intramyocardial or the intracoronary route, in patients with 
ischaemic cardiomyopathy. As detailed in section 2.1, the trial had three arms-peripheral, 
intracoronary and intramyocardial. Each arm had an active and a placebo group (Figure 3.1). 
 
Figure 3.1. Structure of the REGENERATE-IHD trial. Diagram depicting the three arms of the trial and the number of 
participants in the active and placebo groups in each arm.  
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3.2 Results 
 
3.2.1 General characteristics of study population 
 
A total of 1133 patients were referred and screened from heart failure clinics. Of these 1028 were 
ineligible due to the following reasons: non-ischaemic aetiology of heart failure (n=79), 
NYHA<II/normal LVEF (n=236), atrial fibrillation (n=27), refusal to participate in the trial (n=389), 
death before formal consent (n=53) and other comorbidities, including valvular heart disease and 
significantly impaired renal function (n=244). Of the 105 patients who were randomised, 15 
patients were withdrawn either because of unsuitability for the intervention or patient withdrawal. 
90 received the allocated trial intervention (Figure 3.2). 
 
The mean age of the patient population was 62.8 ±9.6 years while the majority of patients were 
male (94.4%). The baseline characteristics were similar across the groups with a mean LVEF of 
30.6% (95% CI 28.53-32.74), a mean NT-pro-BNP of 1187.0±179.9 pg/ml and 97.8% of patients in 
NYHA class II/III. Baseline patient demographics for the entire trial are shown in Table 3.1. The 
majority of patients were on optimal medical therapy (as per ESC guidelines), 221 and there were no 
significant differences across groups in prescribed medication or implanted device therapy.  The 
mean total number of cells injected in the two stem cell groups was 115.1x106 bone marrow 
mononuclear cells. The mean viability of processed cells was 98.2%.   
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Table 3.1. Baseline characteristics 
 
  
Saline 
(n=15) 
 
G-CSF 
(n=15) 
 
IC serum 
(n=15) 
 
IC BMC 
(n=15) 
 
IM serum 
(n=15) 
 
IM BMC 
(n=15) 
 
 
p-
value 
        
Age, years (mean ± 
SD) 
63.3±9.3 63.1±8.2 62.8±10.7 62.1±9.7 60.4±11.2 65.3±9.4 0.841 
Sex M/F n 14/1  13/2  14/1  14/1  15/0  15/0  0.896 
BMI (kg/m
2
) 
(mean±SD)
# 
29.5±4.3 31.4±6.0 31.7±6.5 29.7±4.8 29.6±3.7 30.8±4.0 0.739 
        
Medical History, n (%)        
Hypertension 3 (20.0) 1 (6.7) 2 (13.3) 3 (20.0) 5 (33.3) 5 (33.3) 0.414 
Diabetes 4 (26.7) 5 (33.3) 2 (13.3) 2 (13.3) 4 (26.7) 4 (26.7) 0.748 
CABG 5 (33.3) 4 (26.7) 3 (20.0) 7 (46.7) 6 (40.0) 4 (26.7) 0.653 
MI 13 (86.7) 12 (80.0) 14 (93.3) 13(86.7) 13 (86.7) 13 (86.7) 0.949 
Hypercholesterolaemia 4 (26.7) 6 (40.0) 5 (33.3) 5 (33.3) 8 (53.3) 4 (33.3) 0.715 
Smoker/ex-smoker,  12 (80.0) 8 (53.3) 13 (86.7) 11(73.3) 14 (93.3) 11 (73.3) 0.150 
        
        
Time from last MI, 
days median (IQR) 
1307 
(1064-
5443) 
2527 
(966- 
4928) 
2856 
(1278-
6041) 
1805 
(896- 
3855) 
2406 
(706- 
5402) 
2684 
(706- 
5402) 
0.964 
        
LVEF (%) (mean ± SD) 34.7±10.1 27.9±12.4 31.6±7.4 31.7±8.8 29.0±9.2 28.6±10.2 0.385 
        
Devices number,n (%)        
CRT-D 4 (26.7) 5 (33.3) 4 (26.7)  4 (26.7)  3 (20.0)  7 (46.7) 0.781 
CRT-P 1 (6.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 0.999 
ICD only 7 (46.7) 2 (13.3) 4 (26.7) 5 (33.3) 5 (33.3) 6 (40.0) 0.485 
        
Medication history, n 
(%) 
       
Statin 12 (80.0) 13 (86.7) 13 (86.7) 13(86.7) 14 (93.3) 13 (86.7) 0.995 
ACEi/ARB 14 (93.3) 14 (93.3) 13 (86.7) 14(93.3) 15 (100) 15 (100) 0.896 
Β-blocker 15(100) 14 (93.3) 12 (80.0) 15(100) 11 (73.3) 14 (93.3) 0.079 
Aldosterone 
antagonist 
9 (60.0) 13 (86.7) 9 (60.0) 12(80.0) 9 (60.0) 12 (80.0) 0.351 
Diuretics 10 (66.7) 11 (73.3) 13 (86.7) 12(80.0) 8 (53.3) 12 (80.0) 0.363 
        
NYHA at baseline, n 
(%) 
       
II 10 (66.7) 9 (60.0) 5 (33.3) 8 (53.3) 11 (73.3) 8 (53.3)  
0.376 
III/IV 5 (33.3) 6 (40.0) 10 (66.7) 7 (46.7) 4 (26.7) 7 (46.7)  
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Figure 3.2. CONSORT diagram                                             
*denotes number of patients who were not seen 
as they passed the 2 year mark before the decision 
to undertake 2 year follow-ups 
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At one year, a total of 82 patients were assessed for the primary endpoint (Figure 3.2). In the IM 
arm, 14 patients were assessed in the BMC group (one referred for LVAD) with 13 patients 
assessed in the IM placebo group (one death and one patient lost to follow-up). In the IC arm, all 
15 patients in the BMC group and 13 patients in the placebo group (one lost to follow-up and one 
CT scan not analysable) were assessed for the primary endpoint whilst in the peripheral group, 13 
patients in the G-CSF group (one death and one CT scan not analysable) and 14 in the placebo 
group (one patient lost to follow-up) were assessed for the primary endpoint.  
 
At 2 years, a total of 57 patients attended for follow-up. In the IM BMC group 10 patients attended 
with 7 attended in the IM placebo group. In the IC arm, 12 patients in the BMC group and 10 
patients in the placebo group attended for follow-up. In the peripheral arm, 9 patients attended in 
each of the 2 groups. 55 patients underwent CMR/CT scans at 2 years (2 patients were ineligible 
due to renal impairment) of which 53 scans were analysable. Mortality data was collected on all 90 
participants.  Baseline demographics for the 2 year follow-up attendees are shown in table 3.2. 
 
3.2.2 Change in left ventricular ejection fraction using advanced cardiac imaging 
 
At 1 year no change in LVEF was seen in the G-CSF only treated group with a mean decrease of -
1.25% (95% CI -5.4-2.9%; p=0.520), compared to a reduction of -0.98% (95% CI -4.4-2.5%; p=0.551) 
seen in the peripheral placebo group (saline only). No significant change in LVEF was seen in either 
the IC BMC treated group (0.89% change in LVEF (95% CI -2.2-3.9%; p=0.541)) or the IC placebo 
group (1.1% (95% CI -1.7-3.9; p=0.413). Only patients treated in the IM BMC group met the primary 
endpoint of change in LVEF (increase of 4.99%; 95% CI 0.33-9.6%; p=0.038). Although a trend to 
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improvement in LVEF was seen in the IM serum group {4.15% (95% CI -3.3-11.6%); p=0.246}, this 
did not reach significance. Figure 3.3 shows the change in LVEF across the 6 groups.  
The IM BMC group showed a significant, absolute improvement in LVEF of 5.97% (95% CI 0.4 to 11.5; 
p=0.035) compared to the peripheral placebo group, with no significant difference between the IM serum 
group and the peripheral placebo group (5.14%; 95% CI -2.4 to 12.7; p=0.175). There was no difference in 
LVEF between the IC BMC and IC serum groups (-0.21%; 95% CI -4.2 to 3.8; p=0.916) or between the 
peripheral G-CSF and placebo groups (0.27%; 95% CI -4.8 to 2.4; p=0.913) (Table 3.3 and figure 3.3).   
Left ventricular ejection fraction at 2 years 
The IM BMC group showed a 3.18% (95% CI -4.2-10.6; p=0.356) improvement in LVEF at 2 years. The IM 
placebo group showed a -1.33% (95% CI -14.5-11.8; p=0.804) reduction in LVEF. The IC BMC group showed a 
2.01% (95% CI -4.4-8.4; p=0.503) increase in LVEF at 2 years and the IC placebo group a 0.63% (95% CI -4.2-
5.5; p=0.775) change in LVEF at 2 years.  In the peripheral arm, the G-CSF only group showed a -3.3% decline 
in LVEF (95% CI -10.8 - 4.3; p=0.333) and the placebo group (saline only) showed a -6.3% decrease in LVEF 
(95% CI -18.4 – 5.8; p=0.256).  Figure 3.4 shows the change in LVEF across the groups.   
 
3.4.2.1 Effect of age and baseline LVEF on primary endpoint in patients receiving BMC therapy 
 
The mean change in LVEF in patients in the IC and IM BMC groups who were <60years old at baseline was 
2.5±2.0% and was not significantly different to the change in LVEF at 1 year in those >60 years old (3.0±1.7%; 
p=0.863).  The median LVEF for the entire cohort was 32.0%. An unpaired t-test was performed to compare 
the change in LVEF at 1 year in patients in the IC and IM BMC groups with baseline LVEF≥32% and those with 
baseline LVEF<32%. Although not significant, the change in LVEF was greater in patients with a baseline LVEF 
<32% (3.5±1.5%) compared to those with a baseline LVEF≥32% (0.9±1.9%; p=0.334) (Fig 3.5).  
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Table 3.2 Baseline characteristics of patients attending for 2 year follow-up 
 
  
Saline 
(n=9) 
 
G-CSF 
(n=9) 
 
IC serum 
(n=10) 
 
IC BMC 
(n=12) 
 
IM serum 
(n=7) 
 
IM BMC 
(n=10) 
 
 
p-
value 
        
Age, years (mean ± 
SD) 
65.3±12.2 64.0±9.8 65.4±10.3 58.7±8.9 56.8±9.7 61.8±7.5 0.626 
Sex M/F n 8/1  8/1  9/1  11/1  7/0  10/0  0.945 
BMI (kg/m
2
) 
(mean±SD)
# 
30.0±4.2 30.3±5.2 30.0±5.7 30.9±4.7 31.4±3.7 30.8±4.6 0.990 
        
Medical History, n (%)        
Hypertension 2 (22.2)      0 (0.0) 1 (10.0) 2 (16.7) 4 (57.1) 2 (20.0) 0.122 
Diabetes 1 (11.1) 2 (22.2) 1 (10.0) 2 (16.7) 1 (14.3) 1 (10.0) 0.980 
CABG 2 (22.2) 4 (44.4) 2 (20.0) 6 (50.0) 2 (28.6) 2 (20.0) 0.574 
MI 8 (88.9) 8 (88.9) 9 (90.0) 11 
(91.7) 
7 (100.0) 8 (80.0) 0.967 
Hypercholesterolaemia 2 (22.2) 3 (33.3) 3 (30.0) 4 (33.3) 5 (71.4) 4 (40.0) 0.504 
Smoker/ex-smoker,  6 (66.7) 6 (66.7) 8 (80.0) 10 
(83.3) 
6(85.7) 6 (60.0) 0.871 
        
        
Time from last MI, 
days median (IQR) 
3593 
(5420) 
2788  
(4634) 
2808  
(2288) 
1731  
(3402) 
1894  
(5336) 
3993  
(4957) 
0.894 
        
LVEF (%) (mean ± SD) 34.0±10.8 27.4±12.9 31.7±7.3 31.3±8.4 28.1±12.3 29.3±11.7 0.783 
        
Devices number,n (%)        
CRT-D 4 (26.7) 4 (33.3) 3 (26.7)  3 (26.7)  0 (20.0)  4  (46.7) 0.368 
CRT-P 1 (6.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 0.373 
ICD only 4 (46.7) 2 (13.3) 4 (26.7) 5 (33.3) 3 (33.3) 4 (40.0) 0.946 
        
Medication history, n 
(%) 
       
Statin 7 (80.0)      8 
(86.7) 
9 (86.7) 12 
(86.7) 
7 (93.3) 10 (86.7) 0.328 
ACEi/ARB 8 (93.3) 8 (93.3) 9 (86.7) 12 
(93.3) 
7 (100) 10 (100) 0.659 
Β-blocker 9 (100.0) 9 (93.3) 7 (80.0) 12 
(100.0) 
5 (73.3) 10 (93.3) 0.012 
Aldosterone 
antagonist 
4 (60.0) 7 (86.7) 6 (60.0) 11 
(80.0) 
4 (60.0) 9 (80.0) 0.108 
Diuretics 5 (66.7) 5 (73.3) 8 (86.7) 10 
(80.0) 
4 (53.3) 7 (80.0) 0.612 
        
NYHA at baseline, n 
(%) 
       
II 9 (66.7) 6 (60.0) 3 (33.3) 6 (53.3) 6 (73.3) 5 (53.3)  
0.017 
III/IV 0 (33.3) 3 (40.0) 7 (66.7) 6 (46.7) 1 (26.7) 5 (46.7)  
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Figure 3.3 Change in LVEF at 1 year. Dot plots showing change in LVEF at 1 year. LVEF at baseline and 1 year as 
measured using CMR/CT in each of the treatment groups (A-F). A significant improvement of 4.99% was observed in 
the IM BMC treated group (group F). A-peripheral placebo; B - peripheral G-CSF only; C – peripheral G-CSF + IC serum; 
D - peripheral G-CSF + IC BMC; E - peripheral G-CSF + IM serum; F - peripheral G-CSF + IM BMC. IC-intracoronary; IM-
intramyocardial; G-CSF- granulocyte-colony stimulating factor; BMC-bone marrow derived cells; LVEF-left ventricular 
ejection fraction; CMR-cardiac magnetic resonance imaging; CT-computed tomography. * denotes p<0.05. Large solid 
circles represent the means at baseline and 1 year for each group respectively, and error bars represent 95% CIs.  
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Fig 3.4. Analysis of left ventricular ejection fraction at 2 years. LVEF at baseline, 1 year and 2 years as measured using 
CMR/CT in each of the treatment groups (A-F). A significant improvement of 4.99% was noted in the IM BMC group at 1 year. An 
improvement of 3.2% was observed in the IM BMC treated group at 2 years, although not significant compared to baseline (group F). 
A-peripheral placebo; B - peripheral G-CSF only; C – peripheral G-CSF + IC serum; D - peripheral G-CSF + IC BMC; E - peripheral G-CSF 
+ IM serum; F - peripheral G-CSF + IM BMC. IC-intracoronary; IM-intramyocardial; G-CSF- granulocyte-colony stimulating factor; 
BMC-bone marrow derived cells; LVEF-left ventricular ejection fraction; CMR-cardiac magnetic resonance imaging; CT-computed 
tomography. * denotes p<0.05. Dotted line- change in LVEF in patients reaching primary endpoint at 1 year (n); Continuous line-
change in LVEF at baseline, 1 year and 2 years in patients attending 2 year follow-up (N)  
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Figure 3.5.   Bar charts showing Change in LVEF relative to baseline LVEF. Mean (+SEM) change in LVEF at 1 year 
according to baseline LVEF in the IC and IM BMC groups. Baseline LVEF was classified as being ≥median baseline LVEF or < median 
baseline LVEF. Median baseline LVEF was 32.0%. *p<0.05 Independent samples t-test. BMC-bone marrow derived cells; IC-
intracoronary; IM- intramyocardial 
3.2.3 Left ventricular volumes and mass 
 
Left ventricular end-diastolic volumes 
None of the groups showed any significant change in left ventricular end-diastolic volume (LVEDV) 
at 1 year and all groups showed an increase (or no change) in LVEDV. In keeping with the trend, all 
groups except for the IM BMC group, showed an increase in LVEDV at 2 years. The IM BMC group 
showed a -15.1mls reduction in LVEDV, albeit insignificant (95% CI -56.2 to 26.0; p=0.427). 
Left ventricular end-systolic volume  
Only the IM BMC group showed a reduction in left ventricular end-systolic volume (LVESV) at 1 year 
(-8.6ml (95% CI -38.5 to 21.3; p=0.546), although not significant. All other groups showed non-
significant increases in LVESV. This trend was maintained at 2 years, with the IM BMC group being 
110 
 
the only group to show a reduction in LVESV, albeit non-significant ( -14.6mls; 95% CI -48.5-19.3; 
p=0.355). All other groups showed an increase in LVESV at 2 years.  
Myocardial mass 
No significant change in myocardial mass (MM) was noted in any of the six groups at 1 year. At 2 
years, however, the IM BMC group showed a statistically significant increase in myocardial mass 
(MM) (35.3g; 95% CI 9.5 to 61.1; p= 0.013). None of the other groups showed any significant 
change in MM at 2 years. Tables 3.3 and 3.4 show the values for LVEF, LV volumes and MM at 1 
year and 2 years respectively in each of the groups. Figure 3.6 shows the change in LVEF, LV 
volumes and myocardial mass at 2 years.  
Table 3.3. Change in LVEF, LV volumes and myocardial mass at 1 year 
 Peripheral 
placebo 
Peripheral G-
CSF 
 
IC serum IC BMC IM serum IM BMC 
 N=14 N=13 N=13 N=15 N=13 N=14 
       
EF baseline 35.3 (29.4-41.2) 29.5 (22.1-36.9) 32.6 (28.5-36.7) 31.7 (26.8-36.6) 29.0 (23.4-34.6) 28.6 (22.7-34.5) 
       
EF 1 year 34.3 (28.0-40.6) 28.3 (19.5-37.0) 33.7 (29.8-37.5) 32.6 (26.6-38.6) 33.2 (27.2-39.1) 33.6 (27.2-39.9)
 
       
p-value 0.551 0.520 0.413 0.541 0.246 0.038 
       
       
ESV 
baseline 
164.0 (119.3-
208.6) 
205.7 (147.3-
264.1) 
175.0 (151.5-
198.6) 
179.2 (135.0-
223.4) 
182.8 (141.4-
224.1) 
204.6 (162.0-
247.2) 
       
ESV 1 year 173.7 (121.1-
226.3) 
212.8 (133.5-
292.2) 
177.7 (151.1-
204.2) 
180.9 (129.6-
232.1) 
187.0 (145.6-
228.4) 
196.1 (151.8-
240.3) 
       
p-value 0.179 0.613 0.729 0.870 0.573 0.546 
       
       
EDV 
baseline 
 
246.3 (196.9-
295.6) 
283.3 (226.2-
340.3)  
258.1 (232.0-
284.2) 
254.7 (204.7-
304.7) 
254.5 (204.6-
304.5) 
283.2 (232.8-
333.6) 
EDV 1 year 
 
253.9 (200.4-
307.4) 
291.5 (217.3-
365.6) 
260.9 (228.3-
293.5) 
254.7 (204.3-
305.1) 
278.6 (224.7-
332.5) 
287.0 (242.8-
331.1) 
       
p-value 0.421 0.570 0.696 0.999 0.149 0.836 
       
 
MM baseline 
 
197.7 (157.3-
238.2) 
 
199.0 (150.6-
247.3) 
 
178.7 (146.4-
211.0) 
 
172.6 (145.5-
199.7) 
 
172.3 (143.9-
200.7) 
 
182.4 (161.1-
203.8) 
       
MM 1 year 204.6 (155.5-
253.6) 
182.8 (138.0-
227.5) 
181.2 (140.9-
221.6) 
175.4 (147.3-
203.5) 
174.2 (149.7-
198.6) 
185.3 (167.8-
202.8) 
       
p-value 0.553 0.168 0.730 0.582 0.701 0.584 
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Table 3.4. Change in LVEF, LV volumes and myocardial mass at 2 years 
 
  Peripheral 
placebo 
Peripheral G-
CSF 
  
IC serum IC BMC IM serum IM BMC 
  N=8 N=8 N=10 N=11 N=6 N=10 
EF baseline 33.1 (23.7-42.4) 28.9 (18.2-39.7) 31.7 (26.5-36.9) 31.4 (25.5-37.3) 30.7 (18.8-42.5) 29.3 (21.0-37.7) 
EF 2 years 26.8 (16.4-37.1) 25.6 (17.4-33.8) 32.3 (26.1-38.5) 33.4 (28.2-38.6) 29.3 (14.4-44.3) 32.5 (20.0-45.0) 
p-value 0.256 0.333 0.775 0.503 0.804 0.356 
 Change -6.3 (-18.4-5.8) -3.3 (-10.8-4.3) 0.6 (-4.2-5.5) 2.0 (-4.4-8.4) -1.3 (-14.5-11.8) 3.2 (-4.2-10.6) 
       
ESV baseline 190.6 (117.0-
264.3) 
191.3 (152.1-
230.5) 
182.4 (156.7-
208.0) 
181.2 (126.5-
235.9) 
170.3 (104.2-
236.5) 
203.2 (149.6-
256.8) 
ESV 2 years 224.3 (127.5-
321.0) 
215.8 (158.0-
273.5) 
186.1 (158.9-
213.3) 
188.9 (136.3-
241.6) 
223.0 (131.6-
314.4) 
188.6 (134.1-
243.1) 
p-value 0.061 0.053 0.676 0.493 0.008 0.355 
Change  33.6 24.4 3.8 7.7 52.7 -14.6 
        
EDV baseline 
  
276.3 (201.8-
350.7) 
267.6 (236.2-
299.0) 
265.8 (240.2-
291.3) 
256.6 (193.4-
319.9) 
243.7 (165.4-
321.9) 
284.3 (218.1-
350.5) 
EDV 2 years 
  
301.8 (200.2-
403.3) 
287.1 (231.3-
343.0) 
275.3 (241.0-
309.6) 
276.6 (213.8-
339.5) 
306.3 (240.1-
372.6) 
269.2 (224.4-
314.0) 
p-value 0.095 0.200 0.387 0.100 0.007 0.427 
 Change 25.5 19.6 9.6 20.0 62.7 -15.1 
  
MM baseline 
 
226.4 (186.2-
266.6) 
 
222.8 (178.8-
266.8) 
 
197.7 (170.1-
225.3) 
 
171.3 (136.6-
205.9) 
 
159.7 (114.2-
205.1) 
 
174.9 (148.4-
201.4) 
MM 2 years 240.3 (189.2-
291.4) 
221.4 (161.7-
281.1) 
187.0 (151.5-
222.5) 
181.5 (134.9-
228.1) 
153.2   (89.7-
216.7) 
210.2 (178.0-
242.4) 
 p-value 0.467 0.928 0.319 0.306 0.634 0.013 
Change 13.9 -1.4 -10.7 10.3 6.5 35.3 
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Figure 3.6. Change in LVEF, volumes and myocardial mass by group at 2 years. Change in A) LVEF B) EDV C) ESV D) 
MM as measured using CMR/CT in each of the treatment groups (A-F). Only the IM BMC group showed a reduction in EDV and ESV 
and a significant increase in myocardial mass at 2 years. A-peripheral placebo; B - peripheral G-CSF only; C – peripheral G-CSF + IC 
serum; D - peripheral G-CSF + IC BMC; E - peripheral G-CSF + IM serum; F - peripheral G-CSF + IM BMC. IC-intracoronary; IM-
intramyocardial; G-CSF- granulocyte-colony stimulating factor; BMC-bone marrow derived cells; LVEF-left ventricular ejection 
fraction; EDV-end-diastolic volume; ESV- end-systolic volume; MM- myocardial mass; CMR-cardiac magnetic resonance imaging; CT-
computed tomography. * denotes p<0.05 (paired-t-test). Mean + SEM represented 
3.2.4 New York Heart Association score 
 
In the peripheral placebo group, there was no significant change in New York Heart Association 
(NYHA) score at 6 months (2.29 to 2.25; Δ-0.04; 95% CI -0.45 to 0.38; p=0.862) or at 1 year (2.29 to 
2.29; Δ0.00; 95% CI -0.40 to 0.40; p>0.999) at 1 year. In the G-CSF only group, mean NYHA changed 
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from 2.43 to 2.31 (Δ-0.12; 95% CI -0.57 to 0.33; p= 0.5883) at 6 months and from 2.43 to 2.21, a 
change of -0.21 (95% CI -0.65 to 0.23; p=0.3302) at 1 year. However, the reduction in NYHA scores 
at 6 months and 1 year in the G-CSF only group were non-significant. 
Neither of the IC groups, showed any significant change in NYHA at 6 months or 1 year. In the IC 
arm, mean NYHA changed from 2.71 to 2.41 (Δ -0.41; 95% CI -0.83 to 0.014; p=0.058) in the IC 
placebo group at 6 months and from 2.71 to 2.43 (Δ-0.29; 95% CI -0.70 to 0.13; p=0.169) at 1 year. 
In the IC BMC group, mean NYHA changed from 2.47 to 2.21 (Δ-0.25; 95% CI-0.69 to 0.18; p=0.249) 
at 6 months and from 2.47 to 2.13 (Δ-0.33; 95% CI -0.76 to 0.09; p=0.124) at 1 year. 
In the IM BMC group, there was a significant improvement in NYHA class at six months from 2.57 to 
2.00 (Δ-0.57; 95% CI -1.07 to -0.08; p=0.025), which was maintained at one year (2.57 to 2.07; Δ -
0.50; 95% CI -1.00 to 0.00; p=0.048). In the IM serum group, a significant reduction in NYHA was 
seen at six months from 2.27 to 1.80 (Δ-0.47; 95% CI -0.84 to -0.09; p=0.016) but this was not 
sustained at one year (2.27 to 2.08; Δ-0.15; 95% CI -0.58 to 0.20; p=0.451) (Figure 3.7). 
 
At 2 years, the IM BMC group showed a continued, significant reduction in NYHA class from 2.53 to 
1.80 (Δ-0.73; 95% CI -1.26 to -0.21; p=0.007). No change was seen in any other group (IM placebo 
group-2.27 to 2.14; Δ-0.13; 95% CI -0.62 to 0.37; p=0.615; IC BMC group-2.47 to 2.08; Δ-0.38; 95% 
CI -0.82 to 0.06; p=0.087; IC placebo group-2.67 to 2.50; Δ-0.17; 95% CI 0.63 to 0.30; p= 0.473; 
peripheral G-CSF group-2.40 to 2.33; Δ-0.07; 95% CI -0.63 to 0.50; p= 0.813 and the peripheral 
placebo group-2.40 to 2.11; Δ -0.29; 95% CI -0.87 to 0.30; p=0.326) (figure 3.8).  
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Figure 3.7. NYHA class at 1 year. Bar charts showing mean New York Heart Association (NYHA) class at baseline, 6 months 
and 1 year shown for each of the treatment groups (A-F). A significant reduction in NYHA class was noted in the IM BMC group. A-
peripheral placebo; B - peripheral G-CSF only; C – peripheral G-CSF + IC serum; D - peripheral G-CSF + IC BMC; E - peripheral G-CSF + 
IM serum; F - peripheral G-CSF + IM BMC. IC-intracoronary; IM- intramyocardial; G-CSF- granulocyte-colony stimulating factor; BMC-
bone marrow derived cells * denotes p<0.05; Significance assessed using one-way ANOVA with Bonferroni correction for multiple 
comparisons 
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Figure 3.8 NYHA class at 2 years. Mean New York Heart Association (NYHA) class at baseline, 6 months, 1 year and 2 years 
shown for each of the treatment groups (A-F). A significant reduction in NYHA class was noted in the IM BMC group at all time 
points. A-peripheral placebo; B - peripheral G-CSF only; C – peripheral G-CSF + IC serum; D - peripheral G-CSF + IC BMC; E - peripheral 
G-CSF + IM serum; F - peripheral G-CSF + IM BMC. IC-intracoronary; IM-intramyocardial; G-CSF- granulocyte-colony stimulating 
factor; BMC-bone marrow derived cells * denotes p<0.05; Significance assessed using one-way ANOVA with Bonferroni correction 
for multiple comparisons 
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3.2.5 Canadian Cardiovascular Society score 
 
There was no significant change in Canadian Cardiovascular Society (CCS) angina class seen in any 
of the treatment groups either at 6 months, 1 year (Figures 3.9) or 2 years. 
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Figure 3.9. Canadian Cardiovascular Society (CCS) angina score. Bar charts of CCS score at baseline, 6 months and 1 
year shown in each group A-F. No significant changes were noted in any group. A-peripheral placebo; B-G-CSF only; C-IC serum; D-IC 
BMC; E- IM serum; F-IM BMC.  IC-intracoronary; IM-intramyocardial; BMC= Bone marrow derived cells. G-CSF =granulocyte colony 
stimulating factor.  Significance assessed using one-way ANOVA with Bonferroni correction for multiple comparisons 
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3.2.6 NT pro-BNP  
 
At 6 months, the NT pro-BNP level showed a non-significant increase from 775.7±235.7 to 
907.9±376.3 (p=0.685) in the peripheral placebo group. Similarly, the change in NT pro-BNP was 
also non-significant in the peripheral G-CSF group (1498±602.8 to 1644±639.3; p=0.638).  In the IC 
arm, neither group showed any significant change in NT pro-BNP.  In the IC placebo group, the NT 
pro-BNP level changed negligibly from 1180±298.3 to 1198±334.2 (p=0.608) and in the IC BMC 
group, it decreased from 440.5±58.6 to 396.9±69.7 (p=0.15). The IM serum group demonstrated a 
trend towards a fall in NT pro-BNP at 6 months (572.0±113.5 to 408.6±80.9; p=0.050) although this 
was not significant. At six months, only the IM BMC group showed a significant fall in NT pro-BNP 
(977.5±231.7 to 768.4±201.6; p=0.018) (figure 3.10).  All values were log transformed for within-
group analyses. 
3.2.7 Change in global LVEF measured using transthoracic echocardiography 
 
In the peripheral placebo group, there was a reduction in LVEF of -3.0% (95% CI -16.0 to 10.0; 
p=0.590) at 1 year as compared to baseline. In the G-CSF only group, the LVEF did not change at 1 
year when compared to baseline. The IC serum group showed a -0.5% (95% CI -10.6 to 9.7; 
p=0.927) decrease. The IC BMC group demonstrated an almost negligible change in LVEF (0.2%; 
95% CI -9.6 to 10.0; p=0.973). In the IM serum group, there was a -0.8% (95% CI -10.1 to 8.5; 
p=0.859) reduction at 1 year. In contrast, the IM BMC group showed a 3.5% improvement (95% CI -
3.2 to 10.2; p=0.272) - the highest improvement in LVEF out of all six groups (figure 3.11). At 2 
years, the change in LVEF in the IM BMC group persisted (+4.0%; 95% CI -9.8 to 17.8; p=0.515) 
(figure 3.12). All other groups showed a reduction or marginal increase (+0.70% in IC placebogroup)  
at 2 years. 
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Figure 3.10. Change in NT pro-BNP. Box and whisker plots showing NT pro-BNP (pg/ml) at baseline and 6 months (median 
and range on a logarithmic scale). NT pro-BNP was significantly reduced in the IM BMC group. A-peripheral placebo; B - peripheral G-
CSF only; C – peripheral G-CSF + IC serum; D - peripheral G-CSF + IC BMC; E - peripheral G-CSF + IM serum; F - peripheral G-CSF + IM 
BMC. IC-intracoronary; IM-intramyocardial; G-CSF- granulocyte-colony stimulating factor; BMC-bone marrow derived cells. * 
denotes p<0.05 paired t-test 
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3.2.8 Change in LVEF as measured using quantitative left ventriculography 
 
Quantitative left ventriculography (QLV) was performed at baseline and 6 months in the IC and IM 
arms only. In the IC BMC group, LVEF decreased by -1.8% (95% CI -6.7 to 3.2; p=0.448) and in the IC 
serum group, the magnitude of LVEF reduction was similar (-1.9%; 95% CI -9.1 to 5.3; p=0.504). The 
change in LVEF was not significantly different between the IC serum and BMC groups (p=0.969). In 
the IM BMC group, there was a -1.8% reduction in LVEF (95% CI -5.2 to 1.7; p=0.288). In the IM 
serum group, there was, a 1.2% increase in LVEF (95% CI -3.0 to 5.5; p=0.546). However, none of 
the changes in LVEF were statistically significant. Furthermore, the difference between the change 
in LVEF in the two IM groups was not significant (p= 0.260). 
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Figure 3.11. Change in LVEF as measured using transthoracic echocardiography at 1 year. Box and whisker 
plots of LVEF derived using contrast transthoracic echocardiography at baseline, 6 months and 1 year in each of the treatment 
groups are shown in this figure. No significant changes were noted at 1 year although a 3.5% improvement in LVEF was noted in the 
IM BMC group. A-peripheral placebo; B-G-CSF only; C-intracoronary serum; D-IC BMC; E- IM placebo; F-IM BMC. IC-intracoronary; 
IM-intramyocardial; BMC-bone marrow derived cells; LVEF-left ventricular ejection fraction. *p<0.05. Significance assessed using 
one-way ANOVA with Bonferroni correction for multiple comparisons 
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Figure 3.12. Change in LVEF as measured using transthoracic echocardiography at 2 years.  Box and whisker 
plots showing mean LVEF at baseline, 6 months, 1 year and 2 years shown for each of the treatment groups (A-F). The trend towards 
improvement in LVEF in the IM BMC group at 1 year was sustained at 2 years. A-peripheral placebo; B - peripheral G-CSF only; C – 
peripheral G-CSF + IC serum; D - peripheral G-CSF + IC BMC; E - peripheral G-CSF + IM serum; F - peripheral G-CSF + IM BMC. IC-
intracoronary; IM-intramyocardial; G-CSF - granulocyte-colony stimulating factor; BMC-bone marrow. *p<0.05. Significance assessed 
using one-way ANOVA with Bonferroni correction for multiple comparisons 
 
3.2.9 Quality of Life questionnaires  
MacNew 
Only the IC BMC group showed a significant improvement in the MacNew QoL questionnaire at 1 
year. At 6 months, the IM BMC group showed a significant improvement in the MacNew score but 
this was not sustained at 1 year. All other groups showed no significant change in MacNew scores 
at 1 year (table 3.5). Both the IC groups - IC BMC and placebo- showed significant improvements in 
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the MacNew questionnaire at 2 years. The remaining groups showed no significant change in the 
MacNew questionnaire (Table 3.6) 
 
Table 3.5. Quality of life questionnaire scores at 1 year 
                  MacNew                EQ5D Index/ VAS                SF36 Physical SF36 Mental 
Group Baseline 1 year Baseline 1 year Baseline 1 year Baseline 1 year 
Peripheral         
Placebo (n=14) 
4.54±1.59 
 
4.74±1.14 
 
0.62±0.26/52.7±29.1 
 
0.65±0.19/50.0±24.6 
 
24.0±11.1 
 
28.2±11.9 
 
47.9±14.3 
 
49.0±13.5 
G-CSF (n=13) 3.96±0.87 
 
4.30±1.41 
 
0.61±0.26/51.1±20.4 
 
0.47±0.32/50.4±25.7 
 
21.8±10.5 
 
25.9±12.9 
 
45.1±12.4 
 
42.5±12.5 
 
Intracoronary         
Placebo (n=12) 4.53±1.16 
 
4.64±1.32 
 
0.63±0.26/52.4±18.9 
 
0.65±0.26/59.6±19.2 
 
23.7±8.0 
 
32.3±12.9
* 
 
54.0±12.0 
 
47.7±13.6
 
 
BMC (n=13) 4.29±1.40 
 
4.73±1.33
* 
 
0.50±0.36/49.6±19.8 
 
0.66±0.22/59.5±27.3
 
 
24.7±12.1 
 
28.9±9.9 
 
50.6±14.8 
 
51.0±13.2 
 
Intramyocardial         
Placebo (n=13) 4.15±0.98 
 
4.95±1.47
 
 
0.55±0.29/49.8±12.8 
 
0.63±0.26/55.0±24.5 31.0±9.8 
 
34.7±10.6 
 
40.2±17.7 
 
48.8±15.4 
 
BMC (n=12) 3.80±1.03 
 
4.09±1.34 
 
0.55±0.26/45.5±22.0 
 
0.53±0.41/46.9±26.0 
 
25.5±13.7 
 
29.9±15.4
* 
 
44.1±9.5 
 
44.0±12.6 
 
 
EQ5D 
In the EQ5D questionnaire, only the IC placebo group showed a significant improvement in the EQ5D visual 
analogue score at 6 months. None of the other groups showed any significant improvement in QoL, using 
the EQ5D, at 1 or 2 years (tables 3.5 and 3.6). 
 
SF36 
At 6 months, the peripheral placebo and IC placebo groups showed significant increase in SF36 physical 
wellbeing score. At 1 year, the IC placebo group and IM BMC group showed significant improvement in the 
physical wellbeing score. None of the other groups showed any significant change in SF36 at 1 year.   
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Table 3.6. Quality of life questionnaire scores at 2 years 
                  MacNew                EQ5D Index/VAS                SF36 Physical SF36 Mental 
Group Baseline 2 years Baseline 2 years Baseline 2 years Baseline 2 years 
Peripheral         
Placebo (n=9) 5.01±1.69 
 
4.96±1.20 0.71±0.14/52.6±26.2 0.72±0.17/54.3±16.2 26.9±11.3 34.4±10.9* 51.4±11.3 47.3±12.4 
G-CSF (n=9)  3.77±0.88 
 
3.86±1.13 0.55±0.32/52.3±16.5 0.44±0.33/47.3±17.4 22.0±11.2 26.7±9.9 41.5±10.9 42.7±11.4 
Intracoronary         
Placebo (n=8) 4.49±1.24 
 
4.88±0.99* 0.71±0.16/54.7±25.8 0.75±0.14/50.4±33.4 25.9±8.0 33.7±12.0* 52.0±12.9 48.6±13.2 
BMC (n=11)  3.98±1.29 
 
4.66±1.23* 0.44±0.35/45.9±18.7 0.57±0.27/57.2±28.7 23.4±12.1 24.8±10.7 48.0±14.4 53.4±12.9 
Intramyocardial         
Placebo (n=6) 4.03±0.79 
 
4.90±1.35 0.44±0.25/45.0±6.5 0.52±0.26/56.0±22.6 32.5±11.6 32.0±11.6 36.2±20.5 49.9±17.0 
BMC (n=8) 3.82±0.70 4.42±0.93 0.57±0.19/40.3±16.0 0.47±0.32/50.4±20.4 24.7±11.8 26.8±11.2 45.1±9.6 50.9±10.8 
  
 
At 2 years, the peripheral placebo and IC placebo groups showed significant improvement in the 
SF-36 physical summary score. None of the other groups showed any significant change in the SF-
36  scores. The QoL scores at 1 year and 2 years are shown in table 3.5 and 3.6 respectively. 
3.3 Safety 
 
3.3.1 Adverse effects related to G-CSF administration 
 
The main adverse effect noted was bone pain (12 of 14 recorded events; 85.7% of adverse events 
recorded) (table 3.7). The incidence of adverse effects to G-CSF administration were not 
significantly different across the groups (p=0.686). 
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Table 3.7. Incidence of adverse effects secondary to G-CSF administration across the groups 
Group Bone pain Other adverse 
effects 
 
 
 
 
 
P=0.686 (Fisher’s 
exact test) 
Intramyocardial  
IM Serum 5 0 
IM BMC 0 2 (1 splenomegaly 
and 1 chest pain) 
Intracoronary  
IC Serum 2 0 
IC BMC 2 0 
Peripheral  
G-CSF 3 0 
 
3.3.2 Procedural complications 
 
In the IC arm, there were 4 procedural complications. These were: femoral artery pseudoaneurysm, 
femoral dissection, coronary dissection (managed conservatively), and a small femoral access site 
haematoma. In the IM arm, there were 4 patients who developed small, femoral access site 
haematomas.  One patient developed a major access site bleed and required vascular surgery. 
Three patients had arrhythmias-one patient developing AF, one patient went into VT requiring DC 
cardioversion and one patient had an episode of non-sustained VT. One patient developed a small 
pericardial effusion, which was managed conservatively. There was no significant difference in 
procedural complication rates between the two arms (p=0.209).  
3.3.3 Cardiac enzymes 
 
A small increase in post-procedural troponin was detected in the IM arm (0.02±0.04; p=0.007) 
(Figure 3.13a). However analysis by treatment group, revealed no significant difference in troponin 
increase between the two groups. Clinically this rise was insignificant and was not associated with a 
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significant rise in creatine kinase (85.1 to 129.5; p=0.102) (figure 3.13b). Importantly, no clinical 
events occurred during the procedures. No significant increases in either CK or troponin were seen 
in any other treatment arm. 
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Figure 3.13a. Change in troponin. 
Diagram showing change in troponin between 
day 0 and day 7 (post-intervention) in the A-
Peripheral arm B- Intracoronary arm and C-
intramyocardial arm*p<0.05. BMC-bone marrow 
derived cells  
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Figure 3.13b. Change in creatine 
kinase. Bar chart showing change in creatine 
kinase between day 0 and day 7 (post-
intervention) in A-Peripheral arm B- 
Intracoronary arm and C-intramyocardial arm 
*p<0.05. BMC-bone marrow derived cells 
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3.3.4 MACE 
 
1 year 
Low rates of MACE were seen at 1 year in all treatment groups with no difference between them 
(Logrank p=0.539). There was one cardiac death in the G-CSF only group (6.7%) and one MI in the 
IC placebo group (6.7%). 
2 years 
The MACE rates were as follows: 2 in peripheral placebo group (2 MI; 13.3%), 2 in G-CSF group (2 
cardiac deaths; 13.3%) and 2 in the IC placebo group (1 MI with PCI and 1 cardiac death; 13.3%) and 
2 in the IM BMC group (2 cardiac deaths: 13.3%)  (Figure 3.14). The MACE rates were not 
significantly different between the groups (Logrank p=0.514). 
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Figure 3.13 Kaplan-Meier MACE curves. Major adverse cardiovascular events (MACE) shown for each of the groups to 2 
years. No significant differences were seen in event rates between groups (Logrank p=0.514). MACE defined as cardiac death, MI, 
CABG or PCI. PP-peripheral placebo; IC-intracoronary; IM-intramyocardial; BMC-bone marrow derived cells 
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3.3.5 Serious arrhythmias 
 
No significant difference was noted in the incidence of serious arrhythmias (as defined in chapter 2) 
between the groups at 1 year (Fisher’s exact test; p=0.896). There was 1 serious arrhythmia in each 
of the IM and IC groups and 2 in the G-CSF only group. Between 1 and 2 years, an additional 1 
serious arrhythmia occurred in each of the IC groups. At 2 years, there were a total of 8 serious 
arrhythmias (Table 3.8). There was no significant difference in the incidence of serious arrhythmias 
at 2 years across the groups (Fisher’s exact test; p=0.865). 
 
Table 3.8. Incidence of serious arrhythmias across the groups at 1 year. 
 0-1 year 1-2 years Total 
Peripheral    
G-CSF only 2 0 2 
Placebo  0 0 0 
Intracoronary    
IC BMC 1 1 2 
IC placebo 1 1 2 
Intramyocardial    
IM BMC 1 0 1 
IM placebo 1 0 1 
 
 
3.3.6 Hospitalisation for heart failure exacerbation 
 
Rates of hospitalisation for heart failure were low across the groups (table 3.9), with no significant 
differences between the groups (p=0.982). Interestingly the IM BMC group had no admissions with 
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heart failure over the first year.  At 2 years, a total of 8 patients had admissions with heart failure-4 
in the peripheral arm (3 in G-CSF group and 1 in placebo group). 2 patients in the IC BMC group and 
1 in the IC placebo group required admission. The IM BMC group again had no patients requiring 
admission with heart failure at 2 years. There was no significant difference between the number of 
patients requiring hospitalisation with heart failure across the groups at 2 years (Fisher’s exact test; 
p=0.664). 
 
Table 3.9. Hospitalisation for heart failure at 1 year. 
Group 0-1 year 1-2 years Total 
Peripheral 
GCSF only 2 1 3 
Placebo 1 0 1 
Intracoronary 
IC BMC 1 1 2 
IC placebo 1 0 1 
Intramyocardial 
IM BMC 0 0 0 
IM placebo 1 0 1 
 
3.3.7 Mortality 
There were total of 2 deaths in the whole trial at 1 year {1 non-cardiac (pneumonia), and 1 cardiac 
(MI)} (Table 3.9), with no difference between treatment groups. There were a total of 7 deaths out 
of the 90 participants (7.8%) at 2 years. Of these, there were 5 cardiac deaths-2 in peripheral G-CSF 
group, 1 in the IC placebo group and 2 in the IM BMC group (Table 3.10). 
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Table 3.10. Mortality at 1 and 2 years 
Group All cause deaths 
at 1 year 
Cardiac deaths 
at 1 year 
All cause deaths 
at 2 years 
Cardiac deaths 
at 1-2 years 
Peripheral    
Placebo 0 0 0 0 
G-CSF 1 1 2 1 
Intracoronary    
IC Placebo 0 0 2 1 
IC BMC 0 0 0 0 
Intramyocardial    
IM Placebo 1 0 1 0 
IM BMC 0 0 2 2 
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3.4 Summary 
 
 Administration of intramyocardial  and intracoronary stem cells appear safe in patients with 
ischaemic cardiomyopathy 
 Only the IM BMC group met the primary endpoint with a 4.99% improvement in LVEF at 1 
year as measured using CT/CMR 
 At 2 years, none of the groups showed a significant change in LVEF. The IM BMC group 
showed a sustained increase in LVEF. 
 Change in LVEF was greater in patients with a lower LVEF at baseline (< median LVEF)  
 The IM BMC group showed a significant reduction in NYHA class at 6 months, 1 year and 2 
years; whilst the IM placebo group showed a significant reduction in NYHA class at 6 months 
only. None of the other groups showed any significant change in NYHA class. 
 None of the groups showed any significant change in CCS class at any time point 
 The IM BMC group showed a significant reduction in NT pro-BNP at 6 months 
 None of the groups demonstrated a significant change in LVEF at 1 year or 2 years using 
transthoracic echocardiography or QLV. 
 There was no significant difference in the incidence of adverse events related to G-CSF 
administration or procedural complication across the groups 
 MACE rates were low across the groups at both 1 year and 2 years 
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Chapter 4  The relationship between cytokine levels and cardiac function  
 
4.1 Background 
 
Activation of inflammatory pathways has been linked to the progression of heart failure in several 
studies as detailed in section 1.1.2.3. Heart failure is associated with changes in many different 
cytokines. Since the suggestion of a link between inflammation and heart failure by Levine et al. 
following the discovery of elevated TNF- α in heart failure patients, several studies have shown that 
a number of pro-inflammatory cytokines and chemokines are elevated in HF.222 These include TNF-
α, interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), IL-1, IL-2, IL-18 and 
interferon-γ (IFN-γ) 32. These pro-inflammatory mediators are released from the myocardium and 
other extra-cardiac tissues in response to injury and although their primary purpose is to aid in the 
repair process, sustained and overexpression of these cytokines and chemokines exerts deleterious 
effects on the heart.  These effects include but are not limited to myocyte hypertrophy, oxidative 
stress, increased matrix metalloproteinase secretion by fibroblasts and extracellular matrix 
degradation as well as increased myocyte apoptosis, necrosis and fibrosis. To counteract these pro-
inflammatory mediators, anti-inflammatory cytokines such as IL-10 are released into the 
circulation. However, it appears that in HF patients, this response is blunted with reduced 
responses of anti-inflammatory cytokines compared to pro-inflammatory cytokine levels. 49 Thus it 
appears that the balance between pro- and anti-inflammatory cytokines and chemokines is tilted 
towards the pro-inflammatory state in patients with HF. Several of these cytokines have been 
linked to disease severity and prognosis e.g. TNF-α, IL-6, etc. In this cytokine sub-study, the 
relationship between a panel of cytokines consisting of pro- and inflammatory cytokines as well as 
proangiogenic cytokines was studied in the context of G-CSF and autologous bone marrow derived 
cell therapy to assess any relationships with cardiac function and heart failure progression.  
133 
 
4.2 Hypothesis 
 
 The administration of G-CSF and autologous bone marrow derived cells leads to an improvement 
in cardiac function in patients with ischaemic cardiomyopathy by modulating cytokine levels  
4.3 Specific aims 
1. To measure levels of IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, TNF-α, IFN-γ, IL-1a, IL-1b and MCP-1 
over time in patients with ischaemic cardiomyopathy and correlate these to LVEF 
2. To measure the effect of G-CSF alone and in combination with autologous BMC on the 
levels of IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, TNF-α, IFN-γ, IL-1a, IL-1b and MCP-1 in patients 
with ischaemic cardiomyopathy 
 
For methods-see section 2.2 
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4.4 Results 
 
The 11 cytokines measured were: IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, TNFα, IFNγ, MCP-1, IL-1a and IL-
1b. A total of 50 patients had paired serum samples at baseline and 1 year stored at -80°C that 
were suitable for analysis (figure 4.1). The remainder of the samples were either unsuitable due to 
having undergone multiple freeze-thaw cycles during equipment transfers, incorrect labelling, 
insufficient sample volume or were missing. The inter-assay coefficients of variation (CV) for the 11 
cytokines were within acceptable limits, with the majority of CV’s <15%. 
 
Figure 4.1. Cytokine analysis flowchart. Diagram depicting the distribution of cytokine samples in each group. PP-
peripheral placebo; ICP- intracoronary placebo; BMC- Bone marrow derived cells; IMP- intramyocardial placebo NS/A-samples not 
available or suitable (due to multiple freeze-thaw cycles during equipment transfers, incorrect labelling or insufficient sample 
volume) 
 
 
BASELINE 
1 YEAR 
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4.4.1 Change in cytokines associated with adverse outcomes in heart failure and association with 
LVEF at 1 year 
 
Interleukin-8 
The interleukin-8 (IL-8) level at baseline was 4.01±4.8pg/ml and increased to 5.03±6.5pg/ml. The 
mean increase of 1.02 pg/ml was statistically significant (p=0.042) (Fig 4.2). IL-8 showed a negative 
correlation with LVEF (r2 =0.05; p=0.024) (Fig 4.3). In the peripheral placebo group, IL-8 significantly 
increased by 0.92pg/ml (95% CI 0.05 to 1.79; p=0.042). In the G-CSF only group, IL-8 increased by 
1.95pg/ml (95% CI -2.90 to 6.80; p=0.373). IL-8 increased by 0.48pg/ml (95% CI -2.72 to 3.69; 
p=0.725) in the IC placebo group and by 0.83pg/ml (95% CI -0.93 to 2.58; p=0.315) in the IC BMC 
group. In the IM placebo group, IL-8 increased by 0.74pg/ml (95% CI -0.78 to 2.26; p=0.289). Only in 
the IM BMC group did the mean IL-8 level decrease (-0.21pg/ml; 95% CI -1.38 to 0.97) although this 
was not significant (p=0.695) (Fig 4.4). However, the change in IL-8 between the groups was not 
significant (one-way ANOVA p=0.427).  
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Figure 4.2. Change in IL-8 in the entire cohort. Bar charts showing mean (+SEM) IL-8 level at baseline and 1 year. * 
p<0.05. IL-8- interleukin-8  
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Figure 4.3. IL-8 and LVEF. Correlation curve between IL-8 and LVEF. A significant correlation was observed between IL-8 and 
LVEF. LVEF-left ventricular ejection fraction. IL-8 interleukin 8 
r2=0.05 
p=0.024 
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Figure 4.4. IL-8 level by study group. Bar charts showing change in IL-8 levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IL-8 interleukin 8.  
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Interferon-γ 
The mean interferon-γ (IFNγ) level for the entire cohort did not change significantly between 
baseline and 1 year (0.20±0.2pg/ml to 0.23±0.2pg/ml; p=0.413) (Fig 4.5). There was a significant 
negative correlation between IFNγ and LVEF (r2=0.06; p=0.015) (Fig 4.6). IFNγ did not change 
significantly in any of the six groups. In the peripheral placebo group, IFNγ increased by 0.10pg/ml 
(95% CI -0.09 to 0.28; p=0.245). In the G-CSF only group, IFNγ increased by 0.15pg/ml (95% CI -0.11 
to 0.42; p=0.209). There was negligible change in IFNγ in the IC placebo group (-0.01pg/ml; 95% CI -
0.02 to 0.04; p=0.664) and the IC BMC group (-0.002pg/ml; 95% CI -0.03 to 0.03; p=0.883). 
Similarly, in the IM placebo group, IFNγ change was negligible (0.003 pg/ml; 95% CI -0.09 to 0.09; 
p=0.948). In the IM BMC group, IFNγ levels fell by a mean of -0.09pg/ml (95% CI -0.36 to 0.19; 
p=0.492) (Fig 4.7). The change in IFNγ at 1 year was not significantly different across the groups 
(one-way ANOVA p=0.323)  
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Figure 4.5. Change in IFN-γ in the entire cohort. Bar charts showing mean (+SEM) IFN-γ level at baseline and 1 year. * 
p<0.05. IFN-γ-interferon gamma  
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Figure 4.6. IFN-γ and LVEF. Correlation curve between IFN-γ and LVEF. A significant correlation was observed between IFN-γ 
and LVEF. LVEF-left ventricular ejection fraction. IFN-γ interferon gamma 
r2=0.06 
p=0.015 
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Figure 4.7. IFNγ level by study group. Bar charts showing change in IFNγ levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IFNγ-interferon gamma.  
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Interleukin-6 
The baseline interleukin-6 (IL-6) level was 2.35±1.6pg/ml and increased more than two fold to 
5.90±16.0pg/ml, an increase of 3.6pg/ml, although this was not significant (p=0.127) (Fig 4.8). IL-6 
level was not significantly correlated with LVEF (r2 =0.01; p=0.284). IL-6 increased significantly in the 
IM placebo group (1.22pg/ml; 95% CI 0.05 to 2.40; p=0.044). In the remainder of the groups there 
was no significant change in IL-6 levels.  In the peripheral placebo group, IL-6 levels were virtually 
unchanged (mean change 0.01pg/ml; 95% CI -1.07 to1.09; p=0.988). In the G-CSF only group, IL-6 
increased by 3.28pg/ml (95% CI -0.33 to 6.88; p=0.070). IL-6 also increased in both IC groups- in the 
IC placebo group by 0.85pg/ml (95% CI -1.51 to 3.21; p=0.410) and in the IC BMC group by 
0.67pg/ml (95% CI -1.36 to 2.70; p=0.472). In the IM BMC group, IL-6 increased by 1.49pg/ml (95% 
CI -0.60 to 3.54; p=0.136) (Fig 4.9).  
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Figure 4.8. Change in IL-6 in the entire cohort. Bar charts showing mean (+SEM) IL-6 level at baseline and 1 year. * 
p<0.05. IL-6- interleukin-6  
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Figure 4.9. IL-6 level by study group. Bar charts showing change in IL-6 levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IL-6 interleukin 6.  
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Tumour Necrosis Factor-α 
The tumour necrosis factor-α (TNF-α) level for the entire cohort was not significantly changed 
between baseline and 1 year (2.54±0.9pg/ml to 2.78±1.0pg/ml; p=0.089) (Fig 4.10). No significant 
association between TNF-α and LVEF was seen in our cohort (r2 =0.004; p=0.557).  TNF- α did not 
change significantly in any of the groups. In the peripheral placebo group, TNF-α decreased by -
0.39pg/ml (95% CI -1.07 to 0.29; p=0.210) while in the G-CSF only group, by 1.00pg/ml (95% CI -
0.25 to 2.25; p=0.103). TNF-α increased by 0.22pg/ml in the IC placebo group (95% CI -0.50 to 0.94; 
p=0.478) and by 0.22pg/ml (95% CI -0.15 to 0.60; p=0.211) in the IC BMC group. TNF-α increased by 
0.25pg/ml in the IM placebo group (95% CI -0.25 to 0.74; p=0.279) but was virtually unchanged (-
0.007pg/ml; 95% CI -0.60 to 0.58; p=0.980) in the IM BMC group (Fig 4.11).  
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Figure 4.10. Change in TNF-α in the entire cohort. Bar charts showing mean (+SEM) TNF-α level at baseline and 1 year. * 
p<0.05. TNF-α –Tumour necrosis factor alpha 
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Figure 4.11. TNFα level by study group. Bar charts showing change in TNFα levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells.TNF-α Tumour necrosis factor alpha.  
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Interleukin-1a 
The mean interleukin-1a (IL-1a) level did not change significantly at 1 year (44±0.49pg/ml to 
0.47±0.33pg/ml; p=0.616) (Fig 4.12). No association between IL-1a and LVEF was observed in the 
cohort (r2=0.02; p=0.164). IL-1a levels did not change significantly at 1 year in any of the groups. In 
the peripheral placebo group, IL-1a increased by 0.27pg/ml (95% CI -0.08 to 0.62; p=0.110) while in 
the G-CSF only group, IL-1a increased by 0.12pg/ml (95% CI -0.10 to 0.33; p=0.250). In the IC 
placebo group, the change in IL-1a was minimal (-0.02pg/ml; 95% CI -0.18 to 0.12; p=0.689) as was 
also seen in the IC BMC group (0.05pg/ml; 95% CI -0.04 to 0.14; p=0.211). IL-1a decreased in the IM 
placebo group by -0.26pg/ml (95% CI -0.73 to 0.22; p=0.238). IL-1a level was virtually unchanged in 
the IM BMC group (-0.002pg/ml; 95% CI -0.08 to 0.08; p=0.949) (Fig 4.13).  
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Figure 4.12. Change in IL-1α in the entire cohort. Bar charts showing mean (+SEM) IL-1-α level at baseline and 1 year. * 
p<0.05. IL-1α –Interleukin 1 alpha. 
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Figure 4.13. IL-1a level by study group. Bar charts showing change in IL-1a levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IL-1a-interleukin 1 alpha.  
 
147 
 
Interleukin-1b 
The baseline interleukin-1b (IL-1b) level in the entire cohort was 1.20±1.11pg/ml and changed, non-
significantly, to 1.81±5.26pg/ml, an increase of 0.61pg/ml (p=0.431) (figure 4.14). No association 
was observed between IL-1b and LVEF in our cohort (r2 =0.02; p=0.145). In the peripheral placebo 
group, mean IL-1b increased by 0.62pg/ml (95% CI -0.66 to 1.91; p=0.282) while it increased by 
0.36pg/ml (95% CI -1.66 to 2.38; p=0.691) in the G-CSF only group. IL-1b increased by 0.20pg/ml 
(95% CI -0.68 to 1.08; p=0.603) in the IC placebo group and changed marginally (0.05pg/ml; 95% CI 
-0.04 to 0.14; p=0.211) in the IC BMC group. In the IM placebo group, IL-1b decreased significantly 
by -1.27pg/ml (95% CI -2.44 to -0.11; p=0.036). IL-1b also decreased in the IM BMC group, albeit 
non-significantly, by -0.88pg/ml (95% CI -1.88 to 0.11; p=0.075) (figure 4.15)  . However, the change 
in IL-1b at 1 year was not significantly different across the groups (one-way ANOVA p=0.128).  
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Figure 4.14. Change in IL-1b in the entire cohort. Bar charts showing mean (+SEM) IL-1β level at baseline and 1 year. * 
p<0.05. IL-1b–Interleukin 1 beta.  
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Figure 4.15. IL-1b level by study group. Bar charts showing change in IL-1b levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E--IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IL-1b interleukin 1 beta.  
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Monocyte Chemoattractant Protein-1 
The mean baseline monocyte chemoattractant protein-1 (MCP-1) level in the entire cohort was 
108.4±61.4pg/ml and increased, non-significantly, at 1 year to 124.0±56.7pg/ml, a mean increase 
of 15.5pg/ml (p=0.071) (Fig 4.16). No association between MCP-1 and LVEF was observed in our 
cohort (r2=0.01; p=0.379). In the G-CSF only group, MCP-1 increased significantly by 33.97pg/ml 
(95% CI 4.34 to 63.60; p=0.030) (figure 4.17). In the IM BMC group MCP-1 decreased non-
significantly, by 15.79pg/ml (95% CI -77.42 to 45.84; p=0.571). The remainder of the groups 
showed non-significant increases in MCP-1.  In the peripheral placebo group, MCP-1 increased by 
3.82pg/ml (95% CI -3.82 to 11.46; p=0.267). In the IC placebo group, MCP-1 increased by 
25.93pg/ml (95% CI -24.93 to 76.79; p=0.259) and by 30.64pg/ml (95% CI -32.88 to 94.16; p=0.304) 
in the IC BMC group. In the IM placebo group, MCP-1 increased by 12.24pg/ml (95% CI -10.00 to 
34.47; p=0.234) (Fig 4.17). The change in MCP-1 at 1 year was not significantly different across the 
groups (one-way ANOVA p=0.495). 
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Figure 4.16. Change in MCP-1 in the entire cohort. Bar charts showing mean (+SEM) MCP-1 level at baseline and 1 year. 
* p<0.05. MCP-1 monocyte chemoattractant protein-1. 
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Figure 4.17. MCP-1 level by study group. Bar charts showing change in MCP-1 levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. MCP-1 Monocyte chemoattractant protein-1. 
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Interleukin-2 
In the whole cohort, mean interleukin-2 (IL-2) level at baseline was 2.49±0.4pg/ml compared to 
4.2±6.6pg/ml (p=0.078) at 1 year (Fig 4.18). There was no association seen with LVEF (r2= 0.00003, 
p=0.961). When splitting the IL-2 levels by treatment group no significant change in mean levels 
were seen at 1 year compared to baseline in any group {peripheral placebo group, 1.21pg/ml (95% 
CI -0.30 to 2.7; p=0.097); G-CSF only group, 2.34pg/ml (95% CI -2.95 to 7.64; p=0.337); IC placebo 
group, 0.45pg/ml (95% CI -0.95 to 1.85; p=0.461); IC BMC group, -0.05pg/ml (95% CI -0.51 to 0.41; 
p=0.808); IM placebo group, 5.11pg/ml (95% CI -7.125 to 17.35; p=0.356), and IM BMC group, 
1.12pg/ml (95% CI -0.60 to 2.84; p=0.172)} (Fig 4.19). 
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Figure 4.18. Change in IL-2 in the entire cohort. Bar charts showing mean (+SEM) IL-2 level at baseline and 1 year. * 
p<0.05  
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Figure 4.19. IL-2 level by study group. Bar charts showing change in IL-2 levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05 (paired t-test). G-CSF-
granulocyte colony stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IL-2 interleukin 2. 
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Interleukin-4 
The baseline interleukin-4 (IL-4) level was 2.16±0.3 pg/ml. At 1 year, the IL-4 level did no change 
significantly (2.34±0.7pg/ml; p=0.105) (Fig 4.20). IL-4 levels showed no significant association with 
LVEF (r2 = 0.01; p=0.296). IL-4 did not change significantly in any of the six groups. In the PP group, 
IL-4 levels increased by 0.43pg/ml (95% CI -0.95 to 1.81; p=0.476) while in the G-CSF only group, IL-
4 increased by 0.37pg/ml (95% CI -0.32 to 1.06; p=0.250). IL-4 level changed negligibly in the IC 
placebo group (0.08pg/ml; 95% CI -0.20 to 0.36; p=0.509) and in the IC BMC group (-0.03pg/ml; 
95% CI -0.27 to 0.22; p=0.825).  The IMP group also had a marginal decrease in IL-4 levels (-
0.09pg/ml; 95% CI -0.31 to 0.14; p=0.407) while the IM BMC group had a 0.31pg/ml increase in IL-4 
levels (95% CI -0.22 to 0.85; p=0.210) (Fig 4.21). 
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Figure 4.20. Change in IL-4 in the entire cohort. Bar charts showing mean (+SEM) IL-4 level at baseline and 1 year. * 
p<0.05. IL-4-interleukin-4.   
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Figure 4.21. IL-4 level by study group. Bar charts showing change in IL-4 levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IL-4 interleukin 4.  
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4.4.2 Change in cytokines associated with positive outcomes in heart failure and association with 
LVEF at 1 year 
 
Interleukin-10 
The mean interleukin-10 (IL-10) level at baseline was 0.82±0.3pg/ml and increased significantly to 
1.77±2.8pg/ml, a mean increase of 0.9pg/ml (p=0.020) (Fig 4.22). There was a trend towards a 
positive association between IL-10 levels and LVEF (r2 = 0.04; p=0.062) (Fig 4.23). No significant 
change in IL-10 levels were noted in any of the groups. In the peripheral placebo group, IL-10 
increased by 0.46pg/ml (95% CI -0.10 to 1.02; p=0.093). In the G-CSF only group, IL-10 also 
increased by 0.22pg/ml (95% CI -0.21 to 0.65; p=0.267). IL-10 changed negligibly by -0.07pg/ml 
(95% CI -0.53 to 0.39; p=0.678) in the IC placebo group and remained virtually unchanged in the IC 
BMC group (0.05pg/ml; 95% CI -0.13 to 0.23; p=0.536). In the IM placebo group, IL-10 changed 
marginally by 0.05pg/ml (95% CI -0.77 to 0.87; p=0.880). In the IM BMC group the change in IL-10 
was more pronounced at 0.49pg/ml (-0.55 to 1.53; p=0.301) (Fig 4.24). 
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Figure 4.22. Change in IL-10 in the entire cohort. Bar charts showing mean (+SEM) IL-10 level at baseline and 1 year. * 
p<0.05. IL-10-interleukin 10  
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Figure 4.23. IL-10 and LVEF. Correlation curve between IL-10 and LVEF. A significant correlation was observed between IL-10 
and LVEF. LVEF-left ventricular ejection fraction. IL-10 interleukin 10 
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Figure 4.24. IL-10 level by study group. Bar charts showing change in IL-10 levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. IL-10 interleukin 10  
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Vascular Endothelial Growth Factor 
The mean vascular endothelial growth factor (VEGF) level at baseline was 17.16±17.0pg/ml and 
increased, non-significantly  to 22.07±32.1pg/ml, a mean increase of 4.91pg/ml (p=0.292) (figure 
4.25). There was no association between IL-10 levels and LVEF (r2 =0.01; p=0.307). None of the 
groups showed any significant change in VEGF levels (figure 4.26). In the peripheral placebo group, 
VEGF increased by 2.08pg/ml (95% CI -7.86 to 12.02; p=0.627). In the G-CSF only group, VEGF 
decreased by -1.01pg/ml; 95% CI -8.02 to 5.99; p=0.747). In the IC placebo group, VEGF level was 
marginally decreased by -0.39pg/ml (95% CI -7.31 to 6.53; p=0.890). In contrast, VEGF levels 
increased by 11.65pg/ml (95% CI -9.72 to 33.03; p=0.249) in the IC BMC group although this 
increase was not significant. In the IM placebo group, VEGF levels decreased by 2.16pg/ml (95% CI -
8.11 to 3.80; p=0.420). In contrast to the IM placebo group, VEGF increased in the IM BMC group 
(4.90pg/ml; 95% CI -8.34 to 18.14; p=0.410). The change in VEGF at 1 year was not significantly 
different across the groups (one-way ANOVA p=0.511).  
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Figure 4.25. Change in VEGF in the entire cohort. Bar charts showing mean (+ SEM) VEGF level at baseline and 1 year. * 
p<0.05 VEGF-vascular endothelial growth factor. SEM-standard error of mean.  
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Figure 4.26. VEGF level by study group. Bar charts showing change in VEGF levels in each group at baseline and 1 year 
(mean+SEM). A-peripheral placebo B-G-CSF only C-IC placebo D-IC BMC E-IM placebo F-IM BMC. *p<0.05. G-CSF-granulocyte colony 
stimulating factor. IC-intracoronary. IM-intramyocardial. BMC-bone marrow cells. VEGF-vascular endothelial growth factor.  
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4.5 Summary 
 
Change in cytokines associated with adverse outcomes in heart failure 
 IFN-γ and IL-8 showed a negative correlation with LVEF while IL-10 showed a positive 
correlation with LVEF 
 IL-8 increased significantly in the peripheral placebo group and non-significantly in all 
other groups except the IM BMC group in which there was a non-significant decrease.  
 No significant change in IFN-γ levels were noted in any of the six groups. IFN-γ decreased 
in the IM BMC group and showed an increase or negligible change in the remainder of the 
groups. 
 IL-1b decreased significantly in the IM placebo group and showed a trend towards 
significant reduction in the IM BMC group. All other groups showed an increase or 
marginal change in IL-1b levels.  
 MCP-1 increased significantly in the G-CSF only group and non-significantly in all the other 
groups except the IM BMC group in which it non-significantly decreased. 
 IL-2 was not changed significantly in any of the six groups and showed no correlation with 
LVEF 
 IL-4 was not changed significantly in any of the six groups and showed no correlation with 
LVEF 
 IL-6 increased significantly in the IM placebo group. None of the other groups showed any 
significant change.  
 TNF-α was not changed significantly in any of the six groups and showed no correlation 
with LVEF 
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 IL-1a was not changed significantly in any of the six groups and showed no correlation 
with LVEF 
 
Change in cytokines associated with a positive outcome in heart failure 
 IL-10 increased significantly in the entire cohort at 1 year. IL-10 did not change 
significantly in any of the six groups.  
 VEGF increased in the IC BMC and IM BMC groups while VEGF levels decreased in the IC 
and IM placebo groups but none of the changes were significant. 
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Chapter 5 . Mechanistic insights into the effect of cell therapy in 
ischaemic cardiomyopathy- the relationship between cells and scar, 
cytokines, and diastolic function.  
 
5.1 Background 
 
Despite several previous studies assessing the effect of cell therapy on changes in left ventricular 
function in patients with ischaemic cardiomyopathy (see section 1.2.5.4), few have assessed other 
parameters such as scar burden, diastolic function or looked at relationships between cell counts 
and outcomes. Some trials using cardiac stem cells have reported reduction in scar size including 
CADUCEUS and SCIPIO.114, 116 However, no trial yet has looked at scar size in patients receiving G-
CSF alone or in combination with bone marrow derived cells, as well as the relationship between 
changes in scar burden and cytokine levels, NT pro-BNP and left ventricular volumes.  
 
The vast majority of cell therapy trials have focused primarily on change in systolic LV function. 
However, almost an equal number of patients exist in the community who have heart failure with 
preserved ejection fraction likely secondary to diastolic dysfunction.223, 224 Furthermore, coexistent 
diastolic impairment with systolic impairment is not uncommon. Only one trial has looked at the 
effect of cell therapy on diastolic function and reported an improvement in diastolic function in 
patients receiving bone marrow derived cells. 151  No trial has looked into the effect of G-CSF and 
autologous BMC on diastolic function when administered via different routes. 
 
Aspects of the relationship between progenitor cell count/function and outcomes have been 
studied in a limited number of studies, including the FOCUS-HF, FOCUS-CCTRN and POSEIDON 
trial.145, 146, 155 In the FOCUS-HF trial, CD34+ cell counts as well as CFU-GM and CFU-F (colony 
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forming unit fibroblast) analysis were performed and correlated with demographics and outcomes.  
It has also been observed that cell counts and their functional characteristics deteriorate in patients 
with advanced heart failure.154, 225 The age of the patient and comorbidities such as diabetes can 
affect the cell count. This chapter aims to assess relationship between cell therapy and scar burden, 
diastolic function and looks at the relationship between CD34+, endothelial progenitor cells (EPC) 
and mononuclear cells (MNC) counts and function and change in the primary endpoint (left 
ventricular ejection fraction-LVEF).  
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5.2 Hypothesis  
1. Myocardial scar reduction is associated with improvement in LVEF, cytokine levels and 
cell/G-CSF therapy 
2. Bone marrow derived cell therapy and G-CSF are associated with improved diastolic 
function 
3. Increased peripheral and bone marrow cell counts and improved cell function are 
associated with improved LVEF 
 
 
5.3 Specific aims 
 
1. To assess the mechanisms by which improvements in LVEF may have occurred specifically 
assessing myocardial scar size, cytokine levels and diastolic function.  
2. To assess the relationship between cell characteristics and change in LVEF e.g. numbers of cells 
delivered and CFU-GM colonies  
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5.4 Results 
 
5.4.1 Myocardial scar 
 
Myocardial scar was measured in 27 patients at baseline and 1 year and in 11 patients at 2 years. 
(Figure 5.1) The remainder of the patients did not have CMR based myocardial scar measurements 
because of contraindications to CMR or due to delays in getting approval to initiate 2 year follow-
ups.  
 
Figure 5.1. Diagram showing number of patients eligible for scar analysis using CMR. CMR-cardiac magnetic 
resonance imaging. PP-peripheral placebo. IC-intracoronary IM-intramyocardial BMC-bone marrow cells; G-CSF-granulocyte colony 
stimulating factor. *No CMR-due to MR incompatible device; ^No CMR-logistical reasons; delayed commencement of 2 year follow-
up (see text) 
Baseline 
1 year 
2 years 
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Scar size in the entire patient cohort 
In the whole cohort, the mean scar burden (as percentage of total myocardial mass) was 10.2±1.2% 
at baseline and 9.4±0.9% at 1 year i.e. a change of -0.8±0.8% (p=0.311). A weak trend to a negative 
correlation was observed between percentage change in scar and an increase in LVEF difference 
(r2=0.07;
 p=0.172) at the same time points (figure 5.2).  At 2 years, no statistically significant 
correlation was found between scar burden and LVEF (r2=0.04; p=0.556) (fig 5.3). The low number 
of patients at 2 years undergoing CMR meant that no further sub-analyses of the data was possible. 
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Scar size and change in LVEF 
 
In patients who had an improvement in LVEF (defined as an increase or no change in LVEF) 
(henceforth, referred to as responders) at 1 year, the mean scar burden decreased, albeit non-
significantly, from 10.4±1.4% to 8.7±1.7% i.e. -1.7±1.0 (95% CI -3.9 to 0.5; p=0.127). In comparison, 
in those patients who had a decline in LVEF (henceforth, referred to as non-responders), there was 
an increase in scar burden from 10.0±1.9% to 10.5±1.7% i.e. an increase of 0.5±1.2% (95% CI -2.1 to 
Figure 5.2. Change in scar (%) versus change in LVEF (%) at 1 year. Correlation curve showing lack of 
correlation between scar burden and LVEF.  
 
r
2
=0.07; 
p=0.171 
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3.0; p=0.702). The change in means between the two groups was not significant (p=0.188), the 
difference between the mean changes in the responders (-1.7±1.0%) versus the non-responders 
(0.5±1.2%) was 2.1±1.4% (95% CI -1.1 to 5.4) (figure 5.4). 
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Figure 5.3. Change in scar (%) versus change in LVEF (%) at 2 years. Correlation curve showing lack of correlation 
between scar burden and LVEF.  
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Figure 5.4. Change in scar in LVEF improvers 
(responders) versus decliners (non-
responders). Responders-no decline in LVEF. Non-
responders-decline in LVEF. LVEF-left ventricular 
ejection fraction 
r
2
=0.04 
P=0.556 
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Scar size and correlation with left ventricular volumes and NT pro-BNP in responders  
In responders, the mean end-diastolic volume (EDV) increased at 1 year by 14.1±8.2mls (p=0.105). 
The end systolic volume (ESV) also increased by 2.3±5.5 (p=0.682). The myocardial mass (MM) 
increased by 2.3±3.0g (p=0.452). All the above changes were statistically non-significant. The 
median (IQR) NT pro-BNP decreased from 334.5 (120.3 to 904.8) to 279.0 (146.0 to 858.5) 
(p>0.999). No significant correlation was found between change in EDV, ESV or MM and change in 
scar at 1 year. Although non-significant, a weak trend towards a positive correlation was observed 
between change in scar and change in NT pro-BNP i.e. a reduction in scar size was associated with a 
reduction in NT pro-BNP (r2=0.08; p=0.277) (figure 5.5). 
 
LV volumes and NT Pro-BNP in responders with a reduction in scar size compared to those with 
an increase in scar size 
As expected from the above correlation curves, no significant difference, between those with a scar 
reduction and those with increased scar, was seen in a) EDV (18.5±11.2 v 6.8±11.9; p=0.505) b) ESV 
(6.3±8.0 v -4.3±6.5; p=0.371) c) MM (1.3±3.4 v 4.1±6.1; p=0.673) d) NT pro-BNP (-36.3±103.9 v -
36.5±46.3; p=0.999). 
 
169 
 
 
 S c a r  (% )

L
V
E
D
V
 (
m
l)
-1 0 -5 5 1 0
-1 0 0
-5 0
5 0
1 0 0
A )
r
2
= 0 .0 0 ; p = 0 .9 1 2
 S c a r  (% )

L
V
E
S
V
 (
m
l)
-1 0 -5 5 1 0
-6 0
-4 0
-2 0
2 0
4 0
6 0
B )
r
2
= 0 .0 1 ; p = 0 .7 6 5
 S c a r  (% )

M
M
 (
g
)
-1 0 -5 5 1 0
-2 0
-1 0
1 0
2 0
3 0
4 0
C ) r
2
= 0 .0 1 ; p = 0 .6 5 3
 S c a r  (% )

B
N
P
 (
p
g
/m
l)
-1 0 -5 5 1 0
-5 0 0
5 0 0
D ) r
2
= 0 .0 8  p = 0 .2 7 7
 
Figure 5.5. Correlation between left ventricular volumes, myocardial mass, NT pro-BNP and change in scar 
in responders. Graphs show a lack of any significant association between LVEDV, LVESV, MM or NT pro-BNP and myocardial scar 
burden expressed as a percentage of myocardial mass. LVEDV-left ventricular end-diastolic volume. LVESV-left ventricular end-
systolic volume. MM-myocardial mass. 
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Change in scar size and cell (and G-CSF) therapy 
A significant reduction in scar size was noted in the intracoronary cell therapy group when 
compared to the true placebo (i.e. saline only) group (-2.6±1.2% v 1.0±1.1%; p=0.032). No 
significant difference in scar size was noted between the intracoronary cell therapy group when 
compared to the intracoronary placebo group (-2.6±1.2% v -3.0±1.8%; p=0.706). Furthermore, 
when compared to the true placebo (i.e. saline) group, the change in scar size in the intracoronary 
placebo group was not significant (p=0.111). In the G-CSF group, a greater increase in scar size was 
noted when compared to the peripheral placebo group, although these changes were not 
significant (1.4±1.7% v 1.0±1.1%; p=0.881). Insufficient patient distribution in the IM groups (only 
one patient who underwent cardiac MR in the IM BMC group) meant that it was not possible to 
make a comparison between or within IM cell therapy and placebo groups. Figure 5.6 summarises 
the changes in scar size with cell/G-CSF therapy.  
Change in cytokine levels in patients with a change in scar size in entire group 
A total of 8 patients had 11 different cytokines (IL2, IL4, IL6, IL8, IL10, VEGF, INF-γ, TNF-α, IL1a, IL1b, 
MCP-1) measured at baseline and 1 year. No significant correlation was found between change in 
scar burden and change in any of the cytokine levels at 1 year. No significant changes in any of the 
cytokines were noted in either the scar reduction or scar increase groups. Table 5.1 summarises the 
key changes in the cytokines/chemokines. Figures 5.7 and 5.8 show the changes in mean levels of 
individual cytokines/chemokines in the scar reduction and scar increase groups respectively.  
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Figure 5.6. Change in scar size in the different trial groups. A significant reduction in scar size in the IC 
BMC group was seen when compared to the peripheral placebo group. A-G-CSF v peripheral placebo; B-IC placebo v 
IC BMC; C-IM BMC v peripheral placebo; IC-intracoronary. G-CSF-granulocyte colony stimulating factor; BMC-bone 
marrow derived cells 
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CYTOKINE/CHEMOKINE REDUCED 
SCAR 
INCREASED 
SCAR 
IL-2 + + 
IL-4 - + 
IL-6 + + 
IL-8 + - 
IL-10 + - 
VEGF + - 
TNF - + 
MCP-1 + + 
IL-1 IL1a - 
IL1b - 
IL1a - 
IL1b+ 
 
 
 
 
 
 
Table 5.1. Change in cytokines/chemokines with change in scar. + signifies any increase; - signifies any 
reduction 
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Figure 5.7. Change in mean (±SEM) cytokine levels in the reduced scar group. None of the changes in cytokine 
levels were significant. A. IL-2 B. IL-4 C. IL-6 D. IL-8. E. IL-10 F. VEGF G. IFN H. TNF I. IL-1a J. IL-1b K. MCP-1 *p<0.05 
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Figure 5.8. Change in mean (±SEM) cytokine levels in the increased scar group. None of the changes in cytokine 
levels were significant. A. IL-2 B. IL-4 C. IL-6 D. IL-8. E. IL-10 F. VEGF G. IFN H. TNF I. IL-1a J. IL-1b K. MCP-1 *p<0.05 
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5.4.2 Diastolic function 
 
A total of 68 patients had paired sets of data on all 4 parameters measured for diastolic function at 
both baseline and 1 year. The spread of data across the six groups is shown in figure 5.9. 
 
Figure 5.9. Diastolic function. Diagram depicting the number of patients in whom diastolic function was assessed by 
measuring e:a ratio, deceleration time, E:E’ and left atrial dimensions in each group. IC-intracoronary; IM-intramyocardial; BMC-
bone marrow derived cells; G-CSF- granulocyte colony stimulating factor; Unsuitable-due to insufficient images, poor image quality, 
unable to retrieve  
Peripheral arm 
In the peripheral placebo group, none of the measured diastolic parameters changed significantly. 
The E:A ratio (fig 5.10)  changed by 0.41±1.36 (p=0.362), the deceleration time (DT) (fig 5.11) by 
8.0±48.0 (p=0.611), E:E’ by 3.31±6.00 (p=0.115) and LA size by -0.10±0.52 (p=0.559). In the 
peripheral G-CSF group, the E:A ratio did not change significantly (1.02±0.69 to 1.29±1.19; 
p=0.184). The deceleration time (DT) also did not change significantly (-28.4±117.5; p=0.442). 
Neither was there any significant change in the E:E’ (-1.50±4.18; p=0.260) or the left atrial (LA) size 
Baseline 
 
1 year 
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(-0.02±0.59; p=0.921). The change in E:E’ in the G-CSF only group when compared to the peripheral 
placebo group was significant (Δ-4.81±2.24; p=0.045). None of the other parameters were 
significantly different between the two groups.  
 
Intracoronary arm 
None of the diastolic parameters changed significantly in the IC placebo group. The E:A ratio (fig 
5.10) changed by 0.33±1.21 (p=0.369), DT (fig 5.11) by 4.08±146.2 (p=0.925), E:E’ by -1.56±6.19 
(p=0.401) and LA size by -0.01±0.44 (p=0.949). Similar to the IC placebo group, none of the diastolic 
parameters changed in the IC BMC group either. The E:A ratio changed by 0.14±0.31 (p=0.132), DT 
by 32.7±121.9 (p=0.353), E:E’ by 1.16±6.26 (p=0.518) and LA size by -0.18±0.67 (p=0.361). None of 
the parameters were significantly different between the two groups. 
 
Intramyocardial arm 
No significant change in diastolic parameters were found in either the IM placebo or IM BMC 
groups. In the IM placebo group, E:A (fig 5.10) changed by 0.19±0.52 (p=0.273), DT (fig 5.11) by 
33.5±69.9 (p=0.164), E:E’ by -0.48±5.42 (p=0.785) and LA by -0.14±0.78 (p=0.586). In the IM BMC 
group, E:A changed by 0.03±0.45 (p=0.818), DT by -0.58±52.8 (p=0.970), E:E’ by -0.74±2.65 
p=0.356) and LA by 0.16±0.49 (p=0.286). The change in E:E’ in the IM BMC group was significantly 
different to that in the peripheral placebo group (Δ-4.04±1.92; p=0.048). The rest of the 
parameters were not significantly different to the peripheral placebo group and none of the 
parameters were significantly different between the IM BMC and IM placebo groups.  
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Figure 5.10. Change in mean E:A ratio. Diagram depicting the change in mean (±SEM) E:A ratio at 1 year in each of the six 
groups. No significant change in E:A was noted in any group. IC-intracoronary; IM-intramyocardial; BMC-bone marrow derived cells; 
G-CSF- granulocyte colony stimulating factor.  
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Figure 5.11. Deceleration time. Diagram depicting the mean (±SEM) change in deceleration time (DT) at 1 year in each of the 
six groups. No significant change in DT was noted in any group. A-peripheral placebo; B- G-CSF only; C- IC placebo; D-IC BMC; E- IM 
placebo; F-IM BMC; IC-intracoronary; IM-intramyocardial; BMC-bone marrow derived cells; G-CSF- granulocyte colony stimulating 
factor.  
 
Diastolic function and scar reduction 
In patients who had a reduction in scar burden, there was no significant change in any of the 
diastolic function parameters measured. The E:a ratio changed from 0.90±0.28 to 1.08±0.76 
(p=0.495). The DT changed from 238.4±52.7 to 242.0±126.0 (p=0.935). The E:E’ increased from 
9.95±4.78 to 10.91±4.52 (p=0.651). The LA diameter also increased from 4.42±0.64 to 4.55±0.85 
(p=0.703).  
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5.4.3 Cell count and function analyses 
 
Baseline cell distribution 
Peripheral blood 
The mean (±SD) peripheral blood CD34+ cell counts in the entire cohort at baseline was 
2.90x106±2.03/l cells, the EPC count was 0.08x106/l (±0.30) and the peripheral mononuclear cell 
(MNC) count was 2.31x109/l (±0.74).  There was no difference in the baseline counts between the 
groups: CD34+ (one-way ANOVA p=0.538), EPC (one-way ANOVA p=0.361) and MNC (one-way 
ANOVA p=0.641). 
Response to granulocyte colony stimulating factor (G-CSF) 
All five groups that received G-CSF showed an adequate response in cell counts to G-CSF. The mean 
(±SD) day 6 peripheral blood CD34+ count was 57.51x106/l (±70.75), an approximately x20 increase 
in cell count. The mean EPC count at day 6 was 0.39x106/l (±0.54), a 5-fold increase in cell count. 
The mean MNC count went up 3.4 fold to 7.80x109/l (±8.46) in response to G-CSF (Figure 5.12). 
There was no difference in day 6 cell counts between the groups that had received G-CSF when 
compared using one-way ANOVA: CD34+ (p=0.153), EPC (p=0.195) and MNC (p=0.179). 
Bone marrow 
The mean (±SD) CD34+ cell count in the bone marrow reinfused in the interventional groups (i.e. IC 
and IM groups) was 2.92x106 (±1.74) with a mean EPC count of 136.30x102 (±380.20) and a mean 
bone marrow MNC count in the BM infusate of 109.30x106 (±93.50). There was no difference in cell 
counts across the groups when compared using one-way ANOVA: CD34+ (p=0.282), EPC (p=0.294) 
and MNC (p=0.740).  
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Figure 5.12 Mobilisation of cells after G-CSF. Box and whisker plots showing change in peripheral blood cell counts 
between day 0 and day 6 in response to G-CSF. G-CSF-Granulocyte colony stimulating factor. EPC-endothelial progenitor cell. MNC- 
mononuclear cells 
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Colony forming units granulocyte monocyte (CFU-GM) 
The mean CFU-GM count derived from the bone marrow samples in the intervention arms (IC and 
IM) was 13.1 (±10.2) colonies/plate. The mean CFU-GM count in the IC BMC and IM BMC groups 
was 10.9 (±9.5) colonies/plate. The mean CFU-GM in the IC BMC group was 16.4 (±11.5) 
colonies/plate. The mean CFU-GM in the IM BMC group was 9.0 (±8.7) colonies/plate.  There was 
no difference in CFU-GM count between the four groups when compared using one-way ANOVA 
(p=0.808).  
Cell and CFU counts and outcome 
Correlation between peripheral blood cell counts and LVEF 
There was a trend towards a correlation between CD34+ cell count at baseline (day 0) and change 
in LVEF in the whole cohort (Pearson r2=0.04; p=0.058) (figure 5.13) but no significant correlation 
was seen in any of the six groups. Neither was there any correlation between the change in CD34+ 
cell count between day 0 and day 6 in response to the G-CSF (i.e. all groups except peripheral 
placebo), and change in LVEF (r2=0.04;p=0.100). 
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Figure 5.13. Correlation between 
CD34 count and change in LVEF. 
Correlation curve showing trend 
towards significant correlation 
between day 0 CD34 peripheral blood 
count and change in LVEF at 1 year in 
the entire cohort.  
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No association was found between EPC day 0 cell count and change in LVEF in the whole cohort 
(r2=0.001; p=0.799). Neither was any association found between EPC day 0 cell count and change in 
LVEF in any of the groups. However, an association was observed between change in EPC count 
between day 0 and day 6 and the change in LVEF (r2=0.24; p=0.0003) in the G-CSF receiving groups 
(figure 5.14). 
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 Figure 5.14. 
Correlation between mobilisation in EPC and change in LVEF. Correlation curve showing a significant correlation 
between change in EPC count in peripheral blood between day 6 and day 0 in response to G-CSF and change in LVEF at 1 year. G-
CSF- granulocyte colony stimulating factor. LVEF-left ventricular ejection fraction 
No association was found between MNC day 0 cell count and change in LVEF in the whole cohort 
(r2=0.00; p=0.587). The MNC day 0 counts in each of the groups did not show any association either 
with the change in LVEF in the respective groups. There was, however, a significant association 
between change in MNC count between day 0 and day 6 and the change in LVEF (r2=0.05; p-0.043) 
(figure 5.15).  
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Figure 5.15. Correlation between mobilisation in MNC and change in LVEF. Correlation curve showing a significant 
correlation between change in MNC count in peripheral blood between day 6 and day 0 in response to G-CSF and change in LVEF at 
1 year. G-CSF- granulocyte colony stimulating factor. LVEF-left ventricular ejection fraction. MNC- mononuclear cells 
Correlation between bone marrow cell counts and LVEF 
No association was observed between the BM infusate CD34+ cell count (r2=0.00 p=0.760), EPC 
count (r2=0.15; p=0.150) or reinfusate bone marrow MNC (BMMNC) count (r2=0.02; p=0.474) and 
change in LVEF in the two cell therapy groups combined i.e. IC BMC and IM BMC (r2=0.00 p=0.760). 
Analysing the groups individually, neither was any association found between the BM reinfustate 
CD34+ count, EPC count or BMMNC count and change in LVEF in the IC BMC group (CD34+ r2=0.00; 
p=0.888; EPC r2=0.03; p=0.641; BMMNC r2=0.04; p=0.506) or the IM BMC group (CD34+ r2=0.09; 
p=0.293; EPC r2=0.04; p=0.622; BMMNC r2=0.01; p=0.777). 
Correlation between CFU-GM and LVEF 
A significant association between CFU-GM and change in LVEF was observed in the IM BMC group 
(r2=0.62; p=0.020).  (Figure 5.16). However, in the IC BMC group, no association was found 
between CFU-GM and change in LVEF (r2=0.03; p=0.898).  
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Figure 5.16. Colony forming unit granulocyte-monocyte (CFU GM) count and change in LVEF. The figure 
depicts a significant, linear relationship between the CFU GM count in the bone marrow and the change in LVEF in the 
intramyocardial cell therapy group suggesting a link between the functional capacity of the haematopoietic stem cells and change in 
LVEF. LVEF- left ventricular ejection fraction. Significance shown for correlations determined using Pearson’s linear regression of best 
fit ±95% confidence intervals 
 
DIABETES, AGE AND CELL/CFU COUNTS 
The presence of diabetes mellitus did not affect the baseline peripheral CD34+ (p=0.437), EPC 
(p=0.176) or MNC (p=0.131) cell counts. Neither was there any difference in the mobilisation of 
CD34+ (p=0.155), EPC (p=0.082) or MNC (p=0.596) at day 6 between diabetics and non-diabetics. 
The CD34+ (p=0.843), EPC (p=0.923) and BMMNC (p=0.418) cell counts in the bone marrow re-
infusate were also unaffected by the diabetes status as was CFU-GM (p=0.371) and viability 
(p=0.370). 
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Age was not associated with baseline, peripheral CD34+ (r2=0.02; p=0.156), EPC (r2=0.01; p=0.482) 
or MNC (r2=0.01; p=0.288) cell counts. Neither was there any association between mobilisation of 
CD34+ (r2=0.03; p=0.175), EPC (r2=0.01; p=0.565) or MNC (r2=0.01; p=0.375) at day 6 and age. The 
EPC count in the BM re-infusate was significantly, negatively associated with the age of the patient 
at admission (r2=0.13; r= -0.36; p=0.021). However, the CD34+ (r2=0.04; p=0.150) and BMMNC 
(r2=0.01; p=0.610) cell counts in the bone marrow re-infusate showed no correlation with age. 
Neither was there any association between age and viability (r2=0.01; p=0.535) or CFU-GM (r2=0.03; 
p=0.384). 
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5.5 Summary 
 
 No significant association between change in scar and change in LV volumes, myocardial mass or 
NT pro-BNP was observed 
 In patients with an improvement in LVEF, a non-significant reduction in scar was seen with a non-
significant increase in scar seen with lower LVEFs 
 No significant association between change in scar and cytokine levels were observed; however, 
certain trends were noted:  
 TNF-α, IL-4 and IL-1b decreased in the group with reduced scar as opposed to an increase 
in the group with an increase in scar burden 
 IL-10 and VEGF increased in the group with reduced scar as opposed to an decrease in the 
group with an increase in scar burden 
 In the IC BMC group, a significant reduction in scar was observed as compared to the true placebo 
group 
 No significant association between the parameters measured for diastolic function and G-CSF/cell 
therapy was observed 
 No significant association between diastolic function and scar was noted 
 A good response in cell mobilisation was seen in response to G-CSF  
 The increase in peripheral blood EPC and MNC counts at day 6, compared to day 0, were 
significantly associated with change in LVEF at 1 year 
 No significant association was noted between bone marrow counts of CD34+, EPC or BMMNC and 
LVEF change 
 CFU-GM was significantly associated with change in LVEF in the IM BMC group 
 Only the EPC count in the bone marrow was significantly, negatively associated with age.  
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Chapter 6 Discussion 
 
This thesis reports the first-in-man randomised controlled trial to investigate the effect of G-CSF 
alone or in combination with autologous BMC in ischaemic cardiomyopathy. Heart failure is a major 
cause of morbidity and mortality and there is no doubt that further improvement in treatment is 
needed. Novel strategies are required and stem cell therapy has long been regarded as one 
method, which may be successful in accomplishing this. 
This thesis suggests that G-CSF therapy alone does not result in improved cardiac function or 
changes in functional or biochemical outcomes in patients with ischaemic cardiomyopathy. 
However, the administration of G-CSF together with autologous BMC therapy appears to result in a 
significant improvement in LVEF, NYHA class at 1 year and NT pro-BNP levels at 6 months but only 
when the cells were delivered via the intramyocardial route. Furthermore, this beneficial effect on 
LVEF and NYHA class appears to be sustained in the intermediate term i.e. 2 years. Importantly, no 
safety concerns were evident at 1 or 2 years. Subsequent sections report the findings of the 
mechanistic sub-studies looking at the association between cytokines, myocardial scar, cell 
numbers/function, and diastolic function with G-CSF/cell therapy and outcomes.   
 
Three key aims were set out by this thesis, which will be discussed in detail during this discussion.  
 
The 1st aim in this MDRes was to ascertain if the administration of G-CSF monotherapy resulted 
in a beneficial effect on cardiac function in ischaemic cardiomyopathy patients and whether it 
was safe in this patient group 
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The complex and expensive nature of cell therapy trials entails putting the patient through invasive 
procedures, including bone marrow aspiration and arterial access to deliver the cells, and thus, 
exposing them to the potential risks associated with these procedures. Therefore, the appeal of 
“pharmaco-regenerative” medicine is evident. The concept of pharmaco-regenerative medicine - 
that an established drug or cytokine can activate stem and progenitor cells or act as paracrine 
mediators considered to be the effectors of cell therapy - is attractive. G-CSF is a prime example of 
the former i.e. an activator of mobilisation of bone marrow derived cells. The concept that a few 
days of subcutaneous injections of G-CSF could potentially perform the same function as 
“manually” delivering cells to the heart and result in an improvement in cardiac function and 
symptoms led us to test the safety and efficacy of G-CSF as a sole intervention.  In this thesis, I 
showed that although G-CSF therapy was safe it did not result in an improvement in cardiac 
function or symptoms. 
Although the lack of effect of G-CSF alone is disappointing, particularly in view of the ease of 
administration of G-CSF, three questions remain: 1. why did G-CSF not work in the current study 
cohort? 2. Are these results in keeping with other clinical data? and 3. Does this data add to 
existing knowledge? 
There are several possibilities to explain why G-CSF did not work in this study cohort. G-CSF is a 
potent haematopoietic cytokine that is known to mobilise CD34+ cells as well as non-CD34+ cells, 
including MSCs, from the bone marrow into the circulation. One possibility is that the cell 
mobilisation response to G-CSF is blunted in patients with advanced heart failure and the older 
patient population, however, given the good response in circulating cell numbers seen in our study 
after G-CSF administration and the previous similar findings in other studies, this explanation is 
highly unlikely. Rather, the failure of G-CSF is more likely secondary to functional impairment of the 
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mobilised cells resulting in impaired homing and engraftment. It has already been shown that the 
functional capacity of BMCs in older patients and in those with advanced ischaemic 
cardiomyopathy patients is impaired. 154, 226 G-CSF has been suggested to further impair the 
function of these cells. The exact mechanism of action of G-CSF is still not clear but it appears to 
interact with the SDF-1/CXCR-4 axis.  SDF-1 is present in the bone marrow stroma and the receptor 
CXCR-4 is present on the surface of BMC. SDF-1/CXCR-4 interaction plays a role in the retention of 
BMC in the bone marrow and the homing of cells to the heart. G-CSF is known to activate proteases 
that cleave CXCR-4, as explained in section 1.2.7.   Furthermore, G-CSF downregulates SDF-1 levels 
in the bone marrow.227 The net result is a reduced SDF-1/CXCR4 interaction. This aids in the 
mobilisation of the cells from the bone marrow. However, the attraction of cells towards the 
cardiac target requires chemotactic signalling via the SDF-1/CXCR-4 axis. Unfortunately, the 
cleavage of CXCR-4 by G-CSF induced proteases is irreversible. Thus, although G-CSF promotes 
mobilisation of cells into the peripheral blood, it impedes the homing of the cells towards the 
cardiac target. Furthermore, Ripa et al. have documented similar levels of SDF-1 in the chronic 
ischaemia population as compared to the normal population as opposed to the increased SDF-1 
levels observed after an acute MI.228 Thus it appears that in chronic heart failure patients, there is 
no increased chemotactic stimulus to aid the homing of the G-CSF mobilised cells. Theiss et al. have 
demonstrated in mice acute MI models that administration of G-CSF together with sitagliptin, a 
drug used in managing diabetes but also known to stabilise SDF-1, improves cardiac homing of cells 
and leads to improved cardiac function and reduction in short-term mortality. This has led to the 
ongoing SITAGRAMI phase III trial looking at the effect of combined G-CSF and sitagliptin in acute 
MI patients.229 A similar trial in chronic HF patients is probably warranted.  Further proof that G-CSF 
impairs the functional capacity of cells comes from work by Dimmeler et al. They studied the 
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mobilisation and functional capacity of EPC’s in response to G-CSF and found that although the 
mobilisation was adequate in terms of the quantification of mobilised EPC’s, the functional capacity 
of the EPC’s, as characterised by looking at the migratory capacity of the cells in response to VEGF 
and SDF-1, was reduced.230 
 
The optimal G-CSF dose and length of administration is as yet unclear. There is no literature that 
compares different doses of G-CSF or length of administration in ischaemic cardiomyopathy 
patients. In the TOPCARE-G-CSF trial, both 5µg/kg/day and 10µg/kg/day of G-CSF were used.231 As 
the level of mobilisation of peripheral CD34+ cells were comparable, no further sub-analysis was 
undertaken between the two groups and the groups were pooled. Whether, a lower dose of G-CSF, 
enough to mobilise but yet minimally disrupt the homing of the cells, remains to be tested. This 
would require a direct dose comparison study. 
 
The results of my thesis are in keeping with the majority of studies performed using G-CSF. G-CSF 
was shown to be safe in this study with the main reported adverse event being bone pain 
constituting 85.7% of adverse events. This figure is in keeping with the reported figure of 84% by 
Anderlini et al.158 No significant difference in the rate of MACE was noted in the G-CSF only group 
or in the other groups that had received G-CSF. Two previous studies had raised concern regarding 
the possibility of increased progression of atherosclerosis and an increased rate of in-stent 
restenosis after G-CSF in acute MI patients. However, this was not supported in the study by Ripa 
et al in the STEMMI trial. The findings, in my thesis, of no increased rate of MI or cardiac death in 
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the G-CSF groups extends and supports Ripa’s findings in the chronic ischaemic cardiomyopathy 
setting.  
With respect to efficacy, the lack of benefit is consistent with the literature. In the study by Wang 
et al, 13 patients with severe CAD and a mean baseline LVEF of 39% were treated with a lower dose 
of G-CSF than used in most trials (5µg/kg/day) for 6 days and, in fact, found a reduction in LVEF, 
assessed by MRI, of 5% in the G-CSF group. 157  In the study by Hill et al., they treated 16 patients 
with chronic coronary artery disease with the higher 10µg/kg/day dose of G-CSF for 5 days and 
found no significant change in LVEF. 156 However, both these studies were small and not placebo 
controlled. In the TOPCARE-G-CSF trial by Assmus et al, G-CSF was compared against G-CSF plus IC 
circulating EPC’s (CEPC) with no significant effects of G-CSF or G-CSF mobilised CEPC reinfusion on 
cardiac function.  
In summary, despite the theoretical benefit of G-CSF in terms of bone marrow cell proliferation and 
mobilisation, I found no evidence of G-CSF, as monotherapy, being beneficial in chronic ischaemic 
heart failure patients. The novelty and strength of this trial compared to the previous trials was the 
presence of an appropriate comparator arm consisting of saline only and the presence of other 
study arms allowing us to assess the efficacy and safety of G-CSF both alone and in combination 
with BMC therapy. No other trial has, to date, compared G-CSF, G-CSF plus BMC therapy and cell 
delivery route, all in the same trial with appropriate control arms.  
The 2nd aim in this MDRes was to ascertain if the administration of G-CSF in combination with 
autologous BMC resulted in a beneficial effect on cardiac function in ischaemic cardiomyopathy 
patients. 
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The findings that the combination of G-CSF and IM BMC therapy resulted in a 4.99% improvement 
in LVEF at 1 year along with a reduction in NT pro-BNP at 6 months and a sustained reduction in 
NYHA class at 1 and 2 years are promising. The above findings suggest two interpretations: 1. G-
CSF, in combination with autologous BMC are both safe and beneficial to both cardiac function and 
patients’ functional outcomes and 2. The benefit of autologous BMC is seen when the BMC are 
delivered intramyocardially. These two interpretations bring to the forefront several questions 
which will be addressed in the following sections. They are:  
1. Are autologous BMC delivered safe? 
2. Does G-CSF combined with autologous BMC improve cardiac function in ischaemic 
cardiomyopathy patients? 
3. Is the IM route superior to the IC route? 
4. If so what is the mechanism behind the lack of effect with the IC route and the observed 
effect with the IM route? 
5. What is the physiological basis of the improvement in LVEF seen? 
6. What are the implications of the findings in the context of current clinical practice and in 
guiding further research in the field?  
 
193 
 
 
Are autologous BMC delivered safe? 
This thesis has shown that G-CSF alone and in combination with BMC are safe in the acute 
procedural period as well as at 1 and 2 year follow-up, with no observed increase in G-CSF and 
autologous BMC related safety end-points during this period. . These findings are in keeping with 
the existing safety data from recent meta-analyses including that by Kandala et al and two by 
Doree et al. 199, 201 191 Most cell therapy trials to date have reported follow-up at 6 months or 1 
year. The data in this thesis extends to two years and shows a persistent safety record of G-CSF and 
BMC during this longer follow-up period.  
Does G-CSF combined with autologous BMC improve cardiac function in ischaemic 
cardiomyopathy patients AND is the IM route superior to the IC route?  
The design and findings of the study necessitate that these two questions are discussed together.  
The magnitude of the significant improvement in LVEF seen in the IM BMC group but not in the IC 
BMC group suggests efficacy of G-CSF combined with autologous BMC and superiority of the IM 
route. The lack of effect seen with the IC route has multiple possible explanations. The delivery of 
cells via the IC route is reliant on both the presence of a patent vessel for the cells to be infused via, 
the extravasation of the cells from the coronary artery into the ischaemic and peri-ischaemic tissue 
and the integration of the cells into the target tissue i.e. engraftment. Theoretically, IC delivery is 
an attractive strategy, as it should allow uniform distribution of the cells into the target, peri-
infarct, ischaemic tissue as long as there is a patent epicardial vessel for the cells to travel through. 
Although, epicardial vessel patency can be well assessed on coronary angiography, undertaken pre-
cell infusion, the presence of microvascular disease (MVD) cannot be assessed reliably with simple 
coronary angiography. MVD is associated with traditional coronary heart disease (CHD) risk factors. 
194 
 
Cigarette smoking232, hypercholesterolaemia233, hyperglycaemia234 and hypertension235 have all 
been shown to increase coronary microvascular resistance and microvascular dysfunction. In our 
cohort, all 15 patients in the IC BMC group had ≥1 of the following risk factors: hypertension, 
diabetes, hypercholesterolaemia or smoking (either current or ex-smoker). Thus, although not 
directly assessed for, it can be postulated that a significant number of these patients had a degree 
of MVD that might have prevented adequate numbers of cells reaching the target tissue. Secondly, 
the method of IC reinfusion of BMC used was the stop-flow technique. This involves, as previously 
described, balloon inflation to transiently occlude proximal coronary flow with the aim of 
preventing rapid or early cell washout. The cells were delivered in divided doses with three balloon 
inflations, with balloon deflation in between, and 3.3mls of cell suspension being infused during 
each balloon inflation. The question arises as to whether the rate of cell suspension delivery via this 
method could have resulted in clumps of cells causing microvascular obstruction (MVO) and micro-
coronary infarcts and that modifications of the method would be necessary with single, higher 
pressure infusions over shorter durations to reduce the risk of this phenomenon occurring, as has 
been shown in animal models.236 However, the phenomenon of MVO and micro-coronary infarcts 
is mainly seen with larger cell types e.g. MSC’s237 or CSC’s and not with unfractionated BMC and is 
therefore unlikely to explain the lack of effect seen with IC BMC therapy. This was evident from the 
lack of features on coronary angiography suggestive of MVO post-cell infusion and is further 
supported in the analyses by Assmus et al. who looked at 775 patients undergoing IC BMC delivery 
using the stop-flow technique and found very low rates of slow-flow. 194 Lastly, the cells have to 
travel once they have exited the artery to get to the target peri-infarct zone. The efficacy of this 
process will not only depend on flow in the coronary vessels but also on appropriate chemotactic 
signals and the distance from the last patent vessel exit point to the target tissue. Furthermore, as 
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previously mentioned, G-CSF is known to cleave CXCR-4 and this effect would lead to lower 
migration and engraftment of the cells and could further explain the lack of effect of IC BMC 
therapy seen here compared to other trials which have not used G-CSF.  In summary, the delivery 
of cells via the IC route can be considered “indirectly” delivered as opposed to the “directly” 
delivered cells with the IM route (see below). The larger number of variables influencing the 
process of cells migration and engraftment probably reduces the chances of the cells reaching their 
target.  
The observed efficacy with the IM route is very encouraging. This efficacy of the IM route over the 
IC route could be explained by several possible explanations. In contrast to the IC route, the IM 
route does not require patent epicardial vessels and can be directly delivered to the area of 
interest. With regards to identification of the area of interest, the use of electromechanical 
mapping technology allows the targeting of viable myocardium in the peri-infarct area. This allows 
optimal, controlled delivery of the cells to areas of the myocardium which would theoretically 
derive the greatest benefit. In contrast, the delivery of the cells via the IC route allows no such 
controlled delivery. Furthermore, cell retention at the target site has been a persistent problem in 
cell therapy trials, however, pre-clinical studies, have demonstrated that the IM route had four 
times greater cell retention compared to the IC route in a swine ischaemic model.195 192 Although 
direct evidence of increased cell retention in humans is difficult, the results of the pre-clinical study 
imply that the IM route would be more efficacious. However, the results of the IM placebo group in 
our trial does raise the question of whether the IM injections per se cause a local, “beneficial” 
inflammatory reaction in the myocardium which triggers an unexplained, reparative process and 
thus, demonstrates the 4.15% improvement in LVEF. However, there are several reasons this may 
not be the case. Firstly, there was no significant improvement in LVEF seen in the IM placebo 
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group. Secondly, there was no significant improvement in NT pro-BNP at 6 months or NYHA class at 
1 year in the IM placebo group. Thus, the conclusion that can be derived is that this is likely 
secondary to the small number of patients in each group and that a larger scaled, phase III trial 
would  be necessary to show a more clear lack of effect of the IM injection process alone.  
What is the physiological basis of the improvement in LVEF seen? 
The next question that arises is what is the plausible physiological mechanism of the improvement 
in LVEF seen in the IM group i.e. how does one explain the improvement in LVEF in terms of LV 
volumes and contractility?   LVEF is calculated by expressing the stroke volume (SV) as a percentage 
of the LVEDV. The SV and thus the LVEDV and LVESV are determined primarily by three factors- 
preload, afterload and contractility.  The preload is a reflection of the loading state of the heart 
prior to contraction.  According to the Frank-Starling law, increasing preload increases the force of 
contractility and hence, ejects out a greater SV with each beat.  Contractility (or inotropy) is 
determined primarily by the autonomic nervous system. In the failing heart, as inotropy declines, 
the Frank Starling curve shifts downwards as shown in the figure 6.1, i.e. for a certain LV end-
diastolic pressure (LVEDP, a measure of preload), a lower SV is ejected in the failing heart 
compared to the normal heart and conversely, for a certain SV, a higher LVEDP is needed in the 
failing heart compared to the normal heart, as an attempt to compensate for the reduced inotropy, 
as per the Frank-Starling mechanism i.e. an increase in preload. Two varying patterns were 
observed in the IM BMC group at the two time-points i.e. 1 year and 2 years. At 1 year, the LVESV 
decreased but the LVEDV increased marginally, albeit non-significantly. This was accompanied by 
an increase in myocardial mass.   
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At 2 years, the LVEDV as well as the LVESV decreased together with a significant increase in 
myocardial mass. The natural progression of ischaemic HF would involve initial eccentric 
hypertrophy to minimise wall stress. However, the increased wall stress would eventually result in 
adverse remodelling resulting in continued increase in LVEDV and LVESV. Therefore, it appears, 
that the use of G-CSF and IM BMC in combination halts this adverse remodelling and reverses this 
process-“reverse remodelling”. This was evidenced by the reduction in LV volumes seen initially as 
a reduction in LVESV at 1 year and then both LVESV and LVEDV at 2 years. Whether the increase in 
myocardial mass is mainly accounted for by myocardial regeneration rather than solely by 
compensatory hypertrophy is difficult to distinguish without histological evidence.  
What are the implications of the findings in the context of current clinical practice and in guiding 
further research in the field?  
              The finding of an improvement in LVEF with IM delivered autologous BMC is in keeping with data 
published in the most recent meta-analysis by Fisher et al. of autologous bone marrow stem cells 
in chronic heart disease, which showed a 5.95% mean difference in LVEF in the sub-set of patients 
with heart failure and a 5.30% mean difference in the IM group (which was statistically significant 
Figure 6.1 Relationship between SV 
and LVEDP. Curve A represents a normal 
heart and curve B represents a heart with 
ventricular systolic dysfunction. Reproduced 
with permission from www.cvphysiology.com 
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when compared to the 3.19% improvement in the IC group, suggesting superiority of the IM 
route)191. The findings are also in agreement with three other recent meta-analyses of cell therapy 
and heart failure: Kandala et al. (5.13% via IM route) 199, Jeevanantham et al. (3.96%; not route 
specific) 200  and Fisher et al. (3.47%; 8 of 9 trials via IM route) 201. Importantly, although the 
change in LVEF would appear to be relatively low in these analyses and in this thesis, the 
magnitude of effect is similar to that seen in other trials of heart failure therapies (e.g. angiotensin 
converting enzyme inhibitor), which are now part of standard practice 238 In terms of comparing to 
previous  cell therapy trials, the improvement in LVEF seen in the IM arm of this study agrees with 
a few of them including that by Beeres et al., Perin et al. and Pokushalov et al.140, 176, 239 However, 
the more recent FOCUS trials by Perin et al. showed a lack of improvement in LVEF with 
autologous BMC.145, 146 The latter trials did not use G-CSF as an adjunct for cell mobilisation. 
Furthermore, the study used an automated cell separation technique which is different to the 
manual Ficoll-Hypaque method utilised in our study. However, the larger FOCUS-CCTRN trial did 
show a significant improvement of 3.1% in LVEF in the under 62 years age group. In contrast, the 
results of my thesis failed to corroborate that of recent intracoronary cell therapy trials. The IC arm 
results in my thesis are in keeping with studies done by Yao et al. and against the findings of the 
large IC cell therapy trial-STAR-HEART. 143, 151 However, the results of the STAR-HEART trial are now 
under question due to scrutiny of the methodology used in the trial. In summary, all inference on 
efficacy of BMC therapy and superiority of route to date has been based on meta-analysis of single 
route trials. Furthermore, all the trials to date have either been non-randomised, not placebo-
controlled or did not use advanced cardiac imaging. This is the first trial using autologous BMC in 
ischaemic cardiomyopathy patients that has allowed a direct comparison to be made between IC 
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and IM injection of autologous cells and confirms the results of the meta-analyses suggesting that 
the IM route is most effective in this group of patients.  
 
So what are the implications of the findings of my thesis for the patient with ischaemic 
cardiomyopathy? The improvement of 4.99% in LVEF in the IM BMC group occurred, not in 
isolation, but in combination with an improvement in NYHA class and a reduction in NT pro-BNP 
levels. The change in LVEF of 4.99% is comparable to some of the landmark trials in heart failure 
which have led to the establishment in clinical practice of the commonly used medications used in 
heart failure. In the Val-HeFT trial (investigating the use of the angiotensin receptor blocker 
Valsartan in heart failure), the improvement in LVEF with Valsartan was 4.0%. 240 In the randomised 
trial by Fisher et al. looking at the effect of metoprolol in ischaemic cardiomyopathy, an increase of 
4.0% was observed in the treatment group.241  Similarly, in the RESOLVD pilot study, metoprolol 
increased LVEF by 2.4% in chronic heart failure patients.242 In the CAPRICORN (Carvedilol Post-
Infarct Survival Control in Left Ventricular Dysfunction) echocardiography sub-study, LVEF improved 
by 5.0% in the carvedilol group (at 6 months) as opposed to 1.0% in the placebo group.243 Thus, it 
appears that the magnitude of improvement in LVEF seen in in this thesis is in keeping with that 
observed in landmark heart failure trials. In addition, a number of these trials showed significant 
improvements in NYHA class as well e.g. Val-HeFT, CONSENSUS, MERIT-HF (Effect of metoprolol 
CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart 
Failure)41, Fisher et al.240, 241 An improvement in NYHA class, a well-established  prognostic indicator 
in chronic heart failure, was  also observed in this study. 244  
Together with the improvement in LVEF and NYHA class, a reduction in NT pro-BNP was also noted 
at 6 months in the IM BMC group. NT pro-BNP has been shown to be a prognostic marker in heart 
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failure and a rising level implies worse outcomes, including increased hospitalisation, arrhythmia 
and pump-failure related death, in patients with heart failure. 61 In fact, trials and meta-analyses 
have shown that BNP guided tailoring of heart failure therapy improves outcomes in chronic heart 
failure patients. In a meta-analysis by Li et al., BNP guided heart failure therapy resulted in 
improved mortality.58 The trigger for the release of BNP appears to be cardiomyocyte stretch. Thus, 
the reduction in LV volumes (albeit non-significant) together with the improved LVEF, would, at 
least partially, account for the reduction in NT pro-BNP observed in the IM BMC group.  As 
discussed in section 1.1.6, LVEF is associated with mortality risk in heart failure. The REGENERATE-
IHD trial being a phase II trial, it was not possible to analyse mortality benefit. The improvement in 
three different prognostic factors in heart failure-LVEF, NYHA and NT pro-BNP-in the IM BMC group 
is certainly encouraging and would necessitate larger, phase III trials to assess mortality benefit. 
Most of the landmark trials of drug therapy mentioned above showed reduction in mortality and it 
will not be surprising if phase III cell therapy trials show a similar mortality benefit. Once the phase 
III trials are over, and if confirmatory, the challenges of implementing such a procedure as an 
established treatment modality will require substantial amounts of funding and training. On 
average the cost of treating a single patient with IM BMC therapy is around £4-6k. However, 
considering the potential for savings in terms of reductions in hospital readmissions, GP visits and 
medication costs, the savings to healthcare economies are likely to far outweigh the costs of the 
procedure. Considering the large number of patients with ischaemic cardiomyopathy in the UK and 
worldwide, this is likely to result in significant financial savings for the NHS and other healthcare 
systems. .   
For advanced heart failure patients, the most important concerns are not always based on 
mortality but rather on whether a new trial intervention will bring symptomatic relief and well-
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being and whether the intervention will not make the patient worse i.e. safety. On that note, the 
findings in my thesis have successfully shown an improvement in patients’ functional outcomes as 
well as confirmed the safety record to date of BMC therapy in the ischaemic cardiomyopathy 
population. 
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The 3rd aim was to look at the mechanistic aspects of improvement in left ventricular function by 
studying change in cytokine levels, myocardial scar, diastolic function and cell quantity and 
function. 
 
Does the administration of G-CSF and autologous bone marrow derived cells lead to an 
improvement in cardiac function in patients with ischaemic cardiomyopathy by modulating 
cytokine levels? 
 
Analysis of specific cytokines was undertaken with the aim of gaining further insight into the 
association between G-CSF/cell therapy and cytokines with respect to changes in cardiac function. 
As far as I am aware, my work is the first to have analysed such a wide array of cytokines in a cell 
therapy trial in ischaemic cardiomyopathy patients. The ideal result would have been that G-CSF 
together with cell therapy, when delivered intramyocardially, increases the level of “protective” 
cytokines and reduces the effect of “harmful” cytokines and thus, suggests a mechanistic link 
between cytokines and improvement in LVEF. However, such clear conclusions cannot be derived 
for a number of reasons. Firstly, the number of paired blood samples (at baseline and 1 year) in 
each group were small, bearing in mind this was a phase II study. The study was not powered to 
detect significant changes in cytokine levels. Secondly, each cytokine is not a lone mediator of 
effect but rather part of a complex network of effectors. Thus, any association found between 
cytokine levels and cardiac outcomes would purely be, as mentioned above, an “association” 
rather than a cause and effect relationship. Bearing these two important limitations in mind, 
certain trends in cytokine levels are evident from the findings.  Firstly, the important “positive” 
findings will be discussed. IL-8 was noted to increase in all groups apart from the IM BMC group at 
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1 year with the highest rise seen in the peripheral placebo group. IL-8 is known to be a potent 
mediator of the inflammatory micro-environment involved in the pathogenesis of 
atherosclerosis.245 In the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) 
trial, the cytokine sub study revealed that IL-8 was a significant predictor of all-cause or 
cardiovascular mortality and the composite end-point of hospitalisation from heart failure or 
cardiovascular mortality in multivariate analysis. The study was undertaken in patients with chronic 
ischaemic cardiomyopathy aged ≥60 years and NYHA II-IV. Thus, the patient population was similar 
to our cohort. The finding that the group with the greatest increase in LVEF in my thesis has a 
reduction in IL-8 levels would certainly raise the possibility of an anti-inflammatory mechanism of 
action of G-CSF and IM BMC therapy as a means of improvement of cardiac function and 
symptoms. However, why the IC BMC group fails to show a reduction in IL-8 levels is unclear. One 
possibility is that the greater retention of cells in the IM BMC group allows time for paracrine 
activation of anti-inflammatory pathways to counter the effect of IL-8. From a basic science point 
of view, detailed analysis of the link between cell therapy and IL-8 would require measurement of 
downstream as well as upstream mediators of IL-8 action as well as the effects of IL-8 inhibition 
and outcomes.  However, from a clinical point of view, the results of the CORONA sub study and 
our findings suggest that IM BMC therapy is associated with a reduction of a pro-inflammatory 
cytokine which is known to be a negative prognostic indicator in chronic heart failure.  
 
MCP-1 is a polypeptide known to attract monocytes and macrophages as well as lymphocytes that 
can lead to enhanced fibrosis and adverse remodelling in chronic heart failure. Overexpression of 
MCP-1 has been shown to result in myocarditis and heart failure in transgenic mice and MCP-1 
inhibition using gene therapy resulted in improved survival and attenuation of LV volumes and 
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improvement in cardiac function.246 39 Furthermore, high levels of MCP-1 in chronic heart failure 
patients have been shown to correlate with lower LVEF. In that study, the level of MCP-1 was 
highest in those patients with ischaemic cardiomyopathy. 247 In this thesis a similar trend to IL-8 
was observed in levels of MCP-1 in the IM BMC group. Only in this IM BMC group was there a 
reduction in MCP-1, albeit non-significantly. All other groups showed an increase in MCP-1, with 
the highest increase in the G-CSF only group. Are the reductions in IL-8 and MCP-1 seen in the IM 
BMC group mere observations or is there a mechanistic link between the two? One study has 
investigated the role of mechanical stretch on various different cytokine levels and found that 
cyclic mechanical stretch upregulated the production of IL-8 and MCP-1 in human endothelial cells. 
248 The cohort of patients in our trial are patients with coronary artery disease. The process of 
atherosclerosis is triggered and propagated by various stimuli including high blood pressure which 
contributes to the cyclic mechanical stretch undergone by endothelial cells. Thus it is possible that 
the effect of cell therapy is the secretion of paracrine factors which inhibit the downstream 
mediators of mechanical stretch and thus a reduction in IL-8 and MCP-1 and subsequent 
attenuation in adverse remodelling with improvement in symptoms and cardiac function. 
However, to delineate the exact effect and mechanism of IL-8 and MCP-1 reduction in the context 
of G-CSF and cell therapy will need further pre-clinical studies.  
 
VEGF is a potent pro-angiogenic cytokine involved in neovascularisation that also has anti-
apoptotic properties and is involved in homing of stem cells from the bone marrow to ischaemic 
myocardium. With progressive heart failure, the level of VEGF decreases and as a result there is 
decreased microvascular growth and hence, reduced capillary density. My findings showed an 
increase in VEGF levels in both the IC and IM BMC groups whereas a decrease in VEGF was seen in 
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the IC and IM placebo groups. Although non-significant, these results suggest that upregulation of 
VEGF is seen in association with administration of BMC together with G-CSF but not with G-CSF 
alone. This supports the paracrine hypothesis and suggests that these cells either secrete VEGF 
directly or secrete factors which in turn trigger upregulation of VEGF. However, as to why VEGF 
upregulation results in improvement in LVEF in the IM BMC group but not in the IC BMC group 
implies that this improvement is an end-result of a complex interaction of a multitude of paracrine 
factors acting in an optimal milieu.  
 
Another observation in the cytokine sub-study was that IL-1b and IFN-γ levels both decreased in 
the IM BMC group. IL-1b is a pro-inflammatory cytokine that is known to be a myocardial 
depressant and associated with declining functional status. Van Tassell et al. were the first group to 
conduct a clinical trial using IL-1b blockade in HF patients. They noted an improvement in the 
median peak VO2 consumption on cardiopulmonary exercise testing. However, the study lacked a 
placebo group. 249 Interestingly, in that study, blockade of IL-1b receptor resulted in a reduction in 
IL-1b levels. It thus appears that deliver of BMC via the IM route might result in the secretion of an 
IL-1b receptor blocker which in turn results in a reduction in the negative prognostic marker IL-1b. 
The reduction in IL-1b seen in the IM BMC group is certainly in keeping with the improvement in 
functional status seen in patients in this group. The exact role of IFN-γ on cardiac function is a 
matter of controversy. Contradicting research suggests IFN-γ to be both detrimental to cardiac 
function as well as a protective agent.37 Our study appears to support the former observation in 
that the group with the largest improvement in LVEF and functional status showed a reduction in 
IFN-γ levels in comparison to no decrease in the remainder of the groups. However, until the role 
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of IFN-γ in heart failure is clearer, it is difficult to extrapolate on the importance of the reduction in 
IFN-γ seen in the IM BMC group. 
 
In summary, the cytokine sub-study was a hypothesis generating analysis of cytokine levels in 
response to G-CSF and BMC therapy in ischaemic cardiomyopathy patients. Important signals 
which warrant larger, appropriately powered studies are seen. Namely, that a reduction in the 
detrimental, pro-inflammatory cytokines MCP-1, IL-8, IL-1b and IFN-γ levels and an increase in the 
beneficial, pro-angiogenic cytokine VEGF were seen in the group with the greatest improvement in 
cardiac function is certainly noteworthy. 
 
Is myocardial scar reduction associated with improvement in LVEF, cytokine levels and cell/G-CSF 
therapy? 
CMR with late gadolinium assessment allows the accurate quantification of myocardial scar. 
However, most of the cell therapy studies to date have used non-CMR imaging modalities to assess 
cardiac function. The presence of CMR incompatible devices in advanced heart failure patients as 
well as the lack of widespread availability of CMR have been key reasons for the decreased use of 
CMR in cell therapy trials. As a result, change in scar burden in patients receiving BMC therapy and 
G-CSF has not been very widely characterised. Although MRI was used in this study, the expected 
low number of patients undergoing CMR, due to implanted devices, was a limitation. As a result, 
the distribution of CMR scans across the groups was uneven and hence, prevented a detailed 
analysis of scar burden by group. Furthermore, no analysis of the IM BMC group could be 
undertaken. Hence, analysis of the relationship between scar and outcomes was carried out on the 
pooled group of CMR recipients and then further analysed amongst subgroups with reduction in 
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scar and improvement in LVEF. This was done in an attempt to gain some insight into the 
mechanisms leading to the cardiac outcomes rather than into the mechanism of action of route, 
specific cell delivery or G-CSF therapy.  Bearing in mind these limitations, a few noteworthy 
observations were made. In the patients with an improvement in LVEF, a reduction in scar was 
noted in contrast to an increase in scar size in those with a reduction in LVEF. Survival in HF 
patients is inversely related to LVEF. In a study by Kwon et al., higher myocardial scar burden was 
associated with higher mortality in severe ischaemic cardiomyopathy.250 Thus, the decrease in scar 
burden seen in the group with an improvement in LVEF would imply a better prognosis in this 
group. Whether this reduction in scar is mediated by an increase in viable myocardium through 
myocardial regeneration is still unclear.  A few cell therapy trials have analysed myocardial scar 
burden. In the trial by Ang et al., injection of BMC into scarred myocardium during CABG did not 
result in a reduction in scar size. 180  However, in the CADUCEUS trial, which used cardiac stem 
cells, a reduction in scar size was noted.116 Further to the CADUCEUS study, the same group used a 
porcine model of convalescent MI and demonstrated, using CMR and histology, that MR 
quantification of change in scar was accurate and that the reduction in scar and increase in viable 
myocardium was explained for by cardiomyocytes hyperplasia hence implying activation of 
endogenous regenerative mechanisms.251 Although still not a definitive proof of myocardial 
regeneration in humans, the finding of a reduction in scar burden in those with an improvement in 
LVEF is certainly intriguing and suggests, albeit indirectly, a myocardial regenerative process. 
However, direct evidence for myocardial regeneration would require histological studies as well as 
using radio-labelled cells. The barrier to the former in humans is obvious while radiolabelling cells 
raises concerns regarding impaired cell survival and proliferation.252  
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Assessment of the relationship between myocardial scar and cytokine levels was the first ever 
performed in a cell therapy trial to date. Although the number of patients with cytokines analysed 
who also underwent CMR was small, there were sufficient samples to make a few interesting 
observations. In the group with scar reduction, the pro-inflammatory cytokine IL-1b decreased and 
the increase in MCP-1 was much less pronounced compared to the scar increase group. In 
comparison, an increase in pro-angiogenic cytokine VEGF was seen in the scar reduction group as 
opposed to a reduction in VEGF in the scar increase group. Along with VEGF, IL-10, an anti-
inflammatory cytokine, also increased in the scar reduction group. Although, these findings suggest 
a mechanistic association between scar reduction and IL-1b, VEGF, MCP-1 and IL-10, the exact 
relationship between scar and cytokines is unclear and would necessitate a further study 
specifically designed/powered to address this issue. Furthermore, the above reported associations 
between scar and LVEF or between scar and cytokines are, as mentioned above, “associations” 
only. Due to the limited sample size, these associations provide no insight into the role of cytokines 
in executing the effect of G-CSF and intramyocardial or intracoronary cell therapy. However, they 
provide important signals which should be the focus of future studies.  
 
Is bone marrow derived cell therapy and G-CSF associated with improved diastolic function? 
This thesis did not show any significant effect of either G-CSF alone or in combination with cell 
therapy on diastolic function. The majority of studies have understandably focused on LV systolic 
function and very few studies have looked at diastolic function. The findings in this thesis are in 
contrast to the study by Yao et al. who reported an improvement in LV diastolic indices as 
measured using echocardiography. In that study, IC delivery of autologous BMC resulted in an 
improvement in diastolic function but not in systolic function. This reported improvement in 
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diastolic function was reported at 6 months follow-up however it would have been interesting to 
see if this improvement was persistent at 12 months. The finding of systolic improvement only and 
no diastolic improvement in the IM BMC group implies that the functional improvements noted in 
NYHA class as well as the reduction in NT pro-BNP  were attributable to the improvement in 
systolic function  
 
 
Are increased peripheral and bone marrow cell counts and improved cell function associated 
with improved LVEF? 
The correlation observed between CFU-GM and LVEF in the IM BMC group implies that the 
functional capacity of the cells is intricately linked to outcomes in cardiac function. This provides 
further proof to the concept of the link between functional capacity of the infused cells and 
outcomes in cell therapy trials as described by Assmus et al. in the TOPCARE-CHD trial.231 In that 
trial, a link between CFU-GM and mortality risk was observed. Furthermore, as has been described 
before154, 225 and more recently in the FOCUS-HF trial, the functional capacity of BMC is reduced, as 
measured using CFU-GM, in advanced HF.146 The above trials provided evidence that the functional 
capacity of infused BMC, although impaired in advanced HF, are inversely associated with mortality 
risk. This thesis results add further to the existing literature suggesting that the functional capacity 
of autologous BMC is not only linked to mortality outcomes but also to outcomes in cardiac systolic 
function in patients with severe left ventricular dysfunction.  
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The proliferation and mobilisation of EPC and MNC in peripheral blood in response to G-CSF was 
shown to be associated with change in LVEF at 1 year. These are important observations which 
suggest that EPC’s in peripheral blood i.e. CEPC’s, might be involved in neovascularisation as a 
mechanistic role in the improvement of LVEF. Furthermore, the link between the proliferation and 
mobilisation of MNC, but not CD34+ cells into the peripheral blood, with change in LVEF also 
suggests that the CD34- MSCs might have a role to play in the improvement in cardiac function. 
The FOCUS-HF trial did measure CFU-F to look at the functional capacity of MSCs. However, the 
focus in that trial was to analyse for any variation in CFU-F with respect to age and not cardiac 
function. Future trials to both quantify and qualitatively characterise EPC and MSC and correlate 
result with cardiac outcome are necessary to identify the “key player” amongst the subsets of cell 
types present in the adult bone marrow. No trial has yet done a head-to head comparison of CEPC 
v MSC v HSC v unfractionated BMC in relation to cardiac function.   
 
LIMITATIONS 
 
The study was powered based on within group rather than between group comparisons. However, 
it is important to remember that this study involved invasive procedures with multiple follow-ups 
and investigations for a patient population who are limited in functional capacity from their 
advanced heart failure. Thus, it is very difficult to recruit such patients in vast numbers over a 
specified period of time.  Secondly, the measurement of NT pro-BNP at 6 months but not at the 
time of the primary outcome endpoint at 1 year was undertaken for logistic reasons and to reflect 
early remodelling. It would have been ideal to have measured NT pro-BNP at 6 months, 1 year and 
2 years. Thirdly, one might question the use of both CT and CMR interchangeably when measuring 
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LVEF. However, although this could be seen as a potential limitation, two points need to be made. 
Firstly, the correlation between CT and CMR in measuring LVEF is good.213 Secondly, as each 
individual participant underwent a single imaging modality at all time points, thus allowing 
comparison of measurements between baseline and 1 year or baseline and 2 years, a within group 
analysis was used.   
  
Three different QoL questionnaires were used, however, if the trial was being conducted again it 
would be better to  use a combination of a general QoL questionnaire and a disease specific QoL, 
preferably the combination of the SF-36 and Minnesota living with heart failure (MLHF) 
questionnaires as they have some of the best validity for use in heart failure patients. 253 The latter 
is a heart failure specific questionnaire. None of the QoL questionnaires used in the study were 
heart failure specific QoL questionnaires. Furthermore, it would have been advisable to use the 
Seattle HF model prognosis predictor to identify any suggestions of improved mortality risk in the 
patient cohort over time.  Furthermore, the study was not powered to detect significant changes in 
QoL scores and hence, interpretation of the QoL changes was difficult.  
 
 The mechanistic sub-studies were again limited by the low sample size, particularly in the CMR 
scar study, this made it difficult to conduct within arm comparisons of change in scar. However, 
this limitation is not one unique to this trial and has been a recurring issue with trials on patients 
with advanced HF who have implanted devices. Other limitations in the mechanistic sub studies 
include the lack of acquisition of image frames on echocardiogram that would have enabled me to 
measure diastolic function more comprehensively e.g. interventricular relaxation time, pulmonary 
venous flow. In the cell sub-study, cell quantification of MSC’s and cell characterisation of EPC and 
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MSC using CFU-EPC and CFU-F would have added additional information on cell characteristics and 
outcomes.  
 
FUTURE DIRECTIONS 
The demand for novel therapies in heart failure is enormous. Recently, new pharmacological 
therapy has shown promise.   The PARADIGM-HF trial assessed the efficacy and safety of a new 
class of drug called neprilysin inhibitors. Neprilysin is an endopeptidase that cleaves natriuretic 
peptides and other vasoactive peptides.  In the PARADIGM-HF trial, neprilysin inhibitor, in 
combination with valsartan, reduced the risk of death and hospitalisation for heart failure as 
compared to enalapril alone. 68 However, newer pharmacological therapies in the field of heart 
failure have been few and far between. 
In the field of cell therapy, several unanswered questions remain. The shift from preclinical to 
clinical work had been relatively quick. Trial designs have been heterogeneous with a lack of 
standardised protocols and endpoints. Most studies have looked at global LVEF as a primary end 
point. It is probable that surrogate end-points as opposed to individual tests will best represent 
activity that will translate into harder clinical end-points. 
The optimal cell type remains to be determined. Eduardo Marban’s group compared bone marrow 
derived MSCs, CDCs, ADSCs and BMMC in animal studies. The results suggest the superiority of 
CDC’s in terms of myogenic and angiogenic potency and improvement in cardiac function.113  
Cell function and proliferation capacity can vary secondary to patient characteristics and 
comorbidities. This could imply 'testing' a patient’s cells before deciding on patient suitability - 
hence allogeneic products. It is possible that stem cell therapy will become individualised in the 
future based on the underlying pathophysiology and choice of best cell type to stimulate the 
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necessary mechanism e.g. angiogenic cells to improve symptoms of angina vs. cardiopoietic cell 
types to treat heart failure.  
Ultimately cells alone may not be enough to overcome the overwhelming pathology that 
accompanies myocardial dysfunction. The field of tissue engineering combines regenerative cells 
with bioactive materials (scaffolds) in combination with growth factors to create a structural 
complex or “cardiac patch” that helps support cell survival and proliferation.  Various synthetic and 
natural biomaterials have already been used as scaffolds e.g. collagen, fibrin.  More recently, 
scaffold-free cell sheet technology involving stacking of single layers of cell sheets to create three-
dimensional tissue. Initial results in animal models are promising. 254 Ultimately tissue engineering 
may create a total heart based on a bio structure that has been repopulated with a patients’ own 
stem cells thereby avoiding tissue rejection. Currently this theory is being explored using de-
cellularised hearts255. 
Other exciting developments include genetic and pharmacologic manipulation of stem cells to 
improve their therapeutic efficiency. For example, a study overexpressing GSK 3beta (glycogen 
synthase, a serine/threonine kinase) in MSC’s and then transplanting them into murine hearts 
showed significant improvement in left ventricular function and mortality.256 Small, non-coding 
RNA’s (miRNA’s) appear to regulate gene expression by blocking mRNA translation or inducing 
degradation of mRNA. Expression of miRNAs influences stem cell differentiation and miRNAs are 
potential adjuncts in improving the efficiency of cell therapy. Other approaches include combining 
cell therapy with mechanical support devices e.g. LVAD. Reports have shown significant clinical 
improvement in patients with ischaemic cardiomyopathy administered stem cells while on LVAD 257  
and cell therapy may provide a useful ‘bridge’ in transplant medicine to allow maintenance of 
myocardial function whilst a suitable donor is found.  
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Cell therapy has a big future in heart failure but I don't believe in its current state. My vision of 
stem failure treatment will involve individualised, “tailor-processed” cells which would be first sub-
selected to get the optimal  cell type (suited to the pathology being treated), functionally tested, 
sub-functional cells discarded, the cells genetically modified and/or cultured in appropriate 
“cardiogenic cocktails” and then injected into the myocardium in the correct dose using 
electromechanical mapping. Cell therapy in its current state is quite unselected and crude-a “one 
size fits all” approach. The foreseen advances, however, are a long way away. The findings of this 
research work highlight important “signals” which need further study in phase III trials. 
SUMMARY 
 
The findings of my thesis have shown that G-CSF and intramyocardially delivered autologous bone 
marrow derived cells significantly improve cardiac function, patients’ symptoms and biochemical 
parameters. This is the first time a randomised placebo-controlled trial has explored and shown a 
positive effect of G-CSF in combination with autologous BMC. Furthermore, the mechanistic sub-
studies have investigated the link between cytokines, cell numbers/function, myocardial scar and 
diastolic function and G-CSF± autologous BMC. The results have provided important signals 
including, reduction in pro-inflammatory cytokines with BMC, reduction in scar with improvement 
in LVEF and a positive relationship between CFU-GM and LVEF. The low sample numbers have 
prevented reaching statistical significance. However, these encouraging signals should trigger the 
design of appropriately powered phase II trials to clarify these mechanistic hypothesis.  
 
Furthermore, the positive improvement in LVEF with functional and biochemical parameters along 
with a consistent safety record warrant the design and conduct of phase III trials to provide more 
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definitive answers on efficacy.  Although the magnitude of the improvement in LVEF might not 
appear significant in clinical terms, most of the trials of established pharmacotherapy in heart 
failure have shown similar magnitudes of improvement in LVEF and subsequent mortality benefit. 
The challenges will be to conduct large scale, phase III trials, bearing in mind the invasive nature of 
the procedures, the need for highly trained staff able to operate electromechanical mapping 
systems and the limitations imposed by the morbidity of patients with advance heart failure in 
attending long term follow-up. Overcoming these limitations, and provided phase III trials show a 
significant benefit, G-CSF and autologous BMC administration could revolutionise the treatment of 
advanced ischaemic cardiomyopathy patients.  
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SF36 Your Health and Well-Being 
 
 
 
This survey asks for your views about your health. This information will help 
keep track of how you feel and how well you are able to do your usual activities. 
Thank you for completing this survey! 
 
For each of the following questions, please tick the one box that best describes 
your answer. 
 
 1. In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
 1  2  3  4  5 
 
 
 2. Compared to one year ago, how would you rate your health in general 
now? 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
     
 1  2  3  4  5 
 
Page 224 
 3. The following questions are about activities you might do during a typical 
day.  Does your health now limit you in these activities?  If so, how much?  
 
 
 4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
    a Cut down on the amount of  
  time you spent on work or  
  other activities .............................  1..............  2 .............  3 .............  4 .............  5 
    b Accomplished less than you  
  would like ....................................  1..............  2 .............  3 .............  4 .............  5 
   C Were limited in the kind of  
  work or other activities ................  1..............  2 .............  3 .............  4 .............  5 
   d  Had difficulty performing the  
  the work or other activities (for  
  example, it took extra effort) ........  1..............  2 .............  3 .............  4 .............  5 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
    
 a Vigorous activities, such as running, lifting  
heavy objects, participating in strenuous sports ...................  1 .............  2 ............  3 
 b Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf .........................  1 .............  2 ............  3 
 c Lifting or carrying groceries ................................................  1.............  2 ............  3 
 d Climbing several flights of stairs .........................................  1.............  2 ............  3 
 e Climbing one flight of stairs ................................................  1.............  2 ............  3 
 f Bending, kneeling, or stooping ............................................  1.............  2 ............  3 
 g Walking more than a mile ...................................................  1.............  2 ............  3 
 h Walking several hundred yards ...........................................  1.............  2 ............  3 
 i Walking one hundred yards .................................................  1.............  2 ............  3 
 j Bathing or dressing yourself ................................................  1.............  2 ............  3 
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 5. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or anxious)? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
    a Cut down on the amount of  
  time you spent on work or  
  other activities .............................  1..............  2 .............  3 .............  4 .............  5 
    b Accomplished less than you  
  would like ....................................  1..............  2 .............  3 .............  4 .............  5 
   C Did work or other activities 
  less carefully than usual ...............  1..............  2 .............  3 .............  4 .............  5 
 
 
 
 
 6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbours, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
     
 1  2  3  4  5 
 
 
 
 
 7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
      
 1  2  3  4  5  6 
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 8. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
     
 1  2  3  4  5 
 
 
 
 
 
 9. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time 
during the past 4 weeks… 
 
 
 
 
 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
   a  Did you feel full of life? ...............  1 .............  2 ............  3 .............  4 .............  5 
   b  Have you been very nervous? .......  1 .............  2 ............  3 .............  4 .............  5 
   c  Have you felt so down in the  
dumps that nothing could  
cheer you up? ...............................  1 .............  2 ............  3 .............  4 .............  5 
   d  Have you felt calm and   
peaceful? ......................................  1 .............  2 ............  3 .............  4 .............  5 
   e  Did you have a lot of energy? .......  1 .............  2 ............  3 .............  4 .............  5 
   f   Have you felt downhearted   
and low? ......................................  1 .............  2 ............  3 .............  4 .............  5 
   g  Did you feel worn out? .................  1 .............  2 ............  3 .............  4 .............  5 
   h  Have you been happy? .................  1 .............  2 ............  3 .............  4 .............  5 
   i  Did you feel tired? .......................  1 .............  2 ............  3 .............  4 .............  5 
 10. During the past 4 weeks, how much of the time has your physical 
health or emotional problems interfered with your social activities 
(like visiting with friends, relatives, etc.)? 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
 1  2  3  4  5 
 
 
 
 
 
 11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
      
   a  I seem to get ill more 
easily than other people................  1.............  2 .............  3 .............  4 .............  5 
 b I am as healthy as  
anybody I know ...........................  1..............  2 .............  3 .............  4 .............  5 
 c I expect my health to  
get worse .....................................  1..............  2 .............  3 .............  4 .............  5 
 d My health is excellent ..................  1..............  2 .............  3 .............  4 .............  5 
 
 
 
 
 
 
 
Thank you for completing these questions! 
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Addendum 
(Amendments as per viva outcome recommendations) 
 
In section 2.1.2, the first paragraph in the section titled “Randomisation” should read: 
 
“Patients were randomised in a sequential manner with the first 30 recruited patients allocated to 
the IM arm as the aim was to complete this arm first.  This was done as treatment in this arm 
required the presence of expensive equipment for electromechanical mapping (NOGA®) as well the 
presence of senior clinicians and technical staff trained in the use of such equipment. The next 60 
patients were randomised in a 1:1 manner to the other 2 arms (peripheral or IC) (fig 2.1)   
Randomisation was performed using a dedicated trial software system (HD Clinical, Bishops 
Stortford, Herts, UK).”  
instead of: 
“Patients were randomised to 1 of 3 arms: peripheral, intracoronary (IC) or intramyocardial (IM) 
(figure 2.1). The first 30 patients were allocated to the IM arm as the aim was to complete this arm 
first. This was done as treatment in this arm required the presence of expensive equipment for 
electromechanical mapping (NOGA®) as well the presence of senior clinicians and technical staff 
trained in the use of such equipment.   The remainder of the 60 patients were randomised in a 1:1 
manner to the other 2 arms (peripheral or IC), using a dedicated trial software system (HD Clinical, 
Bishops Stortford, Herts, UK).” 
 
In section 2.1.2, the first paragraph in the section titled “Patient selection” should read: 
Patients were referred to the trial with a confirmed diagnosis of HF from local HF clinics. Patients 
underwent screening by the research nurse or physician prior to inclusion in the study to ensure the 
inclusion criteria were met and that no exclusion criteria were present. Screening for potential trial 
participants started in February 2005 and last patient recruitment was in April 2012. All potential 
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trial participants received detailed information regarding the objectives and methodology of the trial 
and the post-trial follow-up arrangements. A detailed patient information sheet (PIS) was provided 
to each patient by the research nurse. The potential participant was given ample time to think about 
the pros and cons of participating in the trial. Following this period, the research team answered any 
further questions raised by the patient. Once the patient was happy to go ahead, the participant was 
asked to sign a consent form to indicate informed consent. The participant was informed of his/her 
right to change their mind at any point in the trial. The participant also consented to the use of 
his/her data gathered during the trial as well as any remaining bone marrow and stored blood 
sample for future trial related research.  
instead of: 
Patients were referred to the trial with a confirmed diagnosis of HF from local HF clinics. Patients 
underwent screening by the research nurse or physician prior to inclusion in the study to ensure the 
inclusion criteria were met and that no exclusion criteria were present. All potential trial participants 
received detailed information regarding the objectives and methodology of the trial and the post-
trial follow-up arrangements. A detailed patient information sheet (PIS) was provided to each 
patient by the research nurse. The potential participant was given ample time to think about the 
pros and cons of participating in the trial. Following this period, the research team answered any 
further questions raised by the patient. Once the patient was happy to go ahead, the participant was 
asked to sign a consent form to indicate informed consent. The participant was informed of his/her 
right to change their mind at any point in the trial. The participant also consented to the use of 
his/her data gathered during the trial as well as any remaining bone marrow and stored blood 
sample for future trial related research.  
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Table 3.1 should show: 
  
Saline 
(n=15) 
 
G-CSF 
(n=15) 
 
IC serum 
(n=15) 
 
IC BMC 
(n=15) 
 
IM serum 
(n=15) 
 
IM BMC 
(n=15) 
 
       
Age, years (mean ± 
SD) 
63.3±9.3 63.1±8.2 62.8±10.7 62.1±9.7 60.4±11.2 65.3±9.4 
Sex M/F n 14/1  13/2  14/1  14/1  15/0  15/0  
BMI (kg/m
2
) 
(mean±SD)# 
29.5±4.3 31.4±6.0 31.7±6.5 29.7±4.8 29.6±3.7 30.8±4.0 
       
Medical History, n (%)       
Hypertension 3 (20.0) 1 (6.7) 2 (13.3) 3 (20.0) 5 (33.3) 5 (33.3) 
Diabetes 4 (26.7) 5 (33.3) 2 (13.3) 2 (13.3) 4 (26.7) 4 (26.7) 
CABG 5 (33.3) 4 (26.7) 3 (20.0) 7 (46.7) 6 (40.0) 4 (26.7) 
MI 13 (86.7) 12 (80.0) 14 (93.3) 13(86.7) 13 (86.7) 13 (86.7) 
Hypercholesterolaemia 4 (26.7) 6 (40.0) 5 (33.3) 5 (33.3) 8 (53.3) 4 (33.3) 
Smoker/ex-smoker,  12 (80.0) 8 (53.3) 13 (86.7) 11(73.3) 14 (93.3) 11 (73.3) 
       
       
Time from last MI, 
days median (IQR) 
1307 
(1064-
5443) 
2527 
(966- 
4928) 
2856 
(1278-
6041) 
1805 
(896- 
3855) 
2406 
(706- 
5402) 
2684 
(706- 
5402) 
       
LVEF (%) (mean ± SD) 34.7±10.1 27.9±12.4 31.6±7.4 31.7±8.8 29.0±9.2 28.6±10.2 
       
Devices number,n (%)       
CRT-D 4 (26.7) 5 (33.3) 4 (26.7)  4 (26.7)  3 (20.0)  7 (46.7) 
CRT-P 1 (6.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 
ICD only 7 (46.7) 2 (13.3) 4 (26.7) 5 (33.3) 5 (33.3) 6 (40.0) 
       
Medication history, n 
(%) 
      
Statin 12 (80.0) 13 (86.7) 13 (86.7) 13(86.7) 14 (93.3) 13 (86.7) 
ACEi/ARB 14 (93.3) 14 (93.3) 13 (86.7) 14(93.3) 15 (100) 15 (100) 
Β-blocker 15(100) 14 (93.3) 12 (80.0) 15(100) 11 (73.3) 14 (93.3) 
Aldosterone 
antagonist 
9 (60.0) 13 (86.7) 9 (60.0) 12(80.0) 9 (60.0) 12 (80.0) 
Diuretics 10 (66.7) 11 (73.3) 13 (86.7) 12(80.0) 8 (53.3) 12 (80.0) 
       
NYHA at baseline, n 
(%) 
      
II 10 (66.7) 9 (60.0) 5 (33.3) 8 (53.3) 11 (73.3) 8 (53.3) 
III/IV 5 (33.3) 6 (40.0) 10 (66.7) 7 (46.7) 4 (26.7) 7 (46.7) 
       
       
 
Instead of: 
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Saline 
(n=15) 
 
G-CSF 
(n=15) 
 
IC serum 
(n=15) 
 
IC BMC 
(n=15) 
 
IM serum 
(n=15) 
 
IM BMC 
(n=15) 
 
 
p-
value 
        
Age, years (mean ± 
SD) 
63.3±9.3 63.1±8.2 62.8±10.7 62.1±9.7 60.4±11.2 65.3±9.4 0.841 
Sex M/F n 14/1  13/2  14/1  14/1  15/0  15/0  0.896 
BMI (kg/m2) 
(mean±SD)# 
29.5±4.3 31.4±6.0 31.7±6.5 29.7±4.8 29.6±3.7 30.8±4.0 0.739 
        
Medical History, n (%)        
Hypertension 3 (20.0) 1 (6.7) 2 (13.3) 3 (20.0) 5 (33.3) 5 (33.3) 0.414 
Diabetes 4 (26.7) 5 (33.3) 2 (13.3) 2 (13.3) 4 (26.7) 4 (26.7) 0.748 
CABG 5 (33.3) 4 (26.7) 3 (20.0) 7 (46.7) 6 (40.0) 4 (26.7) 0.653 
MI 13 (86.7) 12 (80.0) 14 (93.3) 13(86.7) 13 (86.7) 13 (86.7) 0.949 
Hypercholesterolaemia 4 (26.7) 6 (40.0) 5 (33.3) 5 (33.3) 8 (53.3) 4 (33.3) 0.715 
Smoker/ex-smoker,  12 (80.0) 8 (53.3) 13 (86.7) 11(73.3) 14 (93.3) 11 (73.3) 0.150 
        
        
Time from last MI, 
days median (IQR) 
1307 
(1064-
5443) 
2527 
(966- 
4928) 
2856 
(1278-
6041) 
1805 
(896- 
3855) 
2406 
(706- 
5402) 
2684 
(706- 
5402) 
0.964 
        
LVEF (%) (mean ± SD) 34.7±10.1 27.9±12.4 31.6±7.4 31.7±8.8 29.0±9.2 28.6±10.2 0.385 
        
Devices number,n (%)        
CRT-D 4 (26.7) 5 (33.3) 4 (26.7)  4 (26.7)  3 (20.0)  7 (46.7) 0.781 
CRT-P 1 (6.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 0.999 
ICD only 7 (46.7) 2 (13.3) 4 (26.7) 5 (33.3) 5 (33.3) 6 (40.0) 0.485 
        
Medication history, n 
(%) 
       
Statin 12 (80.0) 13 (86.7) 13 (86.7) 13(86.7) 14 (93.3) 13 (86.7) 0.995 
ACEi/ARB 14 (93.3) 14 (93.3) 13 (86.7) 14(93.3) 15 (100) 15 (100) 0.896 
Β-blocker 15(100) 14 (93.3) 12 (80.0) 15(100) 11 (73.3) 14 (93.3) 0.079 
Aldosterone 
antagonist 
9 (60.0) 13 (86.7) 9 (60.0) 12(80.0) 9 (60.0) 12 (80.0) 0.351 
Diuretics 10 (66.7) 11 (73.3) 13 (86.7) 12(80.0) 8 (53.3) 12 (80.0) 0.363 
        
NYHA at baseline, n 
(%) 
       
II 10 (66.7) 9 (60.0) 5 (33.3) 8 (53.3) 11 (73.3) 8 (53.3)  
0.376 
III/IV 5 (33.3) 6 (40.0) 10 (66.7) 7 (46.7) 4 (26.7) 7 (46.7)  
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Table 3.2 should show: 
  
Saline 
(n=9) 
 
G-CSF 
(n=9) 
 
IC serum 
(n=10) 
 
IC BMC 
(n=12) 
 
IM serum 
(n=7) 
 
IM BMC 
(n=10) 
 
       
Age, years (mean ± 
SD) 
65.3±12.2 64.0±9.8 65.4±10.3 58.7±8.9 56.8±9.7 61.8±7.5 
Sex M/F n 8/1  8/1  9/1  11/1  7/0  10/0  
BMI (kg/m2) 
(mean±SD)
# 
30.0±4.2 30.3±5.2 30.0±5.7 30.9±4.7 31.4±3.7 30.8±4.6 
       
Medical History, n (%)       
Hypertension 2 (22.2)      0 (0.0) 1 (10.0) 2 (16.7) 4 (57.1) 2 (20.0) 
Diabetes 1 (11.1) 2 (22.2) 1 (10.0) 2 (16.7) 1 (14.3) 1 (10.0) 
CABG 2 (22.2) 4 (44.4) 2 (20.0) 6 (50.0) 2 (28.6) 2 (20.0) 
MI 8 (88.9) 8 (88.9) 9 (90.0) 11 
(91.7) 
7 (100.0) 8 (80.0) 
Hypercholesterolaemia 2 (22.2) 3 (33.3) 3 (30.0) 4 (33.3) 5 (71.4) 4 (40.0) 
Smoker/ex-smoker,  6 (66.7) 6 (66.7) 8 (80.0) 10 
(83.3) 
6(85.7) 6 (60.0) 
       
       
Time from last MI, 
days median (IQR) 
3593 
(5420) 
2788  
(4634) 
2808  
(2288) 
1731  
(3402) 
1894  
(5336) 
3993  
(4957) 
       
LVEF (%) (mean ± SD) 34.0±10.8 27.4±12.9 31.7±7.3 31.3±8.4 28.1±12.3 29.3±11.7 
       
Devices number,n (%)       
CRT-D 4 (26.7) 4 (33.3) 3 (26.7)  3 (26.7)  0 (20.0)  4  (46.7) 
CRT-P 1 (6.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 
ICD only 4 (46.7) 2 (13.3) 4 (26.7) 5 (33.3) 3 (33.3) 4 (40.0) 
       
Medication history, n 
(%) 
      
Statin 7 (80.0)      8 
(86.7) 
9 (86.7) 12 
(86.7) 
7 (93.3) 10 (86.7) 
ACEi/ARB 8 (93.3) 8 (93.3) 9 (86.7) 12 
(93.3) 
7 (100) 10 (100) 
Β-blocker 9 (100.0) 9 (93.3) 7 (80.0) 12 
(100.0) 
5 (73.3) 10 (93.3) 
Aldosterone 
antagonist 
4 (60.0) 7 (86.7) 6 (60.0) 11 
(80.0) 
4 (60.0) 9 (80.0) 
Diuretics 5 (66.7) 5 (73.3) 8 (86.7) 10 
(80.0) 
4 (53.3) 7 (80.0) 
       
NYHA at baseline, n 
(%) 
      
II 9 (66.7) 6 (60.0) 3 (33.3) 6 (53.3) 6 (73.3) 5 (53.3) 
III/IV 0 (33.3) 3 (40.0) 7 (66.7) 6 (46.7) 1 (26.7) 5 (46.7) 
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Instead of: 
  
Saline 
(n=9) 
 
G-CSF 
(n=9) 
 
IC serum 
(n=10) 
 
IC BMC 
(n=12) 
 
IM serum 
(n=7) 
 
IM BMC 
(n=10) 
 
 
p-
value 
        
Age, years (mean ± 
SD) 
65.3±12.2 64.0±9.8 65.4±10.3 58.7±8.9 56.8±9.7 61.8±7.5 0.626 
Sex M/F n 8/1  8/1  9/1  11/1  7/0  10/0  0.945 
BMI (kg/m2) 
(mean±SD)
# 
30.0±4.2 30.3±5.2 30.0±5.7 30.9±4.7 31.4±3.7 30.8±4.6 0.990 
        
Medical History, n (%)        
Hypertension 2 (22.2)      0 (0.0) 1 (10.0) 2 (16.7) 4 (57.1) 2 (20.0) 0.122 
Diabetes 1 (11.1) 2 (22.2) 1 (10.0) 2 (16.7) 1 (14.3) 1 (10.0) 0.980 
CABG 2 (22.2) 4 (44.4) 2 (20.0) 6 (50.0) 2 (28.6) 2 (20.0) 0.574 
MI 8 (88.9) 8 (88.9) 9 (90.0) 11 
(91.7) 
7 (100.0) 8 (80.0) 0.967 
Hypercholesterolaemia 2 (22.2) 3 (33.3) 3 (30.0) 4 (33.3) 5 (71.4) 4 (40.0) 0.504 
Smoker/ex-smoker,  6 (66.7) 6 (66.7) 8 (80.0) 10 
(83.3) 
6(85.7) 6 (60.0) 0.871 
        
        
Time from last MI, 
days median (IQR) 
3593 
(5420) 
2788  
(4634) 
2808  
(2288) 
1731  
(3402) 
1894  
(5336) 
3993  
(4957) 
0.894 
        
LVEF (%) (mean ± SD) 34.0±10.8 27.4±12.9 31.7±7.3 31.3±8.4 28.1±12.3 29.3±11.7 0.783 
        
Devices number,n (%)        
CRT-D 4 (26.7) 4 (33.3) 3 (26.7)  3 (26.7)  0 (20.0)  4  (46.7) 0.368 
CRT-P 1 (6.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 0.373 
ICD only 4 (46.7) 2 (13.3) 4 (26.7) 5 (33.3) 3 (33.3) 4 (40.0) 0.946 
        
Medication history, n 
(%) 
       
Statin 7 (80.0)      8 
(86.7) 
9 (86.7) 12 
(86.7) 
7 (93.3) 10 (86.7) 0.328 
ACEi/ARB 8 (93.3) 8 (93.3) 9 (86.7) 12 
(93.3) 
7 (100) 10 (100) 0.659 
Β-blocker 9 (100.0) 9 (93.3) 7 (80.0) 12 
(100.0) 
5 (73.3) 10 (93.3) 0.012 
Aldosterone 
antagonist 
4 (60.0) 7 (86.7) 6 (60.0) 11 
(80.0) 
4 (60.0) 9 (80.0) 0.108 
Diuretics 5 (66.7) 5 (73.3) 8 (86.7) 10 
(80.0) 
4 (53.3) 7 (80.0) 0.612 
        
NYHA at baseline, n 
(%) 
       
II 9 (66.7) 6 (60.0) 3 (33.3) 6 (53.3) 6 (73.3) 5 (53.3)  
0.017 
III/IV 0 (33.3) 3 (40.0) 7 (66.7) 6 (46.7) 1 (26.7) 5 (46.7)  
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The last paragraph in the “Limitations” section in Ch 6 should read: 
The cytokines sub-study was limited by the small sample size and statistical issues with multiple 
comparisons. Each of the 11 cytokines were compared between 6 different groups as well as for 
within group change. Despite using Bonferroni correction and with small sample size, the inherent 
probability of chance findings with multiple comparisons is unavoidable and a significant limitation 
of the cytokine sub-study.  The mechanistic sub-studies were again limited by the low sample size, 
particularly in the CMR scar study, this made it difficult to conduct within arm comparisons of 
change in scar. However, this limitation is not one unique to this trial and has been a recurring issue 
with trials on patients with advanced HF who have implanted devices. Other limitations in the 
mechanistic sub studies include the lack of acquisition of image frames on echocardiogram that 
would have enabled me to measure diastolic function more comprehensively e.g. interventricular 
relaxation time, pulmonary venous flow. In the cell sub-study, cell quantification of MSC’s and cell 
characterisation of EPC and MSC using CFU-EPC and CFU-F would have added additional information 
on cell characteristics and outcomes. 
Instead of: 
The mechanistic sub-studies were again limited by the low sample size, particularly in the CMR scar 
study, this made it difficult to conduct within arm comparisons of change in scar. However, this 
limitation is not one unique to this trial and has been a recurring issue with trials on patients with 
advanced HF who have implanted devices. Other limitations in the mechanistic sub studies include 
the lack of acquisition of image frames on echocardiogram that would have enabled me to measure 
diastolic function more comprehensively e.g. interventricular relaxation time, pulmonary venous 
flow. In the cell sub-study, cell quantification of MSC’s and cell characterisation of EPC and MSC 
using CFU-EPC and CFU-F would have added additional information on cell characteristics and 
outcomes. 
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A new section between 3.2.2 and 3.2.3 has been added which reads: 
The figure below (fig A) shows the inter-observer variability for CT analysis of LVEF, the primary 
endpoint, between myself and the second operator. Where a difference of >5% was observed 
between the two readers, the scan was sent to a level III, consultant imaging cardiologist specialising 
in CT to re-analyse the scan.  
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Figure A. Bland-Altman plot showing inter-observer variability. The Bland-Altman plot shows the 
inter-observer variability for measurement of the primary endpoint of left ventricular ejection 
fraction as measured using computed tomography. The blue lines indicate the 95% limits of 
agreement.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bias -1.95 SD of bias 4.1 
95% limits of agreement -6.8 to 9.3 
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